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Despite effective treatment being available since the 1940s, tuberculosis (TB) remains a 
leading cause of death by a single infectious agent. Continued transmission is one of the 
driving factors of the TB epidemic. In high TB and HIV prevalent settings Mycobacterium 
tuberculosis transmission dynamics are still poorly understood. Throughout adolescence, 
individuals have increasing social contacts with the wider community. Thus, understanding 
M. tuberculosis infection among adolescents has potential for understanding M. tuberculosis 
infection in the population. This thesis reports findings from a cross-sectional study among 
adolescents in a high TB and HIV prevalence setting. 
A sample of adolescents (aged 10-19 years) resident in the southern part of the Africa 
Health Research Institute(AHRI) demographic surveillance area (DSA) was enrolled from 
their homes. Blood samples were obtained, and M. tuberculosis infection was measured 
using the QuantiFERON-TB Gold-plus assay. 
A total, 1,094 adolescents were enrolled, and the prevalence of M. tuberculosis infection was 
22.8% (95% confidence interval [CI]: 20.4-25.3%). Older age, history of lifetime household 
TB contact and living in communities with high HIV prevalence were associated with 
increased odds of M. tuberculosis infection. There was no evidence of association between 
M. tuberculosis infection and Bacillus Calmette-Guérin (BCG) vaccination, household 
socioeconomic status, and increased cumulative monthly contact hours with either adult 
males or females. The spatial distribution of M. tuberculosis infection showed geographical 
variation. Communities with increased M. tuberculosis infection prevalence were observed 
on the south eastern part of the study area where population density and HIV prevalence are 
higher than other parts of the study area. 
The findings in this research show that household contacts of individuals with TB disease 
and individuals from communities with high HIV prevalence remain at risk of infection and 
should be prioritised for TB prevention and care activities. 
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Tuberculosis (TB) is an infectious disease caused by the bacterium Mycobacterium 
tuberculosis or any of the related members of the M. tuberculosis complex family. TB mainly 
affects the lungs (pulmonary TB) but can also affect other parts of the body (extra-pulmonary 
TB). TB is transmitted when infectious individuals with pulmonary TB expel the TB bacilli (by 
for example coughing, sneezing, singing or laughing) into the air and is inhaled by 
susceptible individuals. Transmission usually occurs indoors in poorly ventilated areas, as 
the bacilli are quickly destroyed by ultraviolet light in well ventilated areas [1, 2]. 
Though effective treatment for TB disease has been available since the 1940s, TB remains a 
major health problem globally. In 2017, an estimated 10.5 million people fell ill of the disease 
and an estimated 1.5 million TB deaths were reported making TB the leading cause of death 
by a single infectious agent [1]. 
The current global approach for TB prevention and care is framed in the “End TB Strategy” 
which was endorsed by Member States of the World Health Assembly and adopted by the 
WHO in 2014. The “End TB Strategy” sets out an ambitious goal to end the global TB 
epidemic with the target of reaching a 90% reduction in the TB incidence rate by 2035 
compared to the rate in 2015 [3, 4]. In order to reach this target, there is need to improve our 
understanding of M. tuberculosis transmission dynamics in high prevalence settings. 
South Africa has one of the highest annual TB notification rates [5], driven predominantly by 
the HIV epidemic [5, 6]. Within South Africa, the KwaZulu-Natal province has one of the 
highest annual TB notification rates. Overall, the annual TB notification rates have been 
declining in since 2009, but remain above 500 per 100,000 population [7]. Furthermore, the 
decline is insufficient to reach the global TB targets to reduce incidence by 50% and 
mortality by 75% in 2025 compared to 2015 rates [3, 5]. In KwaZulu-Natal, the decline has 
been slower than other provinces [7]. To reach the global targets the current decline needs 
to be more than doubled by 2020 [3]. 
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1.2. Natural history of Mycobacterium tuberculosis infection 
The natural history of TB infection is classically divided into two distinct progressive stages; 
latent TB infection (LTBI) and TB disease. The WHO defines LTBI as: 
“…a state of persistent immune response to stimulation by Mycobacterium tuberculosis 
antigens with no evidence of clinically manifest active TB.” [2] 
An estimated 5-15% of recently infected individuals progress rapidly (within 2 years) to 
active TB disease [2]. Approximately 23% of the global population are latently infected [8]. 
Latently infected individuals do not manifest signs or symptoms of active disease and do not 
transmit the infection. Infants and individuals with HIV infection or other immunosuppressive 
conditions are at an elevated risk of progressing from TB infection to TB disease. On the 
other hand, individuals with active disease manifest signs or symptoms of TB disease 
(including cough, fever, night sweats and unexplained loss of weight) and can transmit 
infection [2]. 
1.3. Measuring Mycobacterium tuberculosis infection 
There is currently no gold standard diagnostic test for measuring M. tuberculosis infection. 
The two main methods widely used are tuberculin skin tests (TSTs) and interferon gamma 
release assays (IGRAs) [9, 10]. For close to a century, TSTs were the only diagnostic test 
for M. tuberculosis infection. TSTs involve the intradermal injection of standardised purified 
protein derivative (PPD) on the underside of the arm. This produces a delayed 
hypersensitivity reaction on the injected site in infected individuals. Diagnosis is made by 
measuring the size of induration at the injected site within 48-96 hours [10, 11]. The major 
limitations with TSTs is that they are prone to false positive results due to cross-reactivity 
with Bacillus Calmette-Guérin (BCG) vaccination, sensitization to other non-tuberculous 
mycobacteria (NTM) and the ‘booster’ effect due to repeat testing. False negative results 
also occur due to severe illness or immune suppression [11-13].  
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Since the early 2000s, several generations of IGRAs have been developed. IGRAs are 
whole blood tests for M. tuberculosis infection. They measure interferon-gamma (IFN-γ) 
release by T-cells following stimulation by antigens specific to M. tuberculosis infection. 
There are two main IGRAs available: the QuantiFERON-TB and the T-SPOT.TB (Oxford 
Immunotec, Abingdon, United Kingdom). The T-SPOT.TB is an enzyme-linked immunospot 
(ELISPOT) based assay. It measures M. tuberculosis infection by quantifying the number of 
peripheral mononuclear cells producing IFN-γ after stimulation with peptides from early 
secreted antigenic target 6 (ESAT-6) and culture filtrate protein 10 (CFP-10) antigens. On 
the other hand, the QuantiFERON-TB is an enzyme-linked immunosorbent assay (ELISA) 
based assay. It measures M. tuberculosis infection by quantifying the amount of IFN-γ 
produced following stimulation with antigens specific to M. tuberculosis infection [12, 14-16]. 
The latest generation of the QuantiFERON-TB, the QuantiFERON-TB Gold Plus (QFT-Plus) 
(QIAGEN, Hilden, Germany) uses four tubes: the mitogen tube which acts as a positive 
control for checking correct blood handling and incubation; the nil tube acts as a negative 
control i.e. to determine if an individual has a pre-existing immune response and two antigen 
tubes (TB1 and TB2). Both TB1 and TB2 tubes include peptides from ESAT-6 and CFP-10 
antigens. The peptides from the TB1 tube are designed to elicit responses from CD4 T-cells 
while the peptides from the TB2 tube are designed to elicit additional responses from CD8 T-
cells which is expected to improve the test’s sensitivity compared to the previous 
generations. Results are interpreted by comparing IFN-γ values (in international units per 
millilitre [IU/ml]) obtained from the nil tube to the IFN-γ values obtained from either of the 
antigen tubes [11, 12, 17-19].  
Both TSTs and IGRAs are indirect markers of M. tuberculosis exposure and do not 
discriminate latent M. tuberculosis infection from active TB disease. They also do not 
discriminate individuals who have infection from those who have cleared the infection. Both 
tests are affected by severe immune suppression [15]. The antigens used in IGRAs are not 
produced by the strains used in BCG vaccines and most NTMs [11, 19-21]. Thus, IGRAs are 
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considered to be more specific tests M. tuberculosis infection compared to TST. As ex vivo 
tests, IGRAs are not affected by the ‘booster’ effect due to repeat testing [11-13]. IGRAs 
have not been extensively used in low income settings due to the high cost of supplies and 
the requirement for extensive laboratory facilities to perform the test [11]. More details on 
interpreting results of TST surveys is given in Chapter 2, Section 2.2.2. 
1.4. Rationale for measuring Mycobacterium tuberculosis infection among 
adolescents 
The WHO defines adolescents as individuals aged 10-19 years [22]. Individuals aged 10-14 
years are referred to as young adolescents while 15-19-year olds are referred to as older 
adolescents. Adolescence is a period of rapid biological, psychological and social transitions 
[23]. It is a period where individuals learn behaviours that will last their lifetime. Because of 
their uniqueness adolescents require specific attention in terms of policy and service 
delivery. However, for a long-time little consideration has been given as adolescents are 
usually categorised as either children (≤15 years) or adults (≥15 years) [22-24].  
Targeting adolescents is critical in order to have a future TB free generation as adolescents 
form the reservoir for future cases [22] as such adolescents are the target group for 
prevention of infection (POI) TB vaccines [25-28]. However, little is known about the 
prevalence and incidence of M. tuberculosis infection among adolescents in many settings. 
Data on M. tuberculosis infection largely comes from TST surveys among young 
children(<10 years)  [29]. M. tuberculosis infection in young children acts as a marker of 
recent transmission from infectious individuals with TB disease [30]. Thus, M. tuberculosis 
infection among young children has been used to make inferences about transmission in the 
wider population. However, compared to adolescents and adults, young children are more 
likely to be infected within the household [10, 31, 32]. Though household contacts of 
individuals with TB disease remain at increased risk of infection due to close contact, both 
epidemiologic and molecular studies have shown that household transmission accounts for 
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only between 8-20% of all transmissions [33-36]. This suggests that majority of 
transmissions are likely to occur in the wider population. 
Adolescence is period where individuals undergo rapid changes in their social contact 
patterns with increased social contacts in the general community. This increases the 
potential of coming in contact more sources of M. tuberculosis infection [37, 38]. This 
suggests that understanding M. tuberculosis infection among adolescents has potential for a 
better understanding of the dynamics of M. tuberculosis transmission in the wider population. 
1.5. Aims and objectives 
The aim of this thesis is to describe the prevalence of and risk factors for tuberculosis 
infection among adolescents in a rural South African district with high TB and HIV 
prevalence. This thesis is based on a study which was originally designed to measure M. 
tuberculosis infection incidence among adolescents, but to date only the baseline survey has 
been completed, for operational reasons. This thesis reports on findings from the baseline 
survey. 
The specific objectives are: 
1. To estimate the prevalence of M. tuberculosis infection among adolescents. 
2. To describe risk factors for M. tuberculosis infection among adolescents 
3. To explore geospatial distribution of M. tuberculosis infection prevalence among 
adolescents. 
1.6. Thesis outline 
In chapter 1, I describe briefly the current state of the global TB epidemic with an overview 
for the current state in South Africa. I further describe the natural history of TB infection, how 
M. tuberculosis infection is measured and provide the rationale for understanding infection in 
adolescents. Finally, I outline the aim and objectives of this thesis. 
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In chapter 2, I review the published literature on the prevalence, risk factors and spatial 
distribution of M. tuberculosis infection prevalence among adolescents in sub-Saharan 
Africa.  
In chapter 3, I provide a detailed description of the study setting and the methodologies for 
the design and procedures of the cross-sectional study investigating M. tuberculosis 
infection among adolescents. 
The main results from the study pertaining to the characteristics of the study participants, the 
distribution of the main outcome and the description of the geospatial distribution of M. 
tuberculosis infection are presented in chapter 4. In chapter 5, I present the results for the 
prevalence and risk factors for M. tuberculosis infection.  
In chapter 6, I summarize the main findings and discuss the implications on M. tuberculosis 








The aim of this chapter is to provide an overview of the prevalence, risk factors and spatial 
distribution of M. tuberculosis infection among adolescents (10-19 years) in sub-Saharan 
Africa.  
2.2. Methods 
2.2.1. Search strategy 
Two systematic literature searches were conducted in the MEDLINE (Medical Literature 
Analysis and Retrieval System Online), EMBASE and Global Health databases. The first 
search for prevalence and risk factors for M. tuberculosis infection among adolescents in 
sub-Saharan Africa included the following terms: adolescent, latent tuberculosis infection, 
prevalence and sub-Saharan Africa. The second search for spatial distribution of M. 
tuberculosis infection among adolescents included the terms: sub-Saharan Africa, latent 
tuberculosis infection and spatial distribution. The terms were adapted for each database. 
The list of synonyms for each search term and how the searches were performed in the 
MEDLINE database is shown in Table 2-1. References of the articles included in the review 
were reviewed for additional articles which might have been missed in the search. 
2.2.2. Study selection 
Research articles were included in the review if they met the following criteria: published in 
English, reporting a study conducted in any sub-Saharan Africa country, reported M. 
tuberculosis infection among adolescents (10-19 years) or any part of this age group, 
population based and conducted after January 2000 as this was the time when antiretroviral 
therapy (ART) become available in sub-Saharan Africa after the resurgence of TB incidence 
due to the HIV epidemic in the mid-1990s [39].  
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Table 2- 1: Literature search terms as performed in the MEDLINE database 
Search 1 for M. Tuberculosis infection prevalence among adolescents in Sub-Saharan Africa: 1 AND 2 AND 3 AND 4 
Search 2 for spatial distribution of M. tuberculosis infection in Sub-Saharan Africa: 1 AND 3 AND 5 
Tuberculosis infection (1) Adolescent (2) Sub-Saharan Africa (3) Prevalence (4) Geospatial (5) 
(Tuberculosis infection OR TB 
infection OR Latent tuberculosis 
infection OR Latent TB infection OR 
((Latent*) adj3 (infect*)) OR 
Mycobacterium adj3 infect* OR 
((Mycobacterium tuberculosis) adj3 
(infection)) OR ((Latent*) adj3 
(mycobacterium tuberculosis)) OR 





exp tuberculin test/ or exp latent 
tuberculosis/  
(Adolescent* OR child OR 
Children OR Teenage* 
OR School going children 
OR school going child OR 
School going OR Youth* 
OR Young adult OR 
Pubescent OR Juvenile 
OR Underage OR Young 






(South* Africa* OR Africa OR 
sub-Sahara* OR Africa OR sub-
Sahara* Africa OR Malawi* OR 
Botswana OR Namibia OR 
Swaziland OR Lesotho OR 
Mozambique OR Zambia OR 
Zimbabwe OR Tanzania OR 
Rwanda OR Uganda OR Kenya 
OR Gambia OR Ethiopia OR 
Sudan OR Angola OR Congo 
OR Madagascar OR Chad OR 




exp "Africa south of the Sahara"/ 
(Prevalen* OR Risk OR 
Annual risk OR annual 
risk of infection OR risk 
factor* OR Predictive 
factor) 
(Geospatial OR Spatial 
OR Spatial patterns 
OR Cluster* OR 
spatial Distribution OR 
Map OR Mapping OR 
mapped OR Hotspot) 
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2.2.3. Data extraction 
Standard data extracted included: author, year the study was conducted, country (province 
or city), participants (number included in analysis and selection method), method of testing 
TB infection, risk factors for and estimates of M. tuberculosis infection prevalence. For the 
geospatial review, the spatial method used, and key results were extracted. 
2.3. Results 
2.3.1. Study selection 
For the M. tuberculosis infection prevalence review, a total of 947 records were retrieved. 
After removing duplicates and titles reporting other diseases or other NTMs, 538 titles and 
abstracts were screened for reporting M. tuberculosis infection among adolescents in sub-
Saharan Africa and 17 articles were included in the review (Figure 2-1). 521 articles were 
excluded for not including individuals aged 10-19 years, reporting TB disease, reporting 
studies not conducted in sub-Saharan Africa or not population based. The review of 
references of the 17 articles did not yield additional articles. 
For the M. tuberculosis infection spatial distribution searches, 194 records were retrieved. 
Eighteen titles and abstracts were screened for reporting spatial distribution of M. 
tuberculosis infection at population level in sub-Saharan Africa after removing duplicates and 
titles reporting other diseases, other non-mycobacteria infections or not reporting spatial 
distribution of the participants (Figure 2-2). Fifteen articles were excluded for either reporting 
geospatial distribution of TB disease or genomic mapping. Three articles remained and were 
included in the review. Due to the small number of articles included in the review, relevant 
articles reporting spatial distribution of TB disease at the population level were selected from 
the retrieved articles mentioned above to highlight the factors associated with spatial 




Figure 2- 1: Flow diagram for the screening process of studies reporting the prevalence of 
Mycobacterium tuberculosis infection among adolescents in sub-Saharan Africa 
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Titles and abstracts screened for reporting 
TB infection among adolescents 
(n = 538) 
Articles excluded (n = 68) 
- Reporting other diseases or 
non-tuberculous bacterial 
infections. 
Articles excluded (n = 521) 
- Not including 10-19-year olds 
- Reporting TB disease 
- Not in sub-Saharan Africa 
- Not representative of the 
general population  
Studies included in the 
review  
(n = 17) 
Duplicate Records 
excluded (n = 286) 
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Figure 2- 2: Flow diagram for the screening process of studies reporting the spatial 
distribution of Mycobacterium tuberculosis infection in Sub-Saharan Africa. 
 
2.3.2. Studies reporting the prevalence of Mycobacterium tuberculosis infection 
Studies reporting the prevalence of and risk factors for M. tuberculosis infection among 
adolescents in sub-Saharan Africa are summarised in Table 2-2. The definitions for M. 
tuberculosis infection (cut-offs) used and the method for determining prevalence are also 
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spatial distribution (n = 80) 
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- Reporting spatial distribution for TB 
disease. 




presented. The tuberculin skin test (TST) was the most commonly used test. The previous 
generation of the QuantiFERON-TB, the QuantiFERON TB Gold in tube (QFT-GIT) test was 
used alongside the TST in three studies; two studies were conducted in Western Cape, 
South Africa [40, 41] and one study was conducted among individuals aged ≥18 years in 
South Omo Zone, Ethiopia [42]. 
Of the 17 studies, nine were conducted in South Africa, and the other studies were 
conducted among school-going children in The Central African Republic, The Gambia, 
Ghana, Kenya, Tanzania Uganda and Zambia. Two studies were conducted among adults 
(≥18 years) in Ethiopia. Among the studies conducted in South Africa, eight were conducted 
in communities in the Western Cape province and one was conducted in the Gauteng 
province. For the studies conducted in South Africa, a TST induration ≥10 mm for HIV 
negative participants and TST induration ≥5 mm for HIV positive participants was used. For 
the studies in the other sub-Saharan countries other than South Africa, several cut-offs were 
used including TST induration ≥10 mm, TST ≥15 mm and TST≥17 mm for HIV negative 
participants and ≥5 mm for HIV positive participants. In addition, mirror and mixture methods 
were used to determine M. tuberculosis infection prevalence. The mirror method assumes 
that the distribution of indurations among individuals with M. tuberculosis infection is 
symmetrical. The number of participants with M. tuberculosis infection is calculated as the 
number of participants with indurations at the mode plus twice number of participants with 
indurations bigger than the mode [43, 44]. The fixed mirror method assumes that the 
indurations due to cross-reactivity with BCG vaccination or NTMs do not reach 17 mm. 
Therefore, the mode is fixed at 17 mm and the number of participants with M. tuberculosis 
infection is calculated in the same way as the mirror method but fixing the mode at 17 mm 
regardless of the mode obtained from the fitted data [45, 46]. The mixture method uses 
advanced statistical modelling to estimate the proportion of participants with indurations due 
to M. tuberculosis infection by fitting separate component models representing participants 
with indurations due to BCG vaccination, NTMs and M. tuberculosis infection.[47-50] The 
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frequency distributions for non-zero indurations for participants in the studies not conducted 
in South Africa were bimodal with peaks between 6-8 mm [51, 52] and 12-17 mm [53], thus 
suggesting cross-reactivity with NTMs as distributions due to M. tuberculosis infection 
constitute a fairly symmetrical distribution [29, 43, 54]. On the other hand, the frequency 
distributions for non-zero induration for participants in studies conducted in South Africa 
were relatively symmetrical with peaks between 12-17 mm [40, 52, 55, 56] suggesting little 
cross-reactivity with NTMs, warranting the use of lower TST cut offs (TST induration ≥10 
mm). 
2.3.3. Description of studies reporting spatial distribution of M. tuberculosis infection 
The database search retrieved three studies reporting spatial distribution of M. tuberculosis 
and these are shown in Table 2-3. Two of these studies were conducted in a densely 
populated township in the Western Cape province, South Africa [57, 58] and one was 
conducted within a well-defined demographic surveillance area (DSA) in a rural district in 
northern Malawi [59]. The studies in the Western Cape investigated the effect of residential 
plot exposure to notified TB disease on M. tuberculosis infection among children and 
adolescents aged 5-17 years. To do this, the authors (Middelkoop et al) conducted a TST 
survey among school-going individuals aged 5–17 years in 2007. Participants were geo-
located to their residential plot (about 180 m2) within the study area. Records of TB patients 
notified between 1997-2007 in the same area were checked and the TB patients were also 
geo-located to their residential plots basing on the addresses obtained from the hospital 
records [57]. Then the authors produced maps showing residential plots of participants with 
TST positive results and the notified TB patients. The authors repeated the procedure in 
2009 using a TST survey among school-going adolescents and children aged 5–22 years 
and notified TB patients between 1997–2009 in the same study area [58]. 
In the study in rural northern Malawi, Khan et al. estimated the community TB exposure for 
every child (2–4-year olds) enrolled in a TST survey conducted in a well-defined DSA. The 
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community TB exposure was estimated as the average annual TB notification for each 
geographically defined area (consisting of about 450 households) within the DSA. The TB 
patients (≥15 years) were identified between 2007–2012 (the lifetime of the children enrolled 
in the TST survey) from a long-term enhanced case finding cohort of all TB patients in 
Karonga district [60]. The authors also investigated the effect of distance from each child’s 
household to the nearest known smear-positive TB patient during the child’s life on the risk 
of M. tuberculosis infection [59]. 
The limitation with these studies is that classical spatial tools like spatial scanning which help 
identify areas within the population which have a higher number of cases than expected [61-
63] were not used. Classic statistical methods (like logistic regression) were used instead to 
investigate associations between household and community exposure to TB and M. 
tuberculosis infection prevalence. Furthermore, Middelkoop et al. defined residential 
exposure to TB using notified TB patients over a 10-year period. This approach assumes 
that the notified TB patients and the adolescents and children lived on the same residential 
plot at the same time and that the risk of M. tuberculosis transmission for that residential plot 
was the same during the entire period including the time the TST surveys were conducted. 
However, this may not be the case as individuals are bound to migrate over time.  
2.3.4. Description of studies reporting spatial distribution of TB disease 
A separate systematic literature search to identify studies reporting spatial distribution of TB 
disease in sub-Saharan Africa was not carried out. Relevant titles reporting population based 
spatial distribution of TB disease using classical spatial methods from the search described 
above were selected and are summarised in Table 2-4. Among these, three studies were 
conducted in two zones in the South Eastern province, Ethiopia [64-66], two were conducted 
in the KwaZulu-Natal province, South Africa [67, 68] and one was conducted in 
Antananarivo, Madagascar [69]. In all these studies, spatial scanning methods were used to 
identify clustering (locations within the population that have more than expected number of 
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TB cases basing on the underlying population density), size of clusters and the relative risk 
of TB disease in the clusters. Smith et al. investigated spatial distribution of drug resistant TB 
(DR-TB) in rural KwaZulu-Natal. The studies from Ethiopia and Madagascar used notified 
patients from clinic records, while Smith et al. used records of patients admitted at a district 
hospital to identify DR-TB patients and geolocating them to their household within a well-
defined DSA. Tomita et al. used self-reported TB diagnosis from adults (≥15 years) in the 
same well-defined DSA. 
While Smith et al. (in KwaZulu-Natal) and Rakotosamimanana et al. (in Madagascar) 
investigated clustering of DR-TB and notified TB disease respectively at a single point in 
time while Dangiso et al., Tomita et al. and Tadesse et al. investigated temporal changes in 
the spatial distribution and clustering of TB disease between 2003-2013, 2009-2015 and 
2007-2016 respectively. 
The major limitation with these studies is that they relied on TB patients either identified from 
hospital records or participants self-reporting TB diagnosis in the previous year (Tomita et 
al.). Self-reported TB has not been verified and may not be a robust measure of TB disease. 
In addition, the participation rates for the yearly individual health survey which captures self-
reported TB diagnosis in the DSA was below 50%, thus selection bias might have been 
introduced. For the studies relying on hospital records accuracy and completeness of the 
records would be the major issue as in most poor resource settings, hospital records are not 
verified in the same way as research or clinical trial databases [70]. This would make 
linkages to residential address difficult. Selection bias would be introduced if participants 




Table 2- 2: Studies reporting prevalence of Mycobacterium tuberculosis infection among adolescents in sub-Saharan Africa 
Author, year of 
study, Country 
(Province/city) 
Participants (N), method of 
selection 
Definition of TB 
Infection 
Prevalence of TB 
infection (%) 
Risk factors Comments 
Den Boon et al., 
2001, SA, WC 
province [71] 
− Randomly selected 
general population 
children aged 0-14 years 
(n=1344, [439 were aged 
10-14]) 
− TST induration 
≥10mm 
− 32.1 − Passive HH Smoking: OR: 1.35 
(95% CI: 0.86–2.12) 
− Monthly income: ≥R2000 vs 
<R500, OR: 0.47 (95% CI: 0.28–
0.77) 
− History of HH TB contact: OR, 2.01 
(95% CI:1.46–2.77) 
− Prevalence among 10-14-year 
olds was 44%. 
− In a sensitivity analysis 
restricted to HHs where there 
was a TB patient passive 
smoking was significant (OR: 
4.6 [95% CI: 1.3-16.5]) 
Egwaga et al., 
2001-03, Tanzania 
[72] 
− Nation TST survey of 
school-going children aged 
6-14 years (N=96,228). 
− Estimates were obtained 
using children without 
BCG scars (N=10,239) 
− Cluster sampling of 
schools in each district 
was conducted.  
− Mirror method at 
≥17 mm 
− 6.1 (for BCG 
scar negative 
participants) 
− Not specified 
− Participants with visible BCG 
scars: 88.8% 
− TB notification for Tanzania in 
2002 180/100,000. 
− The authors obtained estimates 
using participants without BCG 
vaccination to overcome effect 
of cross-reactivity with BCG 
vaccination. 
Elias et al, 2003, 
Ethiopia [73] 
− Cross-sectional study in a 
rural community in Dendi 
district, Ethiopia.  
− Information about the 
study was given to the 
community and individuals 
were invited to be enrolled 
at a health facility within 
the study area. 
− 2,640 individuals (aged 
13-54 years) were 
included in the study. 
− TST induration 
≥10 mm 
− 29.7% for all the 
participants (13-
54-year olds) 
− Age: aOR: 1.4 (1.3–1.6) for every 
10-year increase. 
− Male sex: aOR: 1.2 (1.01–1.5) 
− History of household TB contact: 
1.8 (1.3–2.3). 
− Low SES: 1.5 (1.12–2.03) 
− Post high school education: aOR: 
1.5 (1.12–2.03). 
− Annual TB notification for 
Ethiopia in 2013 was 230 per 
100,000 population. 
− 8.3% reported history of 
household TB contact. 
− Selection bias as the study 
recruited only those who could 
come to the recruitment point. 
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Author, year of 
study, Country 
(Province/city) 
Participants (N), method of 
selection 
Definition of TB 
Infection 
Prevalence of TB 
infection (%) 
Risk factors Comments 
Den Boon et al., 
2003, SA, WC 
province [74] 
− Randomly selected adults 
≥15 years) (N=2,401) 
− TST ≥10 mm 
− 76% for all ages 
≥15 years 
− 66% for 15-24-
year olds. 
− Smoking (ever smoked for one 
year):  OR, 2.0 [95% CI: 1.6-2.5] 
− New smear positive TB 
notification for the study area in 
1998: 238 per 100,000 
population.  
− No information on BCG 
vaccination or HIV status of 
participants was provided. 
− HIV prevalence for the study 
area in 2002: 12.4% 
Addo et al., 2004-
6, Ghana [75] 
− Nation-wide TST survey 
children 6-10 years 
(N=21,861) 
− TST ≥15 mm − 5.4  − Not specified  
− Participants with visible BCG 
scars: 89.3% 
Kwamanga et al., 
2004-7, Kenya [53] 
− National survey of primary 
school children without 
visible BCG scars aged 6-
14 years (N=12,107). 
− TST ≥17 mm 
− 10.2% (95%CI: 
7.2–13.1). 
− Not specified 
− Participants with visible BCG 
scars: 84.0%. 
− Annual TB notifications for 
Kenya in 2006: 329 per 
100,000population. 
Shanube et al.,  
2005, Zambia and 
SA, WC province 
[52] 
− TST surveys among 
school-going children aged 
6-11 years from Zambian 
and South African 
communities (N=8,776) 





− Zambia: 16.5 
(95% CI: 12.0–
21.1) 
− South Africa: 
30.5 (95% CI: 
22.9-38.2) 
− Age: 20% among 6-year olds vs 
40% among 11-year olds. 
− 85% had visible BCG scars. 
− Prevalence by presence of 
BCG scar: 31.0 (95% CI: 22.8–
39.2) vs 27.8 (95% CI: 11.0–
44.7). wider difference in 6-year 
olds 
Mahomed et al., 
2005-7, SA, WC 
province [40, 76] 
− All adolescents (12-18 
years) attending high 
school in a densely 
populated township 
(N=5,244) 
− TST induration: 
≥5mm,  
≥10mm,  
≥15mm and  
− QFT-GIT (≥0.35 
IU/ml) 
− 55.2 (53.8-56.5)  
− 42.2 (40.9-43.6) 
− 18.7 (17.7-19.8) 
− 50.9 (49.5-52.2) 
respectively for 
the different TST 
cut offs and 
QFT-GIT. 
− Age: 15-18 vs 12-14, OR: 1.4 (1.2–
1.5) 
− No difference by sex: male vs 
female sex OR: 1.2 (1.0–1.3) 
− Low monthly income: OR: 1.6 (1.3–
1.9) 
− Chronic allergy-related conditions, 
OR: 0.4 (0.2–0.9) 
− Current or prior HH TB contact: 
OR: 1.9 (1.7–2.2) 
− ORs are based on QFT results 
− HIV testing was not done, but 
the area had a lower HIV 
prevalence compared to the 
national prevalence i.e. 5-10% 
vs 30% among pregnant 
women 
− All TB notifications for the study 
area in 2004: 1400 per 100,000 
population 
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Author, year of 
study, Country 
(Province/city) 
Participants (N), method of 
selection 
Definition of TB 
Infection 
Prevalence of TB 
infection (%) 
Risk factors Comments 
Wood et al., 2006, 
SA, WC province 
[56] 
− School-going children (5-
17 years)  in a densely 
populated township 
(N=832) 
− TST ≥10 mm 
− 36.0% among 
10-16-year olds. 
− Older age: 28.0% among 10-11-
year olds vs 41.7 among 11-15-
year olds. 
− All TB notifications for the study 
area in 2006: 1,500 per 
100,000 population. 
− The estimate including adults 
(10-40 years) was 45.0%, but 
these were enrolled from an 
HIV testing facility.  
Middelkoop et al.,  
2006-2007, SA 
WC province [77] 
− School-going children 
aged 5-17 years (N=831) 
− TST ≥10 mm 
and 
− TST ≥17 mm 
− 37.4 at ≥10 mm  
− 20.6 at ≥17 mm 
− Age (26.2% for 5-8-year-olds vs 
52.5% for 14-17-year-olds) 
− Annual TB notifications for the 
area changed from 942-
2,140/100,000 between 1999-
2006 
Middelkoop et al.,  
2009, SA WC 
province [78] 
− Randomly selected 
adolescents and young 
people (13-22 year) 
attending secondary 
school in a township 
(N=620) 
− TST ≥10 mm − 53.9 
− Age 47.8% among 13-16-year olds 
vs 63.2% among 19-22-year olds. 
− BCG scar 20% 
− 34 (5.6%) HIV positive 
participants were excluded from 
the analyses. In a sensitivity 
analysis there was weak 
evidence of an association 
between M. tuberculosis and 
HIV infection: (OR = 0.53; 95% 
CI: 0.27-1.05; p = 0.07). 
Mumpe-Mwanja et 
al., 2009-11, 
Uganda [51, 79] 
− Randomly selected 
adolescents (aged 12-18 
years) from a DSA 
(N=4,981) 
− TST ≥10 mm if 
HIV negative (or 
TST ≥5 mm if 
HIV positive) 
− 16.1 (15.1-17.2) 
− Age (15-16 years vs 12-14 years), 
aOR: 1.25 (1.07-1.46) 
− Age (17-18 years vs 12-14 years). 
aOR: 1.46 (1.24-1.71) 
− BCG Scar, aOR: 1.29 (1.12-1.48) 
− Male sex, aOR: 1.37 (1.21-1.56) 
− Not attending school, aOR: 1.31 
(1.05-1.62) 
− HH TB contact, aOR: 1.91 (1.55-
2.35)  
− 6 (0.12%) participants were HIV 
positive. 
Adetifa et al., 
2011, The Gambia  
[80] 
− Nation-wide TST survey of 
school going children (6-
11 years) from randomly 
selected schools 
(N=13,386) 
− TST ≥10 mm,  
− mixture method 
− 11.5 for TST 
≥10 mm  
− 6.9 for Mixture 
− Age (10 vs 6 years), aOR: 2.01 
(1.24–3.42) 
− Age (11 vs 6 years). aOR: 1.98 
(1.19–3.31) 
− BCG scar 72.8% 
− No SES information 
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Author, year of 
study, Country 
(Province/city) 
Participants (N), method of 
selection 
Definition of TB 
Infection 
Prevalence of TB 
infection (%) 
Risk factors Comments 
Minime-Lingoupou 
et al., 2011, CAR 
[81]  
− School-going children 
aged 6-12 years selected 
from cluster sampling of 
school from Bangui and 
Ombella-M’Poko regions. 
(n=2,710) 
− TST≥5 mm 
− TST≥10 mm 
− TST≥15 mm 
− 23 (23.6-25.3) 
− 18.4 (16.8-20.1) 
− 8.9 (7.8-10.0) 
− The odds of infection were not 
different at TST induration ≥5 mm 
and ≥10 mm but were lower at ≥15 
mm (crude OR: 0.7 [0.5–1.0]) 
− BCG scars: 65.9% and was 
similar for the two regions. 
− Reported BCG vaccination: 
83.8% was higher in Bangui 
(Urban) region. 
− Significant digit preference was 
observed at 10 mm and 15 mm. 
Mirror or mixture methods 
should have been used to 
estimate prevalence. 
− Annual TB notification for 
Bangui and Ombella-M’Poko 
regions in 2011 were 284 and 
134 per 100,000 population 
respectively. 




− Randomly selected 
individuals of all ages from 
a densely populated 
community (N=446) 
− TST≥5 mm if 
HIV+ or TST≥10 
mm if unknown 
or HIV negative 
− 34.3 (30.0-38.8) − Age: 18.8% (0-14-year olds) vs 
45.2% (≥45-year olds) 
− Male sex: OR, 2.70 (1.55–4.70) 
− HIV: OR, 0.85 (0.49–1.46) 
− HH TB contact: 2.27 (0.76–6.82) 
− High HH SES: 2.11 (1.04–4.31) 
− Population density of the study 
area: 11,357 per km2 
− 18% of the participants were 
HIV positive 
Bunyasi et al. 
2014-15, Western 
Cape, South Africa 
[41] 
− Adolescents (12-18 years) 
attending state schools 
screened for a TB vaccine 
trial (n=1,968) 
− QFT-GIT (≥0.35 
IU/ml) 
− 48.5 ( 41.1–
55.8) 
− Combined the sample of 
adolescents enrolled in 2005 in the 
same school to determine 
associations with M. tuberculosis 
infection. The associations may not 
reflect the 2015 cohort. 
− TB notifications for the area in 
2014: 710 per 100,000 
population. This was lower than 
in 2015 when the authors 
conducted another survey 
among school-going children in 
the same area, but M. 
tuberculosis infection 
prevalence had slightly 
increased. 
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Author, year of 
study, Country 
(Province/city) 
Participants (N), method of 
selection 
Definition of TB 
Infection 
Prevalence of TB 
infection (%) 
Risk factors Comments 
Teklu et al. 2015-
16, Ethiopia [42] 
− Cross sectional study of 
adults (>18 years) in six 
districts in South Omo 
Zone, Ethiopia (n=497). 
− Sample size for each 
district was determined 
proportion to its size. 
Simple random sampling 
was used to select 
households. 
− Selected houses were 
visited, and participants 
were selected among 
those present during the 
visit.  
− QFT-GIT (≥0.35 
IU/ml) 
− 50.5 (46.00-
55.00) for all the 
participants 
− Residing in a district with very low 
TB detection rate (14.3%): aOR: 
2.89, [ 1.09-7.66] 
− There was no difference by 
age, sex or history of household 
TB contact. 
− Prevalence was lower among 
individuals from households 
with  more than five residents 
compared households with less 
than five residents, aOR: 0.65, [ 
0.42-0.99]. 
− Selection bias might have been 
introduced as only individuals 
present during the home visit 
were enrolled.  
aOR: adjusted odds ratio; ARI: annual risk of infection; BCG: Bacillus Calmette-Guérin; CAR: Central African Republic, DSA: demographic surveillance area; 
HH: household; HIV: human immunodeficiency virus; NS: not specified; OR: odd ratio; QFT-GIT: QuantiFERON gold in tube test; SA: South Africa; SES: 
socioeconomic status; TB: Tuberculosis; TST: tuberculin skin test; WC: Western Cape   
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Table 2- 3: Studies reporting spatial distribution of Mycobacterium tuberculosis infection among adolescents in sub-Saharan Africa 
Author, Year of 
study, Country 
(Province/City) 
Participants (N) Geospatial methods used Results Comments 
Middelkoop et al., 
2007, South Africa 
(Western Cape) 
[57]  
− TST survey among 
school-going children 
aged 5-17 years in a 
township (n=640) 
− Adults (≥15 years) 
notified with TB 
between 1997-2007 
(n=1,212). These were 
extracted from clinic 
records and 
geolocated to their 
residential plot. 
− Produced maps showing locations of 
residential plots of participants with TST 
positive results and adults notified with 
TB for the period 1997-2007. 
− The aim was to compare risk of M. 
tuberculosis infection between 
residential plots that have a history of 
exposure to TB disease and those 
without exposure. 
− TST positivity was higher among 
participants living on residential plots 
with a history of a notified adult TB 
cases (65% vs 51%, p=0.001). 
− In a separate analysis, the authors 
restricted residential TB exposure to the 
last 12 months only (unlike the whole 
10-year period). This showed that 
participants with residential plot 
exposure to TB were more likely to be 
TST positive if the notified TB patient 
was smear positive, but there was no 
difference if the notified adult with TB 
was smear negative. 
− Since exposure to TB was 
defined for the whole 10-year 
period and TST prevalence 
was only measured in the 
10th year, the participant and 
the adult TB patient may not 
have lived at the residential 
plot at the same time.  
− The lack of association if the 
notified TB patient was 
smear negative suggests the 
reduced infectiousness of the 
smear negative TB patients. 
Middelkoop et al., 
2009, South Africa 
(Western Cape) 
[58] 
− TST survey among 
school-going children 
and adolescents aged 
5-22 years (n=1,100) 
− Adult (≥15 years) 
notified TB cases 
between 1997-2009 
(n=1,604). 
− [same area as the 
above study, but with 
an addition of older 
participants] 
− Maps for spatial distribution of  TST 
positive school-going children and 
whether there was an adult notified with 
TB on the same residential plot. 
− Residential TB exposure was defined as 
living on a residential plot with the same 
address as a notified TB patient. 
− Comparisons were made by age group 
(<15 vs ≥15years) 
− Overall, M. tuberculosis prevalence was 
higher among adolescents and children 
living on the same residential plot as an 
adult with notified TB disease whether 
any type of TB (OR: 1.6 [95% CI: 1.2-
2.0]) or smear positive pulmonary TB 
(OR: 1.9 [95% CI: 1.4-2.4]). 
− M. tuberculosis infection was associated 
with residential plot exposure to TB for 
5-9 and 10-14-year olds (OR: 2.0 [95% 
CI: 1.1-3.6] and OR: 1.5 [95% CI: 1.0-
2.3] respectively), but not for ≥15-year 
olds (OR: 1.4 [95% CI: 0.9-2.0]) 
−  
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Author, Year of 
study, Country 
(Province/City) 
Participants (N) Geospatial methods used Results Comments 
Khan et al., 2012, 
Malawi (Karonga) 
[59] 
− TST survey among 
children aged 2-4 
years in a well-defined 
DSA (n=3,170) 
− Adults (≥15 years) 
smear positive 
pulmonary TB patients 
resident in the DSA 
diagnosed between 
2007-2012 (n=108). 
− The DSA is divided into geographically 
defined areas with about 450 
households and the average annual TB 
notification was calculated for each area 
(community TB exposure). 
− Distance to the nearest known smear 
positive TB patient was calculated using 
the GPS coordinates of the TST 
children and smear positive TB patients. 
− Compared M. tuberculosis infection 
prevalence with distance to the nearest 
known adult smear positive TB case, 
population density and community 
exposure to smear positive TB. 
− M. tuberculosis infection in children (2-4 
years) was associated with: 
i) Decreasing distance to the nearest 
known adult smear positive TB case 
(aOR for trend: 1.6 ([95% CI: 1.1-2.4], 
p=0.03) and  
ii) Increased community exposure to SP 
TB (aOR: 2.2 ([95% CI: 1.1-4.6], 
p=0.03) (>30 vs ≤30 cases per 100,000 
population) 
− There was no difference by 
population density (aOR: 1.0 
[95% CI: 0.5-2.1] for 250-
1000 vs <250 residents per 
km2 and 0.8 [95% CI: 0.3-2.0]  
for >1000 vs <250 residents 
per km2, p=0.81) 
aOR: adjusted odds ratio; CI: confidence interval; PTB: pulmonary tuberculosis; OR: odds ratio; SA: South Africa; SP: smear positive; TB: Tuberculosis; TST: 
tuberculin skin test  
38 
Table 2- 4: Studies reporting spatial distribution of tuberculosis disease in sub-Saharan Africa 




Participants (N) Geospatial methods used Results 
Rakotosamimanana 
et al., 2010-11 [69] 
Madagascar 
(Antananarivo) 
− Notified TB cases 
captured from TB 
registers 
(n=4,620) 
− Used spatial methods to identify 
clustering of newly diagnosed TB 
patients  
− Two clusters of newly diagnosed TB patients were identified 
in densely populated townships within the city with RR=1.7 
and 1.6 respectively. 





− Notified TB cases 
over a 10-year 
period captured 
from TB registers 
(n=22,545) 
− Spatial scanning methods (Global 
Moran’s I and Getis-Ordi 
− statistics) were used to identify 
clustering of notified TB cases and 
temporal changes in clustering. 
− Clusters of smear positive pulmonary TB (RR=2.0, p<0.001) 
were identified in urban, peri-urban and densely populated 
rural areas on the north western part of the study area. 
− The clusters were stable over the study period with smaller 
clusters appearing on the south eastern part towards the end 
of the study period. 











− Compared the spatial distribution of 
DR-TB cases and patients admitted 
for other reasons. 
− Used spatial scanning methods to 
identify clustering of DR-TB patients 
in defined DSA population. 
− A cluster with RR 2.5, p=0.057 was identified in a township 
with high HIV prevalence. The cluster contributed 55/111 
(49.5%) of the DR-TB patients in the geographically defined 
DSA population. 






diagnosis as part 
of surveillance at 
the AHRI DSA. 
− Spatial scanning tools were used to 
identify the temporal distribution and 
clustering of self-reported notified TB 
cases. 
− Compared the distribution of TB 
patients with the distribution of ART 
coverage for the area. 
− Spatial clusters (radius between 1.7-2.9 km and RR between 
1.3-1.9) were identified in urban and peri-urban communities 
of the study area which are close to the national highway and 
are characterised with high HIV prevalence. The clusters in 
this area persisted throughout the duration of the study 
period. 
− A smaller persisting cluster was also identified north of the 
densely populated township along a main road with radius 
between 0.27-1.00 km and RR between 2.1-10.1 
− Increase in community ART coverage was associated with 
decreasing odds of self-reported TB diagnosis (aOR: 0.98, 
95% CI:0.97–0.99). . 





− Notified TB cases 
between 2007-
2016 captured 
from TB registers 
(n=15,805) 
− Spatial scanning methods (Global 
Moran’s I, Getis-Ordi and Kulldorff’s 
scan statistics) were used to identify 
clustering of notified TB cases and 
temporal changes in clustering. 
− A cluster of radius 4.45 km with RR=4.16, p<0.01 was 
identified in an area characterised with frequent travel with 
zones in surrounding areas. 
− In each year significant clustering on was observed and the 
cases were clustered on the border areas of the zone. 
AHRI: Africa health research institute; ART: antiretroviral therapy; DSA: demographic area site; DR: drug resistant; KZN: KwaZulu-Natal; PTB: pulmonary 
tuberculosis; RR: relative risk; SE: south eastern; SM: smear positive; TB: Tuberculosis; TST: tuberculin skin test  
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2.3.5. Estimates of prevalence of Mycobacterium tuberculosis infection 
Overall, estimates of M. tuberculosis infection prevalence in studies conducted in South Africa 
ranged from 32.0% among individuals aged 0-14 years to 66.0% among individuals aged 15-24 
years (using TST induration ≥10 mm). Among the studies conducted among school-going children 
and adolescent in countries other than South Africa, the prevalence ranged from 5.4% (using TST 
induration ≥15 mm) among individuals aged 6-10 years in Ghana to 18.4% (using TST induration 
≥10 mm) among individuals aged 6-12 years in Central African Republic (Table 2-2). However, the 
frequency distribution for the participants in the Central African Republic study showed substantial 
digit preference at 10 mm. The prevalence obtained using TST induration ≥15 mm was 8.9%. The 
M. tuberculosis infection prevalence among individuals aged 13-54 years and ≥18 years in Ethiopian 
communities was 29.7% and 50.5% respectively (Table 2-2).  
A plausible explanation for the higher prevalence in the South African studies could be due to 
increased exposure to potentially infectious individuals as reflected in the much higher annual TB 
notification rates in South Africa compared to the other countries (>800 per 100,000 population 
compared to <200 per 100,000 per population) at the time the studies were conducted. 
Furthermore, the studies in South Africa were conducted in townships where individuals are likely to 
have wider and diverse social contacts thereby increasing the chance of contacting infectious 
individuals while the other studies were largely conducted in rural areas where individuals are likely 
to have fewer and less diverse social contacts. Within South Africa, the highest prevalence was 
reported in studies conducted in densely populated townships in the Western Cape province. The 
differences in prevalence are likely to be due to differences in social contacts and crowded living 
conditions between the different settings.  
2.3.6. Risk factors for Mycobacterium tuberculosis infection prevalence 
The risk factors for M. tuberculosis infection are shown in Table 2-2. The factors consistently shown 
to be associated with M. tuberculosis infection included older age, history of household contact with 
TB disease and low socioeconomic status. Furthermore, a nationwide TST survey in Gambia 
showed an increased risk of infection among participants from urban compared to rural communities 
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[80]. Two studies in the same study area in Western Cape province, South Africa reported the effect 
of smoking and passive household smoking (defined as living in the same house as a person who 
smokes) on M. tuberculosis infection [71, 74]. The authors, Den Boon et al., did not find an 
association between passive smoking and M. tuberculosis infection. However, in a sensitivity 
analysis including participants with a history of household TB contacts only, the odds of M. 
tuberculosis infection were four times in households where there was a smoker (odds ratio [OR]: 
4.6; [95% confidence interval (CI): 1.3-16.5]) [71]. In a study, investigating the effect of smoking on 
M. tuberculosis infection among adults (≥15 years), participants reporting having ever smoked had 
an increased odds of M. tuberculosis infection (OR: 2.0 [95% CI: 1.6-2.5]) [74].  
The effect of HIV on M. tuberculosis infection was inadequately reported due to lack of information 
on the HIV status of participants or having a very small proportion of participants who were HIV 
positive. In a study in rural eastern Uganda only 6 (0.12%) participants were HIV positive [51] and a 
study among adolescents and young people in Western Cape province, South Africa, 34 (5.6%) 
participants were HIV positive. In the Western Cape study the authors found weak evidence of lower 
odds of M. tuberculosis infection among HIV positive compared to HIV negative participants (OR: 
0.53; 95% CI: 0.27-1.05) [78]. This is possibly due to reduced reactivity to tuberculin due to the HIV 
infection [82].   
2.3.7. Spatial distribution of Mycobacterium tuberculosis infection 
Both Middlekoop et al. and Khan et al. showed that the odds of M. tuberculosis infection among 
young children (<5 years) and adolescents (10-22 years) were higher among those with a TB 
contact in their residential plots or among those residing in areas with higher community TB 
exposure (≤30 vs >30 TB patients per 100,000 population) respectively (Table 2-3). This reflects 
continued transmission within residential plots and the immediate community of the notified TB 
patients. Comparing the age of the participants and whether there was a TB patient on their 
residential plot, Middelkoop et al. reported that the odds of M. tuberculosis infection were 
significantly higher among individuals aged 5-9 and 10-14 years with a residential plot TB contact 
compared to those without a residential plot TB contact, but the evidence for a difference among 
older participants (15-22-year olds) with or without a residential plot TB contact was weak (OR: 1.4 
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[95% CI: 0.9-2.0]). Overall, the prevalence of M. tuberculosis infection was higher among the older 
adolescents compared to the younger children (28.6 % among 5-9-year olds vs 54.0% among 15-22 
year olds [58, 83]). Khan et al. reported a population attributable fraction of a TB contact in the 
immediate community (within 200 m) of only 17.0%. This further highlights ongoing transmission in 
the wider community.  
Overall, Middlekoop et al. showed that the odds of M. tuberculosis infection were higher for all forms 
of TB, pulmonary TB (PTB) and smear-positive TB, but there was no difference if the adult TB case 
on their residential plot had smear negative TB disease (OR: 0.95, 95% CI [0.59 - 1.54]) [57]. 
However, the authors did not show the spatial distribution of the different forms of TB to show 
whether they were clustered in the same parts of the study area. Khan et al assessed the 
association between population density (250-1000 vs <250 per km2 and >1000 vs <250 per km2) 
and M. tuberculosis infection but did not find a significant association (OR: 1.0 [95% CI: 0.5–2.1] and 
OR: 0.8 [95% CI: 0.3–2.0] respectively, p=0.18). This is possibly because the population density is 
low in this setting. 
2.3.8. Spatial distribution of TB disease 
Studies reporting spatial distribution of TB disease are summarised in Table 2-4. Significant 
clustering of notified TB and DR-TB disease was reported in all the studies. Nearly all the clusters 
were identified in townships or areas characterised with increased social contacts (Table 2-4). 
Tomita et al. and Smith et al. identified clusters of self-reported TB and DR-TB disease in the same 
area which is characterised by high HIV prevalence along a national highway in a rural district in the 
Kwazulu-Natal province, South Africa [67, 68] and Tadesse et al. identified clusters on the border 
areas of the Gurage zone which are characterised with regular movement to neighbouring zones in 
south eastern Ethiopia [66]. 
When looking at temporal changes, significant clustering over the duration of respective study 
periods was identified in both South Africa and Ethiopia [64, 66, 67]. Overall, larger persisting 
clusters (radius 2.9–4.5 km) were identified in the townships and smaller clusters appearing for 
shorter periods were identified in different parts of the studied areas. Tomita et al. identified smaller 
clusters (radius 0.3–1.0 km) in an area not characterised as having high HIV prevalence which 
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persisted the entire duration of the study period (2009-2015) [67]. This might reflect transmission 
among close contacts or recurrence of disease in the same individuals over time. 
2.4. Conclusion  
There is a paucity of data on prevalence of M. tuberculosis infection among adolescents in Sub-
Saharan Africa. The available evidence largely comes from studies conducted in the Western Cape 
province, South Africa (Table 2-2). There is need for data on M. tuberculosis infection prevalence in 
other parts of Africa and South Africa, especially where the prevalence of HIV is still high, to help 
understand the effect of HIV on acquisition and transmission of M. tuberculosis infection. 
The available evidence shows that prevalence of M. tuberculosis infection among adolescents in 
South Africa is high. Prevalence starts to pick up in adolescents and is highest in adults. This is 
largely due to increased number of social contacts [38] and cumulative exposure to potentially 
infectious individuals in the community. 
The literature search for the spatial distribution of M. tuberculosis infection at population level in sub-
Saharan Africa retrieved three studies. The studies revealed that household TB contact including 
living in the same residential plot and in the immediate community (within 200m) of known notified 
TB patients did not explain the majority of prevalent infections even among young children who are 
likely to be infected within their household. Information accurately characterising the spatial 
distribution of M. tuberculosis infection and local areas with higher burden (location of clustering) of 
infection is lacking in sub-Saharan Africa so that targeted inventions can be put in place. 
The studies investigating spatial distribution of TB disease identified spatial clusters of disease 
which were persistent over durations of the study periods (7-10 years) and smaller clusters which 
were identified for shorter periods. These studies show areas in the general population which are 
disproportionally affected with disease. Targeting interventions in these areas would potentially have 
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Chapter 3 Methods 
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3.1. Study Setting 
The study was conducted from November 2017 to December 2018 in the southern part of the Africa 
Health Research Institute (AHRI) DSA which has been under surveillance since 2000. The area is 
situated in Mtubatuba local municipality within uMkhanyakude district in KwaZulu-Natal province, 
South Africa (Figure 3-1). In terms of healthcare management, the area falls under the Hlabisa 
health sub-district (Figure 3-2).  
AHRI is a joint Wellcome Trust and Howard Hughes Medical Institute funded research institution 
affiliated to the University of KwaZulu-Natal. The institution was established in 2016 as a result of a 
merger of two institutions: KwaZulu-Natal Research Institute for TB-HIV (K-RITH) and Africa Centre 
for Health and Population Studies. The Africa Centre for Health and Population Studies was 
originally established in 2000 and had been conducting longitudinal population wide research 
investigating the epidemiology of HIV, understanding population dynamics and utilisation of 
healthcare and other services. In addition to the population surveillance, the DSA also provides a 
sampling frame for population-based studies and a platform for the implementation and evaluation of 
individual and population level interventions [84]. The population surveillance has continued after the 
merge with K-RITH. 
 
Figure 3- 1: Map showing location of the study area within South Africa [84] 
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The study area covers approximately 430 km2 and is demarcated to the east by the N2 national 
highway, to the west by the Hluhluwe-iMfolozi game reserve and on the south by the Mfolozi river 
(Figure 3-2) [84]. The area has a population of around 90,000 and an adult (≥15 years) HIV 
prevalence estimated at 36.6% in 2016 [85]. The inhabitants are predominantly isiZulu speaking. 
The area is predominantly rural and includes a township (KwaMsane) on the south-eastern part and 
informal peri-urban settlements. In the township area, houses are close together and in the rural 
areas dwelling places are organised into multigenerational homesteads of varying sizes which are 
not clustered into clearly identifiable villages . For pragmatic purposes, a homestead is defined as a 
building, or a group of buildings, on a piece of land belonging to a single person or organisation and 
used for one main purpose. Most homesteads are primarily used for residential purposes. The study 
area is sub-divided into 45 geographic areas of varying population densities (25–2,000 population 
per km2) called week-blocks (see Chapter 4 Figure 4–2). Week-blocks were designed such that a 
team of field staff can complete surveillance work within a five-day working week (taken from the 
unpublished ‘Operational and Methodological Procedures of the Africa Centre Demographic 
Information System’). 
The study area includes seven primary healthcare clinics (PHC) which provide healthcare for the 
population. Six of these are located within the study area and one is located just outside at the 
Mtubatuba municipality. Hlabisa district hospital (about 25 km west of the DSA) acts as the main 
referral facility. At these facilities, data on clinic attendance are collected and the members of the 
DSA are linked in real time using their demographics surveillance identifier (DSID). The Somkhele 
field site, where the project office was located, is within the study area close to the Somkhele clinic 
(Figure 3-2).  
3.2. Demographic surveillance activities 
In the demographic surveillance, individuals were first registered when the DSA was set up in 2000, 
registered at birth or in-migration and exit at death or out-migration. Households are visited annually 
and information on births, immunizations, deaths, migration patterns of all members and household 
socioeconomic status is collected from a household informant (usually the head of the household) 
[84]. Resident individuals aged ≥15 years are invited to participate in interviews on general health, 
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sexual behaviour, and anonymised HIV testing. Information on self-reported TB diagnosis in the 
previous year is collected through these interviews. 
3.3. Study design and population 
This was a cross-sectional study of adolescents (aged 10-19 years) randomly selected from a 
sampling frame of about 15,000 resident adolescents in the study area. In the DSA, individuals are 
defined as resident if they report that they intend to sleep majority of nights at a homestead within 
the DSA.  
 
 
Figure 3- 2: Map of Hlabisa health sub-district showing location of the study area (light-brown area 
with a black border), the Somkhele field site and primary health care clinics within the study area 
and surrounding areas.  
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3.4. Data collection procedures 
START
Participants selected (per sampling strategy) , data pre-loaded 
into REDCap and appropriate maps generated
Identify and enter homestead per AHRI policy
Participants aged 10-17 yearsParticipants aged 18-19 years
Obtain permission to speak to participant
[REDCap]
Assess capacity and check eligibility




Assess capacity and check eligibility
Parental Written Informed Consent 
(Excluding HIV)
REDCap Parent/guardian CRF
HIV Decision and Consent
Assent from Participant
(Excluding HIV)
REDCap Main Participant CRF
HIV Decision and Consent
Venous Blood Collection
Rapid HIV Testing




Record contact information if result needs to be 
returned; Leave details; End the interview
If positive, refer
If discrepant, request ELISA
If unable to produce, refer
 
Figure 3- 3: Overview of the study procedures 
AHRI: Africa health research institute; CRF: case report form; ELISA: enzyme-linked immunosorbent assay; 
HIV: human immunodeficiency virus; REDCap: Research electronic data capture system 
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3.4.1. Sampling and contacting selected individuals  
The sampling was stratified by week-block, a fixed 14% proportion of resident adolescents was 
sampled from each week-block to reflect the population distribution of the study area. The number of 
individuals in each week-block were sampled in order to obtain the target sample size (1,100). 
The selected individuals were approached at their homes by a team of research nurses (Figure 3-3). 
Since majority of individuals in this age group are school-going and are hard to find in homes during 
normal working hours (8.00 am–4.00 pm), up to 6 home visit attempts were made to find the 
selected individuals. In addition, field staff were working on weekends to maximise opportunity to 
find the selected individuals when they are not at school. During the home visit, permission to meet 
the selected individual or the parent/guardian of the selected individual was first sought from the 
owner of the homestead. With the help of the selected individual or the parent/guardian, a private 
space to conduct the interview within the homestead was identified (Figure 3-3). In very rare 
situations, if a private space could not be found, questions on more sensitive information like 
previous HIV test results were asked with caution or skipped altogether. 
3.4.2. Screening and enrolment  
During the interview with the selected individual or the parent/guardian, the field staff first cross-
checked the individual’s date of birth and whether they have ever been or are currently on TB 
treatment. Individuals self-reporting current or previous TB treatment were excluded from enrolment. 
Individuals who met the eligibility criteria (age 10-19 years and no previous or current TB treatment) 
and were willing to participate were taken through the informed consent process and were asked to 
sign consent forms (Appendices 1-3). For participants aged 10-17 years, consent was first sought 
from a parent or a designated guardian and assent was obtained from the participant. If the parent 
or designated guardian was not available, a suitable parental/guardian substitute was identified in 
line with the South African department of health (DOH) guidelines [86]. For participants and 
parents/guardians who indicated that they cannot read or write, a witness who was not a member of 
the research team was identified to attest to the informed consent process. 
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3.4.3. Questionnaire 
A standard questionnaire (Appendices 9 and 10) including information on previous TB treatment, 
school attendance, BCG vaccination, contact with TB patients, admission to hospital, chronic illness, 
smoking, alcohol intake, attendance at indoor gathering places, road trips in closed vehicles, history 
of previous HIV testing and ART uptake was administered. Since some events might have 
happened when the participant was still young, a similar questionnaire (Appendix 11) including 
previous TB treatment, BCG vaccination, admission to hospital, HIV testing history, chronic illnesses 
and ART uptake was administered to parents/guardians of participants aged 10-17 years. 
In October 2017, a draft version of the questionnaire was piloted on 50 adolescents from the study 
area and was updated following the experience. The pilot also served as part of training of the study 
procedures for the field staff. 
3.4.4. TB symptom screen and sputum collection 
For all participants a TB symptom screen incorporating cough for at least two weeks (any duration if 
HIV positive), fever, night sweats, and unexplained weight loss was performed. Two sputum 
samples were collected from participants with at least one of these symptoms. Participants who 
could not produce sputum were referred to their nearest PHC for further investigation. 
3.4.5. Blood sample collation and HIV testing 
For all participants a venous blood sample was collected in a generic 6 ml Lithium Heparin (LiHep) 
tubes. Participants without history of HIV testing, participants self-reporting a previous negative HIV 
test result more than three months before the enrolment date and participants with unknown 
previous HIV test results were offered a rapid HIV test by finger prick. The rapid test was done 
based on a parallel test algorithm using Abon HIV 1/2/0 Tri-line [Abon Biophrarm (Hangzhou) Co., 
Ltd] and Advanced Quality™ Rapid Anti-HIV [InTec Products Inc] test kits. Participants not wishing 
to test were given the option to have an anonymous HIV test on their venous blood for research 
purposes, or to decline HIV testing altogether.  
In line with DOH guidelines [86, 87], participants aged 10–11 years were offered the rapid HIV test 
only if their parent/guardian consented to both the participant being offered rapid HIV testing and to 
  50 
being present during the process of testing should the participant independently agree to test. Thus, 
for participants aged 10–11 years, the test was only done in the presence of the parent/guardian. 
Parents/guardians who knew the positive HIV status of their child but had not disclosed the status to 
their child were offered assistance for disclosure by a professional project nurse at their nearest 
PHC. 
3.5. Laboratory procedures 
3.5.1 Sputum samples 
The sputum specimens were collected in sterile containers and were placed in cooler boxes with 
temperatures between 2–8oC immediately after collection. At the end of each working day, the 
research nurses brought the samples to the project laboratory at the Somkhele field site for 
temporary storage.  
On the next working day (within three days), the research nurse transported one of the sputum 
samples to Somkhele clinic where it was shipped using existing DOH procedures to the DOH 
laboratory at Hlabisa district hospital for testing TB disease using Xpert/MTB RIF. The second 
sample was sent to the project laboratory in Durban where it was cultured for Mycobacteria on liquid 
media. The results from the project laboratory were automatically integrated into the Laboratory 
Information Management System (LIMS). The individual reports for the results from Hlabisa Hospital 
were downloaded from the National Health Laboratory Service (NHLS) database and were stored in 
a secured repository on the project server. These were also made available to the collecting nurse 
after they were reviewed by a study doctor. 
3.5.2 Venous blood samples 
Venous blood specimens in the Lithium Heparin (LiHep) tubes were placed in cooler boxes with 
temperatures between 17–27oC and transported to the project laboratory at the end of each working 
day. Upon arrival, the specimen was aliquoted into the four QuantiFERON TB Gold plus (QFT-plus) 
tubes (Nil, TB1, TB2 and Mitogen) and incubated immediately at 37oC for 16–24 hours. After the 
incubation, the samples were sent to the project laboratory in Durban for testing immunological 
  51 
responses to M. tuberculosis infection using the QFT-plus assay. The results were automatically 
integrated into the LIMS systems and were interpreted using manufacturer guidelines [20]. 
Participants who did not wish to have a rapid HIV test but had consented to have an anonymous 
HIV test done on their venous blood were tested for HIV using an enzyme-linked immunosorbent 
assay (ELISA) at the project laboratory in Durban. The ELISA was based on a two-test algorithm 
using HIV-1/HIV-2 ELISA (Vironostika HIV-1 Microelisa System: Biomérieux, Durham, NC, USA) 
which was followed by Wellcozyme HIV-1 + 2 GACELISA (Murex Diagnostics Benelux B.V., 
Breukelen, Netherlands). The results were also automatically integrated into the LIMS system, were 
not made available to investigators during the course of the study and were not fed back to 
participants. 
3.5.3 Result feedback, referral and linkage to care 
All results were reviewed by the study doctor. Results that were clinically relevant were made 
available to the collecting research nurse and were fed back to the participant or parent/guardian 
either by telephone or in person during a home visit (Figure 3-4 and Appendix 6). Two weeks after 
the date of referral to care, all participants who were referred to care for any reason and had not 
linked to care were contacted by phone to check if they had attended PHC (Appendix 7). 
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HIV ELISA: Result From 
EDTA SAMPLE
RESULT FEEDBACK TO PARTICIPANTS





HIV ELISA: Done for 
Discrepant Rapid Test
HIV ELISA: Done because 
rapid test declined









Participant HIV- / 
Unknown / 
Unaware of HIV+ 
status*






and fed back 
successfully
GXP Negative / Positive 
not successfully fed 
back / Indeterminate / 
Not doneDo not Feedback Result
Feedback Result in Person
Feedback by 
telephone
*Unless parent/guardian aware of HIV+ status, then feedback to parent/guardian in person
 
Figure 3- 4: Laboratory result feedback to participants 
EDTA: Ethylenediaminetetraacetic acid; ELISA: enzyme-linked immunosorbent assay; GXP: Xpert MTB/RIF; HIV: human immunodeficiency virus; IGRA: interferon-
gamma release assay; LiHep: Lithium heparin; MTB: Mycobacterium tuberculosis; NTM: non-tuberculous mycobacterium.  
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3.6. Data management 
Data were managed by the AHRI Data Centre and were captured electronically on password 
protected tablets using the REDCap (Research Electronic Data Capture) Android application 
(REDCap Consortium Vanderbilt, Nashville) [88]. Automatic checks for invalid entries and internal 
consistency were pre-programmed into the questionnaire. At the end of each working day, the data 
from tablets was exported to the project database. Additional data validation checks were run after 
data were exported. Laboratory data was managed using the LIMS system. After testing, laboratory 
results were automatically integrated into the LIMS system. Programs written in Pentaho (Hitachi 
Vantara Corporation, Santa Clara) were used to merge participant data and the laboratory results. 
3.7. Definitions 
3.7.1. Outcome of interest 
The outcome of interest was M. tuberculosis infection. This was defined as interferon-gamma (IFN-
γ) concentration ≥0.35 IU/mL (calculated as either QuantiFERON TB1 or QuantiFERON TB2 
antigen minus QuantiFERON nil) as per the manufacturer's guideline [20]. 
3.7.2. Exposures of interest 
The potential risk factors for M. tuberculosis infection are shown in Table 3-1. Information on 
community HIV prevalence, urban/rural location, household socioeconomic status, number of 
household residents and distance to clinic were extracted from the DSA database. To come up with 
HIV status, information collected in the study and information captured in the surveillance was used. 
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Table 3- 1: Potential risk factors for Mycobacterium tuberculosis infection 
Community level Household level Individual level 
- Community HIV prevalence 
- Urban/rural location 
- Household socioeconomic 
status 
- Number of household residents 
- Passive smoking. 




- BCG vaccination Status 
- Household TB contact 
- HIV status 
- Smoking 
- Alcohol intake 
- Education level  
- Admission to hospital 
- Contact hours with adult males 
- Contact hours with adult females 
- Attendance at church 
- Visits to other homesteads 
during the day 
- Sharing sleeping room with 
other people. 
- Visits to health facility 
 
3.7.2.1. Definitions of community level factors 
Community HIV prevalence: Data on community HIV prevalence were extracted from the DSA 
database where it was calculated based on previously-described methods using 2017 population 
data [89]. Briefly, every individual in the DSA was geo-located to a 30 m by 30 m grid superimposed 
at their homestead. Then a two-dimensional Gaussian kernel density of 3 km radius was passed 
across the grid to estimate HIV prevalence for the homestead based on the population and number 
of known HIV positive individuals within the search radius. The estimates of HIV prevalence for each 
household were categorised into four groups based on the distribution of HIV prevalence of the 
households of the selected individuals. The lowest category was coded ‘1’ and included households 
with HIV prevalence below 25%. The highest category was coded ‘4’ and included households with 
HIV prevalence at least 45%. The HIV prevalence was calculated for each homestead but was 
analysed as a community level factor since the estimated HIV prevalence reflects the HIV 
prevalence of the community surrounding the household and not just within the household. 
Rural/urban location: Rural/urban location was defined as either urban or rural. In the DSA, 
communities are defined as urban if the population density is at least 400 per km2. 
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3.7.2.2.  Definitions of household level factors  
Household socioeconomic status: information on household socioeconomic status was extracted 
from DSA database where it was calculated using principal component analysis. The analysis was 
performed using information collected from the annual household socioeconomic survey which 
collects information on ownership or access to the following assets or amenities: electricity, piped 
water in the homestead, flushing toilets, bed, bicycle, block maker, car, cattle, electric cooker with 
oven, electric hotplate, electric kettle, fridge, gas cooker, hoe/spade/fork, van/lorry/tractor, kitchen 
sink, motorcycle, other livestock (not cattle), primus cooker, radio, sofa, sewing machine, tables & 
chairs, telephone, cell phone, television, wheelbarrow, hot water geyser, washing machine, electric 
heater, paraffin heater, stereo or hi-fi, computer or laptop, tractor or farm vehicle, furnishings, 
jewellery and watches. A worth score for each household was created and was categorised into 
worth tertiles with the lowest coded as ‘1’ and the highest coded as ‘3’. 
Distance to the nearest PHC was extracted from the DSA database and was defined as the 
Euclidean distance from the homestead to the nearest PHC within the DSA. Passive smoking was 
defined as living in the same homestead as a person who smokes based on information collected 
during the survey. 
3.7.2.3. Individual level factors 
HIV status: Participants were classified as HIV positive if they either tested positive by the rapid test 
or by ELISA as part of the study; or previously tested positive as part of the DSA surveillance; or 
self-reported being HIV positive or being on ART. Participants were classified as HIV negative if they 
tested HIV negative as part of the study; previously tested negative as part of the surveillance within 
the previous two years before the interview or self-reported testing HIV negative in the previous 2 
years. Participants were classified as HIV unknown status if they self-reported that they had never 
tested before and did not consent to HIV testing by either rapid test or ELISA; previously tested 
negative in surveillance more than 2 years before enrolment; or self-reported an HIV negative test 
more than 2 years before enrolment. 
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Contacts with adult males or females: Participants were asked about the frequency of visits to 
several indoor locations (school, church, bar, clinic, hospital other houses and closed vehicle), and 
the duration and number of individuals  present at the last visit. Contact hours with adult males (≥12 
years) on the last day of visiting an indoor location (school, church, hospital, closed vehicle, bar and 
other houses) were calculated as the maximum number of adult-males present multiplied by the 
duration (in hours) of the visit. Visits lasting less one hour were rounded off to one hour. This was 
multiplied by the number of visits to that indoor location in the previous month to obtain monthly 
contact hours for that location. Participants reporting not visiting a particular indoor location in the 
previous month were assigned zero contact hours for that location. To obtain the overall monthly 
contact hours, the monthly contact hours for all the indoor gathering places captured were summed 
up. Monthly contact hours with adult females were calculated in a similar manner. 
Lifetime household TB contact: Participants were classified as having a lifetime household TB 
contact if they reported having ever lived in the same house as a person with TB disease for at least 
two weeks or had ever cared for  a person with TB during their lifetime. 
BCG vaccination: this was defined as either having documentary evidence of immunisation or 
scars consistent with BCG vaccination on the right deltoid insertion.  
Smoking: Participants were classified as smokers if they reported ever smoking at least 100 
cigarettes. 
3.8. Sample size calculation 
The sample size calculations were based on the following assumptions: 
1. Estimated proportion adolescents with QFT-plus positive results to be 40-50% [90] 
(consistent with studies among adolescents in the Western Cape province, South Africa. 
2. 60% of those approached to participate would be enrolled in the study [91]. 
The sample size required to estimate a prevalence of M. tuberculosis infection of 50% with a ±3% 
precision at 5% significance level was estimated to be 1,100. As this study was initially aimed at 
estimating cumulative M. tuberculosis infection incidence at 12 months, this sample would also 
enable estimation of a cumulative incidence of 5% at 12 months among participants with QFT-plus 
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negative results at baseline. In order to account for non-participation at baseline and loss follow up 
at 12 months, a total of 1,998 participants were initially selected. 
3.9. Statistical analyses 
3.8.1. Participant enrolment and baseline characteristics 
All analyses were done using Stata software version 14.2 (College Station, TX, USA). A flowchart 
for participants from selection to inclusion in analyses was prepared. Characteristics (age, sex and 
age at TB diagnosis) of individuals self-reporting previous TB disease were tabulated using linked 
data from the DSA. Characteristics (age, sex, household SES, rural/urban location and community 
HIV prevalence) of individuals who were included in the analysis and those not included were 
tabulated, using linked data from the DSA. The Chi-squared test was used to make comparisons. 
The individuals not included in the analysis included those not approached, those approached but 
not contacted, those who refused participation those self-reporting previous TB treatment and those 
with missing or invalid QFT-plus results. Baseline characteristics of participants included in the 
analysis were tabulated. 
3.8.2. Mycobacterium tuberculosis infection prevalence 
The crude M. tuberculosis infection prevalence was defined as the proportion of participants with the 
outcome. In addition to the manufacturer cut-off (IFN-γ concentration ≥0.35 IU/mL), the M. 
tuberculosis infection prevalence was also estimated using a stringent (≥0.70 IU/mL) and a less 
stringent (≥0.20 IU/mL) cut off as suggested by Nemes et al. [92]. Finally, estimates for prevalence 
were obtained for all the three cut offs (0.20, 0.35 and 0.70 IU/ml) including individuals self-reporting 
previous TB treatment assuming they have M. tuberculosis infection. To account for non-
participation, the weighted M. tuberculosis infection prevalence was calculated by multiplying the 
crude prevalence by the inverse of probability of participation in strata defined age, sex, and 
urban/rural residence. 
3.8.3. Risk factors for Mycobacterium tuberculosis infection 
Random effects logistic regression taking account of clustering within homesteads was used to 
obtain odds ratios (OR) and corresponding 95% confidence intervals (CI) for the association 
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between M. tuberculosis infection and the proposed risk factors (Table 3-1). Only participants with 
valid QFT-plus results were included in the analysis. Univariate models were fitted for all the 
proposed risk factors. 
To account for inter-relationships between M. tuberculosis infection and the proposed risk factors, a 
hierarchical conceptual framework with three levels (community, household and individual level) was 
used to perform multivariable analyses (see Chapter 5, Figure 1) [93]. At the community level, the 
risk of M. tuberculosis is determined by exposure to infectious individuals which varies by 
community as reflected in differences in annual TB notification rates [7]. M. tuberculosis infection 
prevalence is expected to be high in communities with high TB notification rates. At the household 
level, the risk of exposure to M. tuberculosis is expected to be higher in households of people with 
TB disease and households with low socioeconomic status largely due to poor living conditions like 
overcrowding and poor access to medical care [94]. At the individual level, the risk of infection is 
expected to be higher among individuals with history of exposure to TB disease and older 
individuals due to increased long-term exposure to sources of M. tuberculosis infection and 
increased social contacts. This approach also assumes that the community level factors are the 
more distal, and individual level factors are the proximal. 
Age, and household SES were considered as both a priori confounders and exposures of interest. 
First, community level factors that were associated with the outcome at p-value<0.20 in the 
univariate analyses were included in a multivariable model.  The factors that remained associated at 
p-value<0.20 were retained in a core community-level model (model 1). Next, household factors 
were added to this core model one by one. Those that were associated with the outcome at p<0.20, 
after adjusting for community factors and socioeconomic status, were included in a multivariable 
model and retained if they remained associated with the outcome at p<0.20 (model 2). Associations 
with individual-level factors were determined in a similar way, adjusting for community-level and 
household-level factors, and age (model 3). 
Logistic regression was used to obtain odds ratios (OR) and corresponding 95% confidence 
intervals (CI) for the association between M. tuberculosis infection and the proposed risk factors not 
taking account of clustering within households.  The results are presented in Appendix 12. 
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3.8.4. Missing data 
The proportion of participants with missing data for each variable was calculated and presented in 
the table of the baseline characteristics of participants. Since a small proportion (less than 5.0%) 
had missing information, imputations were not performed. A complete case analysis was performed. 
3.8.5. Spatial distribution of M. tuberculosis infection and previous TB disease 
All individuals assessed for enrolment in the study were geolocated to their week-block using linked 
information from the DSA. A map with gradients for the proportion of individuals self-reporting 
previous TB treatment in each week-block was produced. For participants with valid QFT-plus 
results, maps with gradients for the proportion of participants with QFT-plus positive results and 
those self-reporting history of household TB contact were produced. To compare the spatial 
distribution of M. tuberculosis infection prevalence and population density, a map showing gradients 
for the population density of each week-block was produced. The population densities for the week-
blocks were categorised into quintiles with the lowest category coded as ‘1’ and the highest coded 
as ‘5’. 
3.10. Ethics approval and considerations 
The study was approved by the Ethics Committee of the London School of Hygiene & Tropical 
Medicine, reference 10515 (Appendix 5), the Biomedical Research Ethics Committee of the 
University of KwaZulu-Natal, reference BE483/15 (Appendix 4), and the KwaZulu-Natal Department 
of Health, reference 184/16 (Appendix 6). Approval for the study was also obtained from Hlabisa 
District Hospital and the AHRI Community Advisory Board. To compensate participants for their 
time, a food refreshment or airtime of about ZAR20.00 (about £1.00) was given. Parents/guardians 
were not compensated for their participation. 
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Chapter 4 Results 
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4.1. Participant selection and enrolment 
A total of 1,998 individuals aged 10-19 years resident in the southern part of the AHRI-DSA between 
November 2017 and December 2018 were selected from the project database. By December 2018, 
a total 1,809 (90.1%) had an attempted home visit by field staff and 1,173 (60.8%) were assessed 
for eligibility (Figure 2-1). Among those assessed for eligibility, 35 (3.0%) had a history of TB 
treatment, 3 (0.2%) were not age eligible and 1,135 (96.8%) were enrolled. The QFT-plus test was 
successfully done, and results were available for 1,094 participants. These were included in the 
analyses. 
 




Home visit attempted 
1809 (90.1%) 






Not assessed for enrolment: 636 (35.2%) 
- 460 (73.2%) not at home 
- 115 (18.1%) moved from location 
- 61 (9.6%) refused participation 
Not enrolled: 38 (3.2%) 
- 35 (92.1%) previous TB treatment 
- 3 (7.9%) not age eligible 
Excluded from analysis: 41 (3.6%) 
- 21 (51.2%) insufficient blood sample 
- 14 (34.1%) declined blood sample 
- 6 (14.6%) indeterminate QFT result 
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4.2. Individuals reporting previous TB treatment 
Overall, 35 (3.0%) individuals assessed for enrolment reported a history of TB treatment. Among 
these, 18 (51.4%) were female and the median age was 13 (IQR: 12-16) years. The reported 
median age at diagnosis was 4 (IQR: 2-7) years and 30 (85.7%) reported being diagnosed before 
they reached 12 years (table 4-1). 





Female 18 (51.4) 
Male 17 (48.6) 
Age (years) 
 
10–11 6 (17.1) 
12–14 15 (42.9) 
15–17 9 (25.7) 
≥18 5 (14.3) 
Age at TB diagnosis 
 
<12 years 30 (85.7) 
≥12 years 2 (5.7) 
Missing 3 (8.5) 
TB: tuberculosis 
 
4.3. Comparison of analysed participants and those not analysed 
Compared to individuals who were not included in the analysis, there were no differences by age 
and sex (Table 4-2). There was weak evidence of a difference by household socioeconomic index 
score, with participants included in the analysis slightly over-represented in the lowest tertile (29.1% 
vs 25.3%). The participants included in the analysis were less represented in urban communities 
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Table 4- 2: Comparison of participants included in the analysis (i.e. with valid QFT-plus results) vs. 
selected individuals not included in the analysis 
Variable 
Total included in 
analysis (N=1,094) 
N (column %) 
Total not included in 
analysis (N=904) 
N (column %) 
p-valuea 
Sex    
Male 546 (49.9) 465 (51.6) 0.47 
Female 548 (50.1) 438 (48.4)  
Age    
10–11 years 253 (23.1) 195 (21.6) 0.50 
12–14 years 346 (31.6) 301 (33.3)  
15–17 years 309 (28.2) 239 (26.4)  
18+ years 186 (17.0) 169 (18.7)  
Socioeconomic index score (tertiles)    
Low 305 (29.1) 218 (25.3) 0.08 
Medium 350 (33.4) 325 (37.7)  
High 393 (37.5) 319 (37.0)  
Number of household residents    
1-5 333 (31.1) 342 (38.5) <0.01 
6-7 252 (23.6) 208 (23.4)  
8-10 248 (23.2) 183 (20.6)  
>10 237 (22.2) 155 (17.5)  
Location    
Urban  37 (3.4)  86 (9.5) <0.01 
Peri-Urban 342 (31.3) 319 (35.3)  
Rural 715 (65.4) 499 (55.2)  
Community HIV prevalence (%)    
<25% 85 (8.1)  64 (7.4) <0.01 
25–34.9% 618 (59.1) 454 (52.2)  
35–44.9% 261 (25.0) 265 (30.5)  
≥45% 82 (7.8) 86 (9.9)  
ap-values obtained using Chi-squared distribution 
HIV: human immunodeficiency virus 
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4.4. Characteristics of enrolled participants 
Individual level characteristics of the participants included in the analysis are shown in table 4-3. The 
median age was 15 years (IQR: 12-18) and 548 (50.1%) were female. 43 (3.9%) were HIV positive 
and 196 (17.2%) had an unknown HIV status. Among those who were HIV positive 34 (79.1%) knew 
their HIV positive status. 266 (24.3%) reported having ever lived in the same house as a person with 
TB disease and 34 (3.1%) reported currently living in the same house as a person with TB disease. 
984 (90.0%) had evidence of BCG vaccination (either a BCG vaccination scar or documentation). 18 
(1.7%) reported ever smoked tobacco and 207 (18.9%) reported living in the same homestead with 
a person who smokes with 66 (6.0%) living in the same house. 121 (11.1%) reported having ever 
been admitted to hospital for any reason and 92 (8.4%) reported sleeping in other houses for (≥2 
weeks in the previous year. 
Household and community level characteristics of enrolled participants are presented in table 4-3. 
715 (65.4%) were from rural communities and 34.4% were from communities with HIV prevalence 
≥35.0%. 305 (27.9) were from households in the lowest socioeconomic index tertile. The median 
number of household residents was 7 (IQR: 5-10) and the median distance to the nearest clinic was 
2.7 km (IQR: 1.7-4.2). 
Details of frequency of attendance at selected indoor gathering places are presented in Table 4-5. 
155 (14.2%) participants reported not attending school in the previous seven days. 675 (61.7%) 
reported not travelling in closed vehicles and 720 (65.8%) reported not making visits to other houses 
during the day in the previous seven days. 664 (60.7%) reported not attending church or prayer 
meetings in the previous month and 668 (61.1%) reported not visiting a clinic for any reason in the 
previous 12 months.  
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Female 548 (50.1) 
Male 546 (49.9) 
Age (years) 
 
10-11 237 (21.7) 
12-14 349 (31.9) 
15-17 297 (27.2) 
≥18 211 (19.3) 
HIV status 
 
Negative 855 (78.2) 
Positive 43 (3.9) 
Unknown 196 (17.9) 
Lifetime household TB contact 
 
No 823 (75.2) 
Yes 266 (24.3) 
Missing 5 ( 0.5) 
Current household TB contact 
 
No 1,055 (96.4) 
Yes 34 (3.1) 
Missing 5 (0.5) 
BCG Vaccination a 
 
Vaccinated 984 (90.0) 
Not vaccinated 101 (9.2) 
Missing 9 (0.8) 
Current alcohol intake 
 
No 1,040 (95.1) 
Yes 35 (3.2) 
Missing 19 (1.7) 
Ever smoked tobacco b 
 
No 1,070 (97.8) 
Yes 18 (1.7) 
Missing 6 (0.5) 
Reported smoker in homestead 
 
No 880 (80.4) 
Yes 207 (18.9) 
Missing 7 (0.6) 
Reported smoker in household 
 
No 1,021 (93.3) 
Yes 66 (6.0) 
Missing 7 (0.6) 
Education level 
 
None or primary 631 (57.6) 
Secondary or above 459 (41.0) 
Missing 4 (0.4) 
Admission to hospital (ever) 
 
No 967 (88.4) 
Yes 121 (11.1) 
Missing 6 (0.5) 
Sleep in other houses (≥2 weeks) 
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N (%) 
No 990 (90.5) 
Yes 92 (8.4) 
Missing 12 (1.1) 
Sharing sleeping room with other people 
 
None 363 (33.2) 
1 person 336 (30.7) 
≥2 people 389 (35.6) 
Missing 6 (0.5) 
a based-on BCG vaccination scars or documentation evidence of immunization 
b ever smoked ≥100 cigarettes 
BCG: Bacillus Calmette-Guérin; HIV: Human immunodeficiency virus; TB: Tuberculosis 
 
 





Urban 37 (3.4) 
Peri-urban 342 (31.3) 
Rural 715 (65.4) 
Community HIV prevalence (%) 
 
<25% 85 (7.8) 
25-34.9% 618 (56.5) 
35-44.9% 261 (23.9) 
≥45% 82 (7.5) 
Missing 48 (4.4) 
Distance to nearest clinic (quartiles) 
 
<1.85 301 (27.5) 
1.85-3.41 403 (36.8) 
3.42-5.36 259 (23.7) 
>5.36 131 (12.0) 
Household Social economic status (tertiles) 
 
Low 305 (27.9) 
Medium 350 (32.0) 
High 393 (35.9) 
Missing 46 (4.2) 
Number of household members 
 
<6 333 (30.4) 
6-7 252 (23.0) 
8-10 248 (22.7) 
>10 237 (21.7) 
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Table 4- 5: Frequency of attendance at indoor gathering places (n=1,094) 
  
N (%) 
Attendance to school (seven days) 
 
0 times 155 (14.2) 
1-3 times 203 (18.6) 
≥4 times 704 (64.4) 
Missing 32 (2.9) 
Road trips (previous seven days) 
 
0 trips 675 (61.7) 
1 trip 158 (14.4) 
≥2 trips 245 (22.4) 
Missing 16 (1.5) 
Visiting other houses during the day (seven days) 
 
None 720 (65.8) 
1-2 houses 227 (20.8) 
≥3 houses 136 (12.4) 
Missing 11 (1.0) 
Attendance to church (four weeks) 
 
0 times 664 (60.7) 
1-2 times 176 (16.1) 
≥3 times 233 (21.3) 
Missing 21 (1.9) 
Visit to bars (four weeks)* 
 
No 1,059 (96.8) 
Yes 25 (2.3) 
Missing 10 (0.9) 
Attendance to hospital (12 months)* 
 
No 1,071 (97.9) 
Yes 16 (1.5) 
Missing 7 (0.6) 
Clinic attendance (12 months)* 
 
No 668 (61.1) 
Yes 419 (38.3) 
Missing 7 (0.6) 
*At least once  
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4.5. Prevalence of Mycobacterium tuberculosis infection 
The proportion of participants with positive QFT-plus results using a less stringent (≥0.20 IU/ml), 
more stringent (≥0.70 IU/ml) and manufacturer cut off (≥0.35 IU/mL) are shown in Table 4-6. The 
crude prevalence ranged from 19.9% to 25.1%. Assuming individuals self-reporting previous TB 
disease have M. tuberculosis infection, the crude prevalence ranged from 22.4% using the more 
stringent cut off to 27.4% using the less stringent cut off. The M. tuberculosis infection prevalence 
weighted for non-participation by age, sex and rural/urban residence was 23.0% (95% CI:20.6-
25.6%). Detailed results for M. tuberculosis infection prevalence and risk factors are presented in 
Chapter 5. 
Table 4- 6: Mycobacterium tuberculosis infection prevalence using different criteria and including 
and excluding self-reported previous TB treatment 
Criteria (Cut off) 
Positive participants  
(n/N) 
Prevalence % 
(95 % CI) 
≥0.20 IU/mL 275/1094 25.1 (22.7-27.8) 
≥0.35 IU/mL 249/1094 22.7 (20.4-25.3) 
≥0.70 IU/mL 218/1094 19.9 (17.7-22.4) 
≥0.20 IU/mL plus previous TB 310/1129 27.4 (24.9-30.1) 
≥0.35 IU/mL plus previous TB 284/1129 25.2 (22.7-27.8) 




4.6. TB symptoms and chronic illnesses 
Among the participants who were included in the analysis, 13 (1.2%) reported having a cough of at 
least two weeks (any duration if HIV positive), 6 (0.6%) reported fever, 6 (0.6%) reported night 
sweats and 11 (1.0%) reported weight loss (Table 4.7). Overall, 13 (1.2%) had least one TB 
symptom and were asked to submit sputum. Sputum samples were successfully collected in eight 
participants and one participant tested Xpert MTB/RIF positive. 21 (1.9%) participants reported 
having asthma, 34 (3.1%) reported being HIV positive and none reported being diabetic. 
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Table 4- 7: TB symptoms and chronic illnesses among enrolled participants (n=1,094) 
  
N (%) 
Cough a (n=1,092) 13 (1.2) 
Weight loss (n=1,088) 11 (1.0) 
Fever (n=1,090) 6 (0.6) 
Night sweat (n=1,090) 6 (0.6) 
TB symptoms (≥1 symptom) [n=1,092] 13 (1.2) 
Sputum collection (n=1,092) b 13 (1.2) 
Xpert MTB/RIF positive results (n=1,092) c 1 (0.1) 
MTB Culture positive (n=1,092) 0 (0.0) 
Diabetes (n=1,087) 0 (0.0) 
Asthma (n=1,089) 21 (1.9) 
HIV 31 (2.8) 
a Cough of at least two weeks if HIV negative and any duration if HIV positive. 
b Five participants with TB symptoms were unable to produce sputum and were referred to their nearest clinic 
for further management.  
c Among those who submitted sputum samples 
 
4.7. Spatial distribution of M. tuberculosis infection prevalence 
4.7.4 Population density 
The gradients of the population density for the study area by week-block are shown in Figure 4–2. 
The median area for the week-blocks was 8.9 (IQR: 1.8-15.5) km2 and the median population 
density was 128.1 (IQR: 48.6-527.9) per km2. The highest population density (>1,000 individuals per 
km2) was observed in week-blocks in the south eastern part of the study area. 
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Figure 4- 2: Population density by week-block (sub-divisions of the study area) 
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4.7.5 Spatial distribution of M. tuberculosis infection prevalence 
A total 249 participants had QFT-plus positive results giving a crude M. tuberculosis infection 
prevalence of 22.8% (95% CI: 20.4–25.3). The median M. tuberculosis infection prevalence in the 
week-blocks was 21.4% (IQR: 16.0–29.2). Among participants reporting history of household TB 
contact 78 (31.7%) had QFT-plus positive results. The map of the study area with gradients for M. 
tuberculosis infection prevalence for each week-block is shown in Figure 4–3  panel A. Overall, the 
distribution of M. tuberculosis infection prevalence was similar across rural areas of the study area 
with 30 (66.7%) week-blocks having M. tuberculosis infection prevalence below 25.0%. Eight week-
blocks had intermediate prevalence (25.1–35.0%). Among these, seven were either along the 
national highway on the eastern part of the study area or along the R618 main road from Mtubatuba 
to Hlabisa Municipality across the middle of the study area (east to west). The highest prevalence 
(35–66.7%) was observed in four week-blocks on the south-eastern part of the study area (where 
the population density is higher than other parts of the study area), in one week-block at the centre 
of the study area and in another week-block on the north-western part of the study area (where only 
six participants were included in the analysis). 
The spatial distribution for M. tuberculosis infection and self-reported previous TB diagnosis among 
adolescents did not show similarities. Only one week-block close to the centre of the study area had 
high prevalence for both M. tuberculosis infection (12/31 [38.7%]) and self-reported previous TB 
treatment (4/40 [10.0%]) among the adolescents (Figure 4–3 panels A and B). 
The spatial distribution for the prevalence of self-reported household TB contact shows week-blocks 
with intermediate (25–45%) prevalence largely along the R613 main road (Figure 4–3 panel C) but 
these are not exactly the same week-blocks with intermediate M. tuberculosis infection prevalence. 
The distribution also shows week-blocks with household TB contact prevalence >45% on the south-




      72 
A. Mycobacterium tuberculosis infection 
prevalence 
B. Previous TB disease prevalence among 
adolescents C. Reported household TB contact 
   
Figure 4- 3: Map of the study area showing spatial distributions:  
A: gradients of Mycobacterium tuberculosis prevalence by week-block. The number shown in week-block is the number of enrolled participants with positive QFT-
plus results and the number in brackets is the total number of enrolled participants.  
B: self-reported lifetime TB prevalence among adolescents by week-block. The number shown in each week-block is the number of individuals self-reporting previous 
TB treatment and the number in brackets is the individuals assessed for enrolment. 
C: gradients for prevalence of self-reported lifetime household TB contact by week-block. The number shown in each week-block is the number of enrolled 
participants self-reporting lifetime household TB contact and the number in brackets is the total number of enrolled participants. 
TB: tuberculosis. 
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Chapter 5: Prevalence of and risk factors for Mycobacterium tuberculosis 
infection among adolescents in rural KwaZulu-Natal, South Africa  
 
This chapter presents results for the analysis of prevalence and risk factors for 
Mycobacterium tuberculosis infection among adolescents. The chapter is presented in the 
format of a Journal article to be submitted to the International Journal of Tuberculosis and 
Lung Disease (IJTLD) 
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Abstract 
Background: We aimed to estimate the prevalence and explore risk factors for Mycobacterium 
tuberculosis infection among adolescents in a high tuberculosis (TB) and HIV prevalence setting. 
Methods: A cross-sectional study of adolescents (10–19 years) randomly selected from a 
demographic surveillance area (DSA) in rural KwaZulu-Natal, South Africa. We determined M. 
tuberculosis infection status using the QuantiFERON-TB Gold-plus assay. We used HIV data from 
the DSA to estimate community-level adult HIV prevalence and random effects logistic regression to 
identify risk factors for TB infection. 
Results: We enrolled 1,094 adolescents (548 [50.1%] female); The M. tuberculosis infection 
prevalence (weighted for non-response by age, sex, and urban/rural residence) was 23.0% (95% 
confidence interval [CI]: 20.6–25.6%). M. tuberculosis infection was associated with older age 
(adjusted odds ratio [aOR]: 1.37; 95% CI: 1.10–1.71, for increasing in age-group [12–14, 15–17, 18–
19 years vs. 10–11]), ever (vs. never) having a household TB contact (aOR: 2.13, 95% CI: 1.25–
3.64) and increasing community-level HIV prevalence (aOR: 1.43, 95% CI: 1.07–1.92, for every 
increase in community-level HIV prevalence category [25–34.9%, 35–44.9%, ≥45% vs. <25%]). 
Conclusion: Our data support prioritising TB prevention and care activities in TB-affected 
households, and high HIV prevalence communities. 
Key words: latent Mycobacterium tuberculosis infection, IGRA, risk factors 
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Introduction 
As an airborne infection, the risk of Mycobacterium tuberculosis infection is determined, in part, by 
the risk of contact with individuals with infectious tuberculosis (TB) disease [1]. M. tuberculosis 
infection in young children (<10 years) is used as a marker of recent transmission and to make 
inferences about transmission in the population [2, 3]. Compared to older children and adults, young 
children have limited social contacts and are more likely than older children and adults to be infected 
within the household [4-7]. However, empirical evidence from both epidemiologic and molecular 
studies in high TB prevalence settings has shown that household transmission accounts for only 
between 8%–20% of all transmission [8-12]. 
Throughout adolescence, young people have increasing social contact with the wider community 
and thus increased risk of M. tuberculosis exposure and infection [7, 13, 14]. This suggests that M. 
tuberculosis infection in adolescents might be a more representative measure of community-wide 
transmission, but there are few population-based studies from sub-Saharan Africa. We aimed to 
determine the prevalence of and risk factors for M. tuberculosis infection among adolescents in a 
high TB and HIV prevalence setting. 
Methods 
Study setting  
The study was conducted in the southern part of the Africa Health Research Institute’s (AHRI) 
demographic surveillance area (DSA), in uMkhanyakude district, KwaZulu-Natal, South Africa, which 
has a resident population of around 60,000 and an adult HIV prevalence estimated at 36.6% in 2016 
[15]. The annual notification rate of all TB cases was 394 per 100,000 population in 2018 [personal 
communication from Jacqueline Ngozo].  
Study participants and procedures 
We randomly selected adolescents (aged 10–19 years) from the complete sampling frame of all 
residents (individuals reported as intending to spend the majority of nights at a household within the 
DSA). Between November 2017 and December 2018, the selected individuals were visited at home 
and invited to take part. Individuals reporting any history of treatment for active TB were excluded 
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from the main study. A standard questionnaire was administered that included questions on 
education level, Bacillus Calmette-Guérin (BCG) vaccination, history of lifetime household TB 
contact, admission to hospital, smoking (and passive smoking), alcohol intake and history of HIV 
testing. All participants were examined for presence of BCG scars (documentation of immunisations 
was also checked) and were asked history of attendance (including frequency of attendance in the 
previous month; duration and number of people present at the last visit) at relevant indoor gathering 
places (school, church, health facility, and public transport). Data were collected on electronic 
tablets using the REDCap application (Vanderbilt University, Nashville, Tennessee) [16]. 
Participants who were not known to be HIV positive, or whose most recent negative HIV test was 
more than three months previously, were encouraged to check their HIV status via a rapid HIV test 
on a fingerpick blood sample. Those who declined rapid testing were offered the option of 
undergoing anonymised laboratory enzyme-linked immunosorbent assay (ELISA) for research 
purposes only (further details on HIV testing are presented in the supplementary material Section 1). 
Participants newly testing HIV positive and those previously diagnosed with HIV but not on 
antiretroviral therapy (ART), were referred to initiate ART [17]. Participants with TB symptoms (any 
of cough [≥two weeks, or any duration if HIV positive], fever, night sweats, and weight loss) were 
asked to submit sputum for Xpert MTB/RIF testing. Those unable to produce sputum were referred 
to their nearest clinic for further management in accordance with national guidelines [18]. 
Information extracted from the DSA database included previous HIV test results (for those aged ≥15 
years), and household data including urban/rural location, number of residents, socioeconomic 
status (SES), and distance to the nearest clinic. Community HIV prevalence (for ≥15-year-olds) was 
calculated using 2017 surveillance data by means of a two-dimensional Gaussian kernel density of 3 
km search radius based on previously described methods [19]. 
Laboratory procedures 
Details of laboratory testing are provided in the supplementary material Section 1.  Briefly, venous 
blood was tested for M. tuberculosis infection using the QuantiFERON-TB Gold Plus (QFT-Plus) 
assay (QIAGEN, Hilden, Germany) according to the manufacturer's instructions [20]. Sputum 
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samples were tested using Xpert MTB/RIF (Cepheid, Sunnyvale, CA) at Hlabisa district hospital 
laboratory. 
Definitions 
M. tuberculosis infection was defined as interferon-gamma (IFN-γ) concentration ≥0.35 IU/mL 
(calculated as either TB1 or TB2 antigen minus nil) per the manufacturer's guideline [20]. Lifetime 
household TB contact was defined as either having lived in the same household as a person with TB 
disease for ≥two weeks or having cared for a person with TB during the participant’s lifetime. 
Detailed definitions for exposures are provided in the supplementary material Section 2.  
Statistical analysis 
A sample size of 1,100 was sufficient to estimate the prevalence of M. tuberculosis infection of 50% 
with a precision of ±3% at 5% significance level. To account for non-participation (both inability to 
contact participants and refusal to participate), a total 1,998 adolescents were selected.  
Prevalence was weighted to account for non-response, calculated as the inverse probability of 
participation in strata defined by age, sex, and urban/rural residence.  
To account for non-participation, the weighted M. tuberculosis infection prevalence was calculated 
by multiplying the crude prevalence by the inverse of probability of participation in strata defined 
age, sex, and urban/rural residence. Characteristics of individuals included in the analysis were 
compared with those who were selected but not included (because of non-participation or missing 
results) using Chi-squared tests. Random effects logistic regression taking account of clustering 
within households was used to estimate odds ratios (OR) and 95% confidence intervals (CI) for the 
association of M. tuberculosis infection with potential risk factors. To account for the 
interrelationships between the potential risk factors, a hierarchical approach [21] with three levels 
(community, household, and individual) was used to build a multivariable model. First, community 
factors associated with the outcome at p<0.20 on univariable analysis were retained in a core 
model. Next, household factors were added sequentially to the core model, and retained if they 
remained associated with the outcome at p<0.20, after adjusting for community factors and SES. 
Associations with individual-level factors were determined similarly, with age included in all the 
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models as an a priori confounder. A complete case analysis was performed. Analyses were 
performed using Stata version 14.2 (College Station, TX, USA). 
Ethics approval 
The study was approved by the London School of Hygiene & Tropical Medicine Ethics Committee 
(ref. 10515), the Biomedical Research Ethics Committee of the University of KwaZulu-Natal (ref. 
BE483/15), and the KwaZulu-Natal Department of Health (ref. 184/16). Individual informed written 
consent was obtained from participants aged 18–19 years and from parents/guardians of 
participants aged 10–17 years, with informed assent from the participant. For participants or 
parent/guardians who could not read and/or write, a witness who was not a member of the research 
team attested to the informed consent procedure. 
 Results 
Participant enrolment 
Field workers successfully visited the homes of 1,809/1,998 (90.5%) selected individuals (Figure 
2);1,173/1,809 (64.8%) were screened for eligibility, 575 (31.8%) were not found and 61 (3.4%) 
refused participation. Among those screened, 35 (3.0%) had a history of TB treatment, three (0.2%) 
were ineligible after crosschecking their date of birth, and the remaining 1,135 (96.8%) were 
enrolled. QFT-plus results were available for 1,094 participants (Figure 2). 
Individuals included in the analysis compared to those not included were more likely to be from rural 
communities, and from communities with lower HIV prevalence (Supplementary Table 1). There 
were no differences by age, sex or SES. 
Among 1,094 participants, 548 (50.1%) were female, 266 (24.4%) had a lifetime household TB 
contact, 379 (34.6%) were from urban communities, 965 (88.6%) had evidence of BCG vaccination, 
and 43 (3.9%) were HIV positive (Table 1). Overall, 898 participants had a known HIV status: 641 
were through testing in the study, 103 through surveillance activities, and 154 through self-reporting. 
      83 
M. tuberculosis infection prevalence 
249 participants had IFN-γ values ≥0.35 IU/mL, giving a crude M. tuberculosis infection prevalence 
of 22.8% (95% CI: 20.4%-25.3%). The M. tuberculosis infection prevalence weighted for non-
participation by age, sex and rural/urban residence was 23.0% (95% CI:20.6-25.6%). The 
distribution of IFN-γ values for all participants is presented in Supplementary Figure 1. 
Risk factors for M. tuberculosis infection 
At community level, there was evidence of an association between M. tuberculosis infection and 
community HIV prevalence (Table 2). The odds of M. tuberculosis infection increased with 
increasing community HIV prevalence (linear OR: 1.43 for each unit increase in community HIV 
prevalence category). 
At the individual level, M. tuberculosis infection was positively associated with older age and having 
a lifetime household TB contact (Table 2). The odds of M. tuberculosis infection increased with 
increasing age (linear OR: 1.37 for each unit increase in age group) and were 2.1 times higher 
among participants with history of a household TB contact compared to those without. There was no 
evidence of association between M. tuberculosis infection and BCG vaccination or HIV infection 
after adjusting for community, household, and individual level factors (Table 2). M. tuberculosis 
infection was inversely associated with number of visits to church in the previous month, and houses 
visited during day hours in the previous week. There was no evidence of an association with sharing 
a sleeping room with other people, or with other estimates of social contacts (Supplementary Table 
2). 
Discussion 
In this high TB/HIV prevalence setting, the prevalence of M. tuberculosis infection (23.0%) among 
adolescents was lower than found in the Western Cape province, South Africa [22, 23] . To our 
knowledge, this is the first study reporting a strong evidence of an association between M. 
tuberculosis infection and increased community-level HIV prevalence. 
Recent data on M. tuberculosis infection among adolescents largely comes from two studies 
conducted in densely-populated townships in Western Cape province where prevalence (defined as 
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tuberculin skin test induration ≥10 mm) was much higher: 37% among individuals 5–17 year-olds 
[23] and 42.2% (95% CI: 40.9-43.6) 12–18 year-olds [22]. Possible explanations for this difference 
include differences in social contact patterns, as our study was conducted in a less densely-
populated rural area. A second explanation could be differences in population prevalence of active 
TB; at the time of the studies in Western Cape, the annual TB notification was about 1,400 per 
100,000 [22, 23] compared to 577 per 100,000 in 2015 for uMkhanyakude district (the setting of our 
study) [24]. A third possible explanation is differences in HIV prevalence among notified TB patients. 
For example, in 2015 the HIV prevalence among people notified with TB was 64.3% in 
uMkhanyakude district compared to 44.6% in Cape Town [24]. At individual level, HIV-positive 
individuals are likely to be less infectious due to cavitary lung disease being less common [25].   
A 2013 TST survey among school-going children aged 6–8 years in our setting reported a M. 
tuberculosis infection prevalence of 12.4% (95% CI: 10.2%–15.0%) using TST ≥10 mm [26]. The 
study did not find an association between age and community-level HIV prevalence. However, the 
odds of M. tuberculosis infection for participants living in households with at least two HIV-positive 
individuals were slightly higher (adjusted odds ratio: 1.8, 95% CI: 1.1–3.1). The higher M. 
tuberculosis infection prevalence and the association with increased age in our study (in older 
individuals) reflects longer cumulative exposure to people with infectious TB, increased social 
contact of older adolescents with the wider community [7, 14]. In addition, the older adolescents in 
our study would also have experienced a higher risk of TB infection in their early lives, because TB 
notification rates in KwaZulu-Natal have fallen over the last decade [24]. 
Similar to the Western Cape study [22], we found increased odds of M. tuberculosis infection among 
participants with a lifetime household TB contact. Thus, transmission within households of 
individuals with TB disease remains an important consideration for TB prevention and care 
programmes and highlights the need for enhancing household TB contact tracing to reduce 
transmission. Despite this, 63% of our participants with M. tuberculosis infection reported to have 
never lived in the same house as an individual with TB disease. 
The DSA setting of our study allowed us to investigate the effect of the participant’s community HIV 
prevalence on M. tuberculosis infection. Though ART reduces the risk of TB disease following 
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infection and ART access has improved over the years [27], HIV-positive individuals remain at 
elevated risk of TB disease [28, 29]. Through long-term population-based surveillance, we have 
shown that HIV prevalence has remained consistently high in certain communities within the DSA 
over a number of years [19, 27]. We have also shown that active TB, and specifically drug-resistant 
TB, are associated with those high HIV prevalence areas [30, 31]. The association between higher 
M. tuberculosis infection prevalence among adolescents with higher community HIV prevalence 
suggests continuing transmission in these communities. Targeted efforts to find and treat TB in such 
communities could be effective in reducing TB transmission. 
The odds of M. tuberculosis infection were lower among participants who reported visiting at least 
three houses during day hours in the previous week and those who attended at least three prayer 
meetings in the previous month. This might reflect limitations with our retrospective method for 
social contacts. 
This study has several limitations. First, participants from urban communities and communities with 
high HIV prevalence were under-represented. Since M. tuberculosis infection prevalence was higher 
in communities with HIV prevalence ≥45%, our overall estimate for M. tuberculosis infection 
prevalence may have been slightly underestimated. 
Another limitation is that social contact information was captured retrospectively by asking 
participants about their attendance at indoor gathering places and details of the last visit. Though 
knowledge of attending an indoor gathering place would still be in memory, reporting errors might 
have been introduced concerning the frequency and duration of visits, and numbers of people 
present, resulting in misclassification that may have obscured associations. 
Strengths of this study include a large sample size allowing us to estimate prevalence with high 
precision, and power to detect important associations with potential risk factors. We believe that our 
estimate is reflective of M. tuberculosis infection prevalence among adolescents in this setting. 
Secondly, the QFT-plus test was used, which is a more specific test for M. tuberculosis infection 
than the TST. Furthermore, we experienced a very low proportion of indeterminate results. Another 
strength is that this study was nested within in a well-defined DSA which provided a comprehensive 
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sampling frame and allowed us to determine the effect of non-participation on the estimate for 
prevalence. 
Conclusion 
In this high TB and HIV burden setting, the prevalence of M. tuberculosis infection among 
adolescents was lower than reported from the Western Cape in South Africa. Community-level HIV 
prevalence, age, and lifetime household TB contact were associated with increased odds of M. 
tuberculosis infection. Enhancing TB household contact tracing and targeted case finding in high 
HIV prevalence communities has potential to reduce the burden of TB in this setting. 
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Tables and Figures 
 
 
Figure 1: Conceptual framework for the hierarchical risk factor analysis for Mycobacterium tuberculosis infection among adolescents  
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Home visit attempted 
1,809 (90.5%) 






Not assessed for enrolment: 636 (31.8%) 
- 460 (73.2%) not at home 
- 115 (18.1%) moved from location 
- 61 (9.6%) refused participation 
Not enrolled: 38 (1.9%) 
- 35 (92.1%) previous/current TB treatment 
- 3 (7.9%) not age eligible 
Excluded from analysis: 41 (2.1%) 
- 21 (51.2%) insufficient blood sample 
- 14 (34.1%) declined blood sample collection 
- 6 (14.6%) indeterminate QFT result 
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Table 1 : Characteristics of study participants (n=1,094)  
 N (%) 
Sex  
Female 548 (50.1) 
Male 546 (49.9) 
Age (years)  
10–11 237 (21.7) 
12–14 349 (31.9) 
15–17 297 (27.2) 
≥18 211 (19.3) 
Lifetime household TB contact (n=1089)  
No  823 (75.6) 
Yes 266 (24.4) 
HIV status  
Negative 855 (78.2) 
Positive  43 ( 3.9) 
Unknown 196 (17.9) 
BCG vaccination (n=1085)  
Vaccinated  984 (90.7) 
Not vaccinated 101 (9.3) 
Education level (n=1090)  
Primary 631 (57.9) 
Secondary or above 459 (42.1) 
Location   
Rural 715 (65.4) 
Urban 379 (34.6) 
Household socioeconomic index tertiles (n=1048)  
Low 305 (29.1) 
Middle 350 (33.4) 
High 393 (37.5) 
Number of household residents (n=1070)  
<6 333 (31.1) 
6–7 252 (23.6) 
8–10 248 (23.2) 
>10 237 (22.2) 
Church attendance in previous 4 weeks (n=1073)  
None 664 (61.9) 
1–2 times 176 (16.4) 
≥3 times 233 (21.7) 
BCG: Bacillus Calmette-Guérin; HIV: Human immunodeficiency virus; TB: tuberculosis 
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Table 2: Risk factors for Mycobacterium tuberculosis infection 
Hierarchical 
level 




p-value Adjusted OR1 
(95% CI) 
p-value 
Community Community HIV prevalence (%)      
 <25% 12/85 (14.1)     
 25–34.9% 133/618 (21.5)     
 35–44.9% 61/261 (23.4) 1.43 (1.07–1.92)* 0.02*   
 ≥45% 26/82 (31.7)     
Household Household social economic index score (tertiles)      
 Low 74/305 (24.3) 1 0.72 1a 0.75 
 Middle 79/350 (22.6) 0.87 (0.51–1.47)  0.81 (0.46–1.41)  
 High 83/393 (21.1) 0.81 (0.49–1.36)  0.89 (0.52–1.54)  
Individual Sex      
 Female 123/548 (22.4) 1 0.85 1b 0.80 
 Male 126/546 (23.1) 1.04 (0.72–1.50)  0.95 (0.62–1.45)  
 Age      
 10–11 years 49/237 (20.7)     
 12–14 years 62/349 (17.8) 1.32 (1.09–1.59)* <0.01* 1.37 (1.10–1.71) b  0.01* 
 15–17 years 71/297 (23.9)     
 ≥18 years 67/211 (31.8)     
 Lifetime household TB contact      
 No  168/823 (20.4) 1 <0.01 1b 0.01 
 Yes 78/266 (29.3) 1.90 (1.20–3.01)  2.13 (1.25–3.64)  
 HIV status      
 Negative 193/855 (22.6) 1 0.88 1b 0.35 
 Positive 9/43 (20.9) 0.91 (0.34–2.40)  0.65 (0.20–2.09)  
 Unknown 47/196 (24.0) 1.11 (0.69–1.81)  1.43 (0.80–2.56)  
 BCG vaccination      
 Vaccinated  216/984 (22.0) 1 0.24 1b 0.65 
 Not vaccinated 28/101 (27.7) 1.43 (0.78–2.65)  1.19 (0.32–2.98)  
 Church attendance in previous month      
 None 165/664 (24.8) 1 0.08 1b 0.04 
 1–2 times 37/176 (21.0) 0.75 (0.44–1.26)  0.59 (0.32–1.10)  
 ≥3 times 41/233 (17.6) 0.58 (0.35–0.95)  0.49 (0.27–0.89)  
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Hierarchical 
level 




p-value Adjusted OR1 
(95% CI) 
p-value 
 Visiting other houses during the day (previous 
week) 
     
 None 169/720 (23.5) 1 0.02 1b 0.01 
 1–2 houses 59/227 (26.0) 1.20 (0.76–1.88)  1.00 (0.60–1.69)  
 ≥3 houses 17/136 (12.5) 0.38 (0.19–0.78)  0.28 (0.12–0.66)  
BCG: Bacillus Calmette-Guérin; CI: confidence interval; HIV: Human immunodeficiency virus; OR: odds ratios; QFT: QuantiFERON TB-Gold plus; TB: 
tuberculosis 
* Odds ratios modelled as a linear trend across the categories; n and % QFT positive in each category shown for information only. 
1The adjusted odds ratios were obtained at each level (community, household and individual) of the hierarchical approach as described in the methods 
section. 
a Adjusted for community HIV prevalence and household socioeconomic status. 
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Supplementary material 
Section 1: Laboratory procedures 
Participants without history of HIV testing or with a previous negative HIV test result more 
than three months earlier were encouraged to have a rapid HIV test (parallel test using Abon 
HIV 1/2/0 Tri-line [Abon Biophrarm (Hangzhou) Co., Ltd] and Advanced Quality™ Rapid 
Anti-HIV [InTec Products Inc]) based on a fingerpick blood sample. Those not wishing to test 
were given the option to have an anonymised HIV enzyme-linked immunosorbent assay 
(ELISA) test using their venous blood sample, or to decline HIV testing altogether. The 
anonymised results were not fed back to participants or made available to investigators 
during the course of the study. The ELISA was done at the project laboratory based on a 
two-test algorithm using HIV-1/HIV-2 ELISA (Vironostika HIV-1 Microelisa System: 
Biomérieux, Durham, NC, USA) which was followed by Wellcozyme HIV-1 + 2 GACELISA 
(Murex Diagnostics Benelux B.V., Breukelen, Netherlands).  
For participants aged 10–17 years, we sought consent from the parent/guardian to approach 
the child and encourage HIV testing as part of the study. In line with national guidelines, HIV 
testing for participants aged 10–11 years was done in the presence of the parent/guardian 
after the participant had independently assented to the test [1]. 
Participants with positive Xpert MTB/RIF results were referred to their nearest primary health 
care clinic (PHC) to initiate TB treatment. Participants with negative results but persistent 
symptoms were also referred for further assessment. All HIV-positive participants with QFT-
plus positive results were referred for assessment to their nearest PHC to initiate TB 
preventive therapy, if this was not contraindicated [2]. 
Section 2: Definitions 
HIV status: participants were classified as HIV positive if they either tested positive by rapid 
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surveillance area (DSA) annual HIV surveillance (which includes individuals aged ≥15 
years); or self-reported being HIV positive. Participants were classified as HIV negative if 
they tested HIV negative as part of the study; previously tested negative as part of the 
annual surveillance within the previous two years before enrolment, or self-reported testing 
HIV negative in the previous two years without evidence of being HIV positive. Participants 
were classified as HIV unknown status if they self-reported that they had never tested before 
and did not consent to HIV testing by either rapid test or ELISA in the study; previously 
tested negative in the annual surveillance more than two years before enrolment, or self-
reported an HIV negative test result more than two years before enrolment. Details of HIV 
testing for participants with known HIV status are provided below. 
BCG vaccination was defined as either the presence of a BCG scar or documentary 
evidence of immunisation. 
Household: a group of individuals living on the same residential plot regardless of whether 
they lived in the same building or a different building. 
Household socioeconomic status:  
A household socioeconomic index score was calculated using principal component analysis 
(PCA) [3]. The PCA used ownership or access to the following assets or amenities, as 
measured in the annual DSA surveillance, to create worth index scores for each household: 
electricity, piped water in the homestead, flushing toilets, bed, bicycle, block maker, car, 
cattle, electric cooker with oven, electric hotplate, electric kettle, fridge, gas cooker, 
hoe/spade/fork, van/lorry/tractor, kitchen sink, motorcycle, other livestock (not cattle), primus 
cooker, radio, sofa, sewing machine, tables & chairs, telephone, cell phone, television, 
wheelbarrow, hot water geyser, washing machine, electric heater, paraffin heater, stereo or 
hi-fi, computer or laptop, tractor or farm vehicle, furnishings, jewellery and watches. The 
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This was based on the definition used in the DSA where areas with population density below 
400 per km2 are classified as rural, areas above 400 km2 as peri urban and KwaMsane (a 
township on the south eastern part of the DSA) as urban. For the purposes of this analysis, 
urban and peri-urban were combined as only 37 (3.4%) participants were from urban areas. 
Monthly contact hours with adult males and females: 
Contact hours with adult males (aged ≥12 years) on the last day of visiting an indoor location 
were calculated as the number of people present times the duration (in hours) of the visit. 
Visits lasting less one hour were captured as one hour. This was multiplied by the number of 
visits to that indoor location in the previous four weeks to obtain monthly hours for that 
location. Participants reporting not visiting a location in the previous four weeks were 
assigned zero contact hours for that location. The monthly contact hours for the selected 
indoor gathering locations (school, church, hospital, closed vehicle, bar, and other houses) 
were summed to obtain overall monthly contact hours. The procedure was repeated to 
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Section 3: Comparison of individuals included vs. not included in the analysis 
Supplementary Table 1: Comparison of participants included in the analysis and individuals 
randomly selected but not included in the analysis 
 Included in analysis 
(n=1,094) 
n (column %) 
Not included in 
analysis (n=904) 
n (column %) 
p-value* 
Sex    
Male 546 (49.9) 465 (51.6) 0.47 
Female 548 (50.1) 438 (48.4)  
Age (years)    
10-11  253 (23.1) 195 (21.6) 0.50 
12-14 346 (31.6) 301 (33.3)  
15-17 309 (28.2) 239 (26.4)  
18+ 186 (17.0) 169 (18.7)  
Location    
Urban 379 (34.6) 405 (44.8) <0.01 
Rural 715 (65.4) 499 (55.2)  
Social economic index score 
(tertiles) 
   
Low 305 (29.1) 218 (25.3) 0.15 
Medium 350 (33.4) 325 (37.7)  
High 393 (37.5) 319 (37.0)  
Missing 46 (4.2) 42 (4.7)  
Community HIV prevalence (%)    
 <25%  85 (7.8)  64 (7.1) 0.02 
25–34.9% 618 (56.5) 454 (50.2)  
35–44.9% 261 (23.9) 265 (29.3)  
≥45%  82 (7.5)  86 (9.5)  
Missing  48 (4.4)  35 (3.9)  
* p-values were obtained from Chi-squared test 
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Section 4: Interferon-gamma concentration distribution 
 
Supplementary Figure 3: Interferon-gamma concentration distribution for all participants (n=1,094). 
The red line indicates the manufacturer defined cut-off for Mycobacterium tuberculosis infection (0.35 
IU/mL). 
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Interferon-gamma (IFN-γ) concentration distribution for all participants are shown in 
Supplementary Figure 1. 361 (33.0%) had IFN-γ values ≤0.00 IU/mL; 56 (5.1%) had values 
between 0.20-0.70 IU/mL, 218 (19.9%) had values ≥0.70 IU/mL and 44 (4.0%) had IFN-γ 
values ≥7.59 IU/mL. 
Section 5: HIV status and referral to care 
43 participants were classified as HIV-positive. Among these, 20 were known through self-
reporting being HIV positive and on antiretroviral therapy (ART), 13 though testing in the 
DSA, 8 through testing in the study (5 anonymised ELISA testing and 3 by rapid testing) and 
2 through self-reporting being HIV-positive but not taking ART. 855 participants were 
classified as HIV-negative. Among these 633 were known through testing in the study (470 
through rapid test and 163 through ELISA), 131 through self-report and 91 through testing in 
the DSA. 
13 (1.3%) participants had least one TB symptom and were asked to submit sputum. 
Sputum samples were successfully collected in eight participants and one participant (0.1% 
of all participants) tested Xpert MTB/RIF positive. Overall, among all the participants with 
QFT-plus positive results, 7 (2.8%) were also HIV-positive and were referred for assessment 
for TB preventive therapy in line with national guidelines [2] . 
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Section 6: Hierarchical risk factor analysis 
Supplementary Table  2: Risk factors for Mycobacterium tuberculosis infection showing odds ratios obtained from the crude, partial and fully 
adjusted models at each level of hierarchical approach. 




p-value  Adjusted OR1 
(95% CI) 




Community Level factors 
 
       
Community HIV prevalence (%)        
 <25% 12/85 (14.1)       
25–34.9% 133/618 (21.5)       
35–44.9% 61/261 (23.4) 1.43 (1.07–1.92) 0.023     
≥45% 26/82 (31.7)       
Location        
Rural 156/715 (21.8) 1 0.34 1a 0.54   
Urban 93/379 (24.5) 1.21 (0.81–1.80)  0.84 (0.48–1.47)    
 
Household Level factors 
 
       
Distance to nearest clinic (km) 
(quartiles) 
       
 <1.85 84/301 (27.9) 1 0.13 1a 0.21 1b 0.30 
1.85-3.41 80/403 (19.9) 0.56 (0.34–0.92)  0.59 (0.35–1.01)  0.64 (0.36–1.14)  
3.42-5.36 55/259 (21.2) 0.64 (0.38–1.08)  0.78 (0.43–1.42)  0.82 (0.43–1.59)  
 >5.36 30/131 (22.9) 0.71 (0.37–1.37)  1.02 (0.50–2.06)  1.21 (0.56–2.65)  
Household social economic index 
score (tertiles) 
       
Low 74/305 (24.3) 1 0.72 1a 0.75 1b 0.75 
Middle 79/350 (22.6) 0.87 (0.5–-1.47)  0.81 (0.46–1.41)  0.81 (0.46–1.41)  
High 83/393 (21.1) 0.81 (0.49–1.36)  0.89 (0.52–1.54)  0.89 (0.52–1.54)  
Number of residents        
<6 87/333 (26.1) 1 0.25 1a 0.32 1b 0.41 
6-7 58/252 (23.0) 0.83 (0.49–1.41)  0.83 (0.47–1.45)  0.89 (0.48–1.65)  
8-10 50/248 (20.2) 0.62 (0.35–1.09)  0.61 (0.34–1.11)  0.61 (0.32–1.18)  
>10 46/237 (19.4) 0.60 (0.34–1.07)  0.64 (0.35–1.14)  0.65 (0.34–1.24)  
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p-value  Adjusted OR1 
(95% CI) 
p-value Adjusted OR2 
(95% CI) 
p-value 
Reported smoker in household        
No 197/880 (22.4) 1 0.96 1a 0.53 1b 0.58 
Yes 47/207 (22.7) 0.99 (0.62–1.59)  0.85 (0.50–1.43)  0.85 (0.49–1.50)  
 
Individual Level factors 
 
       
Sex        
Female 123/548 (22.4) 1 0.85 1c 0.96 1d 0.80 
Male 126/546 (23.1) 1.04  (0.72–1.50)  0.99 (0.64–1.52)  0.95 (0.62–1.45)  
Age (years)        
10-11  49/237 (20.7)       
12-14 62/349 (17.8)       
15-17 71/297 (23.9) 1.32 (1.09–1.59) <0.014 1.36 (1.09–1.71) 0.01c,4 1.37 (1.10–1.71) 0.01d,4 
≥18 67/211 (31.8)       
Lifetime household TB contact        
   No  168/823 (20.4) 1 0.01 1c 0.02 1d 0.01 
   Yes 78/266 (29.3) 1.90 (1.20–3.01)  1.90 (1.12–3.12)  2.13 (1.25–3.64)  
HIV Status        
Negative 193/855 (22.6) 1 0.88 1c 0.39 1d 0.35 
Positive 9/43 (20.9) 0.91 (0.34–2.40)  0.65 (0.20–2.11)  0.65 (0.20–2.09)  
Unknown 47/196 (24.0) 1.11 (0.69–1.81)  1.41 (0.78–2.53)  1.43 (0.80–2.56)  
BCG vaccination        
Vaccinated  216/984 (22.0) 1 0.24 1c 0.99 1d 0.65 
Not vaccinated 28/101 (27.7) 1.43 (0.78–2.65)  1.00 (0.47–2.15)  1.19 (0.32–2.98)  
Smoking        
No 240/1070 (22.4) 1 0.32 1c 0.81 1d 0.54 
Yes 6/18 (33.3) 1.98 (0.52–7.54)  0.82 (0.17–4.07)  0.61 (0.12–2.26)  
Alcohol intake        
No 226/1021 (22.1) 1 0.21 1c 0.76 1d 0.75 
Yes 16/54 (29.6) 1.59 (0.72–3.54)  1.17 (0.44–3.06)  1.17 (0.45–3.04))  
Education level        
Primary 130/631 (20.6) 1 0.06 1c 0.23 1d 0.36 
Secondary or above 118/459 (25.7) 1.45 (0.98–2.13)  0.64 (0.30–1.37)  0.71 (0.34–1.49)  
Admission to hospital        
No 221/967 (22.9) 1 0.67 1c 0.40 1d 0.27 
Yes 25/121 (20.7) 0.87 (0.48–1.60)  0.74 (0.37–1.48)  0.68 (0.34–1.36)  
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p-value  Adjusted OR1 
(95% CI) 
p-value Adjusted OR2 
(95% CI) 
p-value 
Social contact factors 
 
Contact hours with adult men        
<100 63/274 (23.0) 1 0.95 1c 0.76 1d 0.69 
100-1047 63/275 (22.9) 0.99 (0.58–1.67)  1.30 (0.70–2.43)  1.47 (0.78–2.76)  
1048-2400 59/272 (21.7) 0.89 (0.53–1.52)  1.00 (0.53–1.87)  1.16 (0.62–2.18)  
>2400 64/273 (23.4) 1.04 (0.62–1.76)  1.24 (0.66–2.32)  1.24 (0.66–2.31)  
Contact hour with adult females        
<160 68/277 (24.5) 1 0.47 1c 0.83 1d 0.89 
160-1216 53/274 (19.3) 0.69 (0.41–1.18)  0.80 (0.43–1.49)  0.91 (0.49–1.66)  
1216-2880 66/270 (24.4) 1.03 (0.61–1.74)  1.07 (0.57–2.00)  1.16 (0.63–2.16)  
>2880 62/273 (22.7) 0.89 (0.53–1.50)  0.99 (0.53–1.84)  1.09 (0.59–2.00)  
Church attendance in previous month        
None 165/664 (24.8) 1 0.08 1c 0.13 1d 0.04 
1-2 times 37/176 (21.0) 0.75 (0.44–1.26)  0.66 (0.35–1.23)  0.59 (0.32–1.10)  
≥3times 41/233 (17.6) 0.58 (0.35–0.95)  0.58 (0.33–1.03)  0.49 (0.27–0.89)  
Health facility attendance (12 months)        
No 142/667 (21.3) 1 0.26 1c 0.88 1d 0.83 
Yes 104/422 (24.6) 1.24 (0.85–1.81)  1.03 (0.66–1.61)  1.04 (0.68–1.62)  
Visiting other houses during the day        
None 169/720 (23.5) 1 0.02 1c 0.02 1d 0.01 
1-2 houses 59/227 (26.0) 1.20 (0.76–1.88)  1.17 (0.69–1.91)  1.00 (0.60–1.69)  
≥3 houses 17/136 (12.5) 0.38 (0.19–0.78)  0.31 (0.13–0.72)  0.28 (0.12–0.66)  
Sharing sleeping room with other 
people 
       
None 84/363 (23.1) 1 0.88 1c 0.71 1d 0.56 
1 person 78/336 (23.2) 0.97 (0.61–1.54)  1.24 (0.73–2.11)  1.33 (0.78–2.26)  
≥2 persons 84/389 (21.6) 0.89 (0.57–1.40)  1.08 (0.64–1.83)  1.13 (0.66–1.93)  
BCG: Bacillus Calmette-Guérin; CI: confidence interval; HIV: Human immunodeficiency virus; OR: Odds ratios; QFT: QuantiFERON TB-Gold plus; TB: 
tuberculosis 
* Odds ratios modelled as a linear trend across the categories; n and % QFT positive in each category shown for information only. 
1 Partially adjusted by a priori confounders and variables remaining significant (p<0.2) at higher levels in the hierarchy 
2 Adjusted by a priori confounders, variables remaining significant (p<0.2) at higher levels in the hierarchy and variables remaining significant (p<0.2) that 
levels in the hierarchy. 
3 Assuming a linear trend across the categories. 
a Adjusted by community HIV prevalence 
b Adjusted by community HIV prevalence and socioeconomic status (a priori confounder at household level) 
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c Adjusted by community HIV prevalence, socioeconomic status and age (a priori confounder at individual level) 
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Chapter 6: Discussion 
The aim of this thesis was to describe the prevalence and determinants of M. tuberculosis infection 
among adolescents in a high TB and HIV prevalence setting. In this chapter, I summarize the main 
findings and discuss the implications for TB prevention and care. I highlight the limitations of the 
research work carried out and make recommendations for TB prevention and care policy and future 
research. 
Main findings 
In this high TB and HIV prevalence setting the weighted M. tuberculosis infection prevalence was 
23.0% (95% CI:20.6–25.6%). Older age, having a lifetime household TB contact and living in 
communities with high HIV prevalence were associated with increased odds of M. tuberculosis 
infection There was no evidence of association between M. tuberculosis infection and urban/rural 
residence, household socioeconomic status, household number of residents, passive smoking, sex, 
HIV status, BCG vaccination, smoking, alcohol intake and increased cumulative monthly contact 
hours with either adult males or adult females during visits to indoor gathering places. The spatial 
distribution of participants with M. tuberculosis infection showed geographical variations with M. 
tuberculosis infection prevalence above 35% observed in week-blocks in the south-eastern part of 
the study area. 
Comparison with previous studies  
The estimate for M. tuberculosis infection prevalence obtained in this study (the AHRI study) 
(23.0%) was higher than the prevalence among school-going children aged 6-14 years in a national 
TST survey in Kenya  where a M. tuberculosis infection prevalence of 10.2% was reported (using 
TST induration ≥10 mm) [53]. The prevalence was similar to the prevalence reported among school-
going children aged 6-11 years from 16 communities in Zambia (16.5%) [52] and among 
adolescents (12-18 years) in two rural districts in eastern Uganda (16.1%) [51] (both using TST 
induration ≥10 mm). As mentioned in chapter 2, the higher prevalence in South Africa reflects the 
higher annual TB notifications [1, 7]. 
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Within South Africa, recent data on M. tuberculosis infection prevalence among adolescents largely 
comes from studies conducted in the Western Cape province, where much higher estimates of M. 
tuberculosis infection prevalence have been reported. In one township close to Cape Town, 
Middelkoop et al. reported a M. tuberculosis infection prevalence of about 53.9% among school-
going adolescents aged 13–22 years (using TST≥10 mm)  [78] and in another community, Mohamed 
et al. reported a prevalence of 50.9% among school-going children aged 12-18 years (using IGRA) 
[40]. However, these studies were conducted among adolescents attending primary and secondary 
schools in the study areas. Though school enrolment is high among individuals aged 10–15 years in 
South Africa (95-97%), school attendance rapidly drops when individuals finish secondary school 
(after 17 years) [95]. Thus, the prevalence of M. tuberculosis infection might have been 
underestimated as the prevalence was higher among the older participants. In addition, adolescents 
not attending school are more likely to be from households with low socioeconomic status where the 
risk of M. tuberculosis is usually high due to poor living conditions [94, 96-98]. The plausible 
explanation for the difference in M. tuberculosis infection prevalence between the AHRI study and 
the studies in the Cape Town could be differences in social contact patterns as the studies in Cape 
Town were conducted in townships where homesteads are usually close together unlike in the AHRI 
study area (in rural KwaZulu-Natal) where homesteads are scattered except for the communities in 
the township on the south eastern part of the study area which is a smaller part of the study area. 
The other difference could be the difference in infectiousness of the TB patients in the two 
provinces. Between 2012-2015, the annual TB notifications for all TB patients in Western Cape and 
KwaZulu-Natal provinces remained similar (from 776.5 in 2012 to 681.4 per 100,000 population in 
2015 for Western Cape province and from 1,060.4 to 685.2 per 100,000 population for KwaZulu-
Natal). However, in uMkanyakude district within KwaZulu-Natal province about 64.3% of all TB 
patients in 2015 were HIV positive while only 44.6% were HIV positive in Cape Town [99]. Thus, the 
TB epidemic in the current setting is largely driven by the very high HIV prevalence. Immune 
suppressed HIV positive individuals are likely to be less infectious as they normally present with 
sputum smear negative TB disease compared to HIV negative individuals [100]. 
The finding of increased odds of M. tuberculosis infection with increasing age are compatible with 
findings from the above mentioned studies among adolescents in the Western Cape province and 
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rural districts in Uganda [40, 55, 56, 58, 77, 78, 101, 102]. In a study investigating the effect of  
passive smoking in a township in Western Cape, Den Boon et al. reported the odds of M. 
tuberculosis infection was 3.6 (95% CI: 2.6-5.0) times higher among 10-14-year olds compared to 0-
4-year olds [103]. Mahomed et al. reported an odds of M. tuberculosis infection of 1.3 (95% CI: 
1.20–1.5) times among adolescents aged 16-18 years compared to 12-15-year olds. The increased 
odds of infection among older individuals reflects both overall increased cumulative exposure to 
sources of M. tuberculosis infection and increase in social contact as individuals grow older [104]. 
This is further reflected in studies which enrolled participants of all ages which reported much higher 
M. tuberculosis infection prevalence among older individuals (>18 years). In Western Cape province, 
Den Boon et al. reported a M. tuberculosis prevalence of 80.4% among individuals aged >25 years 
compared to 66.4% among 15-24-year olds [105]. In the same province, Wood et al. reported a 
prevalence of 74.7% among 25-40-year olds compared to 41.7% among 11-15-year olds. However, 
the estimates in the older participants (>18 years) were obtained using individuals attending an HIV 
testing clinic which may not be representative of the general population [56] while Den Boon et al. 
enrolled participants using a listing of residential addresses of two communities [105]. However, the 
completeness of this listing was at the time of the study is not clear. 
Since M. tuberculosis transmission is determined by risk of contact with infectious individuals, 
household contacts of individuals with TB disease are at increased risk of infection  [106]. 
Consistent with previous studies, we found increased odds of M. tuberculosis infection among 
individuals with a lifetime household TB contact [40, 55, 58, 101]. Though household TB contact was 
important as also seen in the previous studies, only 78 (31.7%) of all the participants with QFT-plus 
positive results reported to have ever lived in the same house as a person with TB disease during 
their lifetime. This might indicate transmission in the wider community as well as transmission from 
undiagnosed household contacts [107]. Thus, there is need for a better understanding the locations 
where transmission occurs in the wider community in this setting. 
Since majority of transmission are likely to occur in the wider population and not just within 
households of people diagnosed with TB, there has been interest in understanding social contacts 
with potential for M. tuberculosis transmission. Contacts with adult men (≥15 years) are of interest 
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as globally the prevalence of TB disease is higher among men. In a recent meta-analysis of 56 
population based TB prevalence surveys from middle and low income countries, Horton et al. 
reported an estimated male to female prevalence ratio of 2.2 (95% CI 1.9–2.5) for bacteriologically-
confirmed TB disease [108]. In the AHRI study, we did not find an association between M. 
tuberculosis infection and increased cumulative monthly contact hours with either adult males or 
adult females. This possibly reflects limitations with the social contact diary method in measuring 
social contacts and teasing out the social contacts with potential for increased risk of M. tuberculosis 
transmission. Furthermore, a recent mathematical modelling analysis combining of data on social 
contacts, TB disease incidence among adults and M. tuberculosis infection incidence among 
children (6-11 years) suggested that though household and non-household repeated contacts 
contribute about 50% of contact time, they only contribute about 13% and 8% of disease 
transmissions respectively and that majority of transmissions (about 79%) possibly occurs from non-
repeated contacts [109]. This potentially further explains the lack of association with increased 
contact hours with adult males or females as the social contacts measured in this study (for example 
contacts at church or school) are more of repetitive nature. 
The exploratory analyses for the spatial distribution of M. tuberculosis infection showed geographical 
variations with the highest prevalence (above 35%) observed in week-blocks on the south eastern 
part of the study area. Long-term surveillance has shown that HIV prevalence has consistently 
remained high in this part of the DSA [89, 110]. Previous work in the DSA has also shown that both 
self-reported and drug resistant TB are associated with the high HIV prevalence communities [67, 
68]. The high M. tuberculosis infection prevalence in these communities suggests continuing 
transmission. Targeted efforts to find and treat TB in these communities could be effective in 
reducing TB transmission. There were no clear similarities between the spatial distribution for M. 
tuberculosis infection and self-reported lifetime household TB contact. This possibly reflects 
movements within the DSA as the participants might have had a household TB contact in a different 
house other than the current one. This also possibly reflects transmission in the wider population 
and not just within households of individuals with TB disease. 
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Tobacco smoking has long been shown to increase the risk of progression to TB disease as well as 
death from TB disease [111-113]. Though definitive evidence of the effect on M. tuberculosis 
infection is lacking, tobacco control is an important component in the control of the TB epidemic 
[114-116]. A recent large study investigating M. tuberculosis infection among school-going children 
(aged 6-13 years) in Mongolia reported an increasing odds of M. tuberculosis infection with increase 
in the number of reported smokers in the living in the same house [102]. The lack of association with 
passive smoking in the AHRI study possibly reflects differences in the prevalence of smoking. In 
2010, the prevalence of current smoking among men in Mongolia was estimated at 46.1% [117] 
compared to 29.2% among South African men in 2012 [118]. However, this may not reflect the 
prevalence of smoking in the study area as the prevalence among black South African men was 
estimated to be lower than other races like coloureds and Indians who are not members of the AHRI 
study area. The lack of association may also reflect differences in levels of exposure to tobacco 
smoking within the household in Mongolia and the AHRI study area. In the rural communities of the 
AHRI study are homesteads are organised into separate dwellings within a bounded residential plot. 
Thus, individuals of the same household may not share the same indoor space for extended 
periods. 
Estimates for M. tuberculosis infection prevalence from TST surveys among young children (<10 
years) are complicated by among other things cross-reactivity with BCG vaccination [52, 53, 119, 
120]. This was less likely the case in this study as the QFT-plus test was used, which is a more 
specific test for M. tuberculosis infection as it contains antigens which are specific to M. tuberculosis 
and are not present in the strains used in BCG vaccination [13, 16, 19]. Similar with previous studies 
using QuantiFERON TB tests among adolescents (10-19-year olds) in the Western Cape province, 
South Africa and Mongolia, [40, 102] we found no association between BCG vaccination and M. 
tuberculosis infection. This may reflect the fact that absence of visible scars does not mean that the 
participants were not vaccinated as scars are not visible in other individuals [121, 122]. A re-analysis 
of three nationwide TST surveys conducted in Tanzanian between 1990-2002 including 215,739 
participants with visible BCG scars and 61,849 without visible scars found a 11.0% protective effect 
of BCG vaccination on M. tuberculosis infection at ≥19 mm TST induration cut off with higher 
protective effect at higher cut offs [123]. In addition, a meta-analysis of 14 studies of children and 
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adolescents (<16 years) exposed to TB disease from high and low TB prevalent settings reported a 
protective effect of BCG vaccination of about 19% [124]. This has rekindled interest on the 
protective benefit of BCG vaccination. A recent phase II trial evaluating the protective effect of BCG 
revaccination among adolescents who were BCG vaccinated at birth and without evidence of M. 
tuberculosis infection in a high TB prevalence setting reported that BCG revaccination reduced rates 
of sustained QFT conversion from <0.35 IU/ml to ≥0.35 IU/ml with an efficacy of 45.4% [26]. 
However, the clinical relevance of conversion at this cut off is not established as values around this 
cut off may represent variation due to repeat testing [92]. 
Limitations 
There are some limitations with the research work presented in this thesis. Firstly, as mentioned in 
chapter 5, participants from urban week-blocks which have a higher population density and HIV 
prevalence were underrepresented. Since the odds of M. tuberculosis infection were higher in 
communities with HIV prevalence, the estimate for M. tuberculosis infection prevalence may have 
been underestimated. Though the urban communities in this study area are have a higher 
prevalence of both M. tuberculosis and HIV infection, they form a smaller part (about 12%) of the 
DSA population [89]. In addition, the estimate for M. tuberculosis infection prevalence takes account 
of non-participation by age, sex and urban/rural residence. Thus, the estimate is less likely 
influenced by the poor participation in urban communities. We believe that our estimate is reflective 
of this population. The results are also applicable to other rural communities in KwaZulu-Natal 
province where dwelling places are organised into multigenerational homesteads and not clustered 
into villages. Furthermore, the analysis for risk factors for M. tuberculosis infection took account of 
clustering within households. Thus, the estimates for the odd ratios obtained for the associations 
with M. tuberculosis infection were more robust compared to the analysis not adjusted for clustering 
within households. Overall, adjusting for clustering within households resulted in increased odds 
ratios and wider confidence intervals as would be expected. 
Secondly, with the cross-sectional design, we could not establish causal relationships between the 
outcome and the exposures of interest. We also could not establish whether the outcome happened 
after the exposure. For example, the M. tuberculosis infection might have occurred before the 
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participant had a household TB contact. The other limitation is with the QFT-plus test, though it is 
more specific to M. tuberculosis infection than the TST, it does not inform whether the infection 
occurred recently (for example in the last year) or further in the past [11, 19, 21, 125]. In addition, it 
has a low predictive value for progression to TB disease. Using a cohort of adolescents (aged 18-20 
years) in a high TB prevalence setting in Western Cape province, Nemes et al. reported that 
adolescents converting from IFN-γ values <0.2 IU/ml to IFN-γ >0.7 IU/ml were 10.3 (2.4–93.6) times 
more likely to progress to TB disease. However, there were only two participants who developed TB 
disease among the non-convertors, the risk ratio might have been overestimated as shown by the 
very wide confidence interval [92]. With the cross-sectional design, we could not verify this finding. 
The other limitation is with the social contacts data. Social contacts are classically measured by 
collecting detailed information (including, age, sex, duration of the contact and whether the contact 
occurred indoor) on each individual that the participants made on a selected day (usually a day 
before the interview) [126-132]. As mentioned in chapter 5, in the AHRI study, participants were 
asked history of attendance at selected indoor gathering places (including school, church, health 
facility and travel in closed vehicles) and details of the last visit (including duration and number of 
people present). Reporting errors were likely introduced in estimating actual frequency of 
attendance, duration and number of people present at the last visit resulting in the obscuring of the 
associations between M. tuberculosis infection and the estimated increased monthly contact hours 
with either adult males or females. In addition, we defined adults as individual at least 12 years old 
as individuals with TB disease at this age are more likely to present with pulmonary TB disease 
which is more infectious than disseminated TB disease in younger children [133, 134]. However, the 
prevalence of notified disease is highest among older (>18 year) individuals [1]. This may explain 
the lack of association with increased monthly contact hours with adult males or females. 
A major limitation with the geospatial analyses was that participants were geo-located to their week-
blocks which are wide geographic areas. The estimates for M. tuberculosis infection prevalence 
obtained in the week-blocks were prone to random error, especially in week-blocks with a small 
number of participants. This may explain the high M. tuberculosis prevalence observed in one week-
block on the north-western part of the study area where only six participants were enrolled and 
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among them, four (66.7%) had M. tuberculosis infection. Secondly, the analysis did not take account 
of time spent at the “current” household as regular mobility within the DSA is common and 
individuals may concurrently belong to more than one household. Thirdly, data on the underlying 
spatial distribution of active TB disease in the area were not available. Comparison with spatial 
distribution of active TB disease was based on self-reported information may not be a robust 
measure of adult TB disease. 
Strengths of the study 
There are several strengths of the results presented in this thesis. Firstly, the sample size was large 
enough to estimate M. tuberculosis infection prevalence with a high precision and the study was 
powered to detect associations with potential risk factors. However, the estimated prevalence 
(23.0%) was lower than an anticipated prevalence of 50% based on studies among adolescents in 
the Western Cape province [40, 83]. The precision would be lower than initially intended. 
Secondly, the QFT-plus test which is a more specific test (compared to the TST) was used to 
measure M. tuberculosis infection. The tests were performed in a specialised project research 
laboratory with highly trained and experienced staff. A batch of the first 100 samples was sent to an 
external accredited laboratory as a quality control measure and a 100% agreement was achieved. 
Thus, the measure for M. tuberculosis infection was both objective and more specific. 
Thirdly, reporting bias was reduced by interviewing parents/guardians of the younger participants 
(10-17 years) on questions about BCG vaccination, previous TB treatment and household TB 
contact. The parent/guardian was more suited to give accurate information as the exposure might 
have happened when the participant was still too young to recall. In addition, where available  
immunization records were cross-checked to ascertain the BCG vaccination status of the 
participants and the proportion of participants where the immunization records were available was 
reasonably high (756 [69.1%]).  
The other strength of this study was that it was conducted in a DSA setting. Unlike in many 
situations where the sampling frame is not available, the DSA provided a complete sampling frame 
of all eligible individuals in the study area and we were able to make comparisons between 
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individuals who participated and those who did not. Thus, we were able to determine the effect of 
non-participation on the estimate for prevalence. Information on household socioeconomic status, 
household number of residents, urban/rural residence and individual HIV status (for ≥15-year olds) 
is routinely collected in a standardised way during the surveillance and was available. In addition, 
we collected individual information on a wide range of exposures including, chronic illnesses, 
smoking, admission to hospital, lifetime household TB contact and attendance at indoor gathering 
places. This enabled testing associations with M. tuberculosis at community, household and 
individual level.  
Recommendations 
Our results show that adolescents reporting history of a household TB contact had higher odds of M. 
tuberculosis infection. This suggests that adolescents who are household contacts of people with TB 
disease in this area remain at increased risk of infection regardless of when the contact occurred 
during the adolescent’s lifetime. The current national South African TB prevention and care 
guidelines recommend contact investigation of individuals with laboratory confirmed TB disease. 
However, this is hardly done in practice largely due to low yield of new confirmed TB patients 
identified with the increased intensified effort [135]. Thus, opportunity to identify individuals at risk of 
disease is missed. For example, in a high HIV prevalence setting like this study area, HIV positive 
household contacts who are latently infected with M. tuberculosis can benefit from preventive 
therapy even though they do not have TB disease at the time of the screening. 
Our results also suggest that majority of infections in this area might be clustered in communities 
with very high HIV prevalence. Spatially targeting these communities with interventions like ACF 
(active case finding) has potential to make an impact in identifying individuals with disease early. 
However, evidence for this approach is lacking. Research work is needed to explore how best 
spatially targeted interventions can be implemented and their benefit.  
Since the risk of M. tuberculosis infection is determined by risk of contact with infectious individuals 
[106], research work is needed to understand better social contacts and locations with potential for 
M. tuberculosis transmission in the wider community so that effective interventions can be put in 
place. Information on social contacts is largely captured using social contact diaries which are prone 
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to recall and reporting biases [136]. To eliminate biases with social contact diaries, more recent 
studies have collected social contact data using wireless proximity sensors which detect presence of 
other devices within a defined distance [129, 137-139]. However, this approach is not robust enough 
as it is limited to contacts with other study participants only. Another approach was used in Cape 
Town where wearable carbon dioxide (CO2) monitors were used to measure ventilation during visits 
at indoor gathering places [140]. Future studies can explore the effect of increased indoor exposure 
to CO2 on the risk of M. tuberculosis infection.    
Measuring M. tuberculosis infection remains a challenge as there is no gold standard test. Both TST 
and IGRA are indirect markers of M. tuberculosis exposure and do not discriminate latent M. 
tuberculosis infection from active disease [11, 13, 19]. TST is cheaper and has been mass 
administered in different populations [54, 141, 142]. However, TST is prone to false positive results 
due to BCG vaccination and infection with other NTMs as such interpretation of TST data is 
complicated [54, 143]. Though IGRAs are more specific to M. tuberculosis than TSTs, they have 
limited use in low income settings due to high cost and the need for extensive laboratory 
infrastructure [11, 19]. There is need for development of better simpler tests for M. tuberculosis 
infection. The C-Tb ( Statens Serum Institut, Copenhagen, Denmark)  is a newer skin test containing 
M. tuberculosis specific antigens ESAT-6 and CPF-10 [18]. The C-Tb promises to offer the 
specificity of IGRAs without the requirement for extensive laboratory infrastructure. However, it still 
needs to be validated. 
Nemes et al. suggested that IGRA conversion from low IFN-γ values to higher values may 
determine progression to TB disease [92]. Further research is required to validate this finding. 
Further research is also required to determine the predictive value of high baseline IFN-γ values on 
the progression to TB disease.  
Conclusion 
The prevalence of M. tuberculosis infection among adolescents in this high TB and HIV prevalence 
area was lower than the prevalence in Western Cape province. Increased community HIV 
prevalence, older age and having a lifetime household TB contact were associated with increased 
odds of M. tuberculosis infection. This reflects continued transmission both within households of 
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people with TB disease and in the wider community. Enhancing household contact tracing will help 
identify household contacts who are infected and at risk of developing TB disease early. Spatially 
targeting worst affected communities especially those with high HIV prevalence with interventions 
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Appendix 9: Study questionnaire for participants (10-19 years) 
Contact Attempts 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
 Contact Attempts - Memory Aid 
* Introduce AHRI 
* I am a nurse (AHRI uniform and badges) 
* Structure and time outline 
* Find private space to speak with the participant 
 
 Section taken from PIP 
[Up to 6 attempts will be made. At 4th attempt, provide information to study coordinator to evaluate 
whether further attempts are necessary.] 
 
Personal Information 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  Personal Information Memory Aid 
* If participant is below 18 years and parent/guardian has already been interviewed, skip to Q10 




Participant’s (child’s) name: [Text] c_parti_name 
[Text, 50 characters] 
 2.1 
Interview 
Is the participant’s pre-loaded name correct? Radio 
0 No 
1 Yes 
If Yes, Skip to Q3.1 
Do not show if Q1.1 is YES 
c_partnam_corr 
[integer; 1 digit; range 0–1] 
  2.1.1 
Interview 









[Text, 50 characters] 
 3.1 
Preloaded 





[integer; 1 digit; range 1,2] 
 4.1 
Pre-loaded 
Participant's date of birth [Date] c_dobd 
[standard AHRI date variable; range 
1999/01/01-2009/12/31] 
  4.1.1 Age Number c_age 
 
176 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
Pre-loaded [integer; 2 digit; range 10-19] 
 5.1 
Interview 
Is the participant’s pre-printed date of birth correct? Radio 
0 No 
1 Yes 
(If Yes, Skip to Q6.1) 
c_d_prep_dob 
[integer; 1 digit; range 0–1] 
 5.1.1 Interview If not correct, please provide the correct date of birth 
 
If exact date of birth is not known, please request to see 
a ID or birth certificate and check the date of birth from 
this document.  
 
If document is not available and only the year of birth is 
known, enter 15 as the day of birth and June as the 
month of birth. 
[date] c_correct_dob 
   Age Eligibility Memory Aid 
* Participants are eligible if date of birth if after 1 May 1999 and before 30 April 2008 
 
  calculated Participant’s correct age on day of interview Number c_age_correct 
  5.1.2 
Interview 





(If Yes, Go to Q6.1) 
c_age_eligible 
[integer; 1 digit; range 0–1] 
   If No, Pop Up Message: 




BSID Number c_resp_bsid 




BS Owner Text c_bs_owner 
[text; 50 characters] 
 8.1 
Pre-loaded 
Location/Isigodi Text c_location_isigodi 
[text; 50 characters] 
 9.1 
Pre-loaded 
Household Head Text c_hh_head 







Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  10.1.1 
Interview 







[integer; 1 digit; range 1,2] 
  10.2 
Interview 
Start time of interview [Time] c_resp_dob 
[standard AHRI time variable; 00.00-
23:59] 
  10.3 
Interview 
Date of Interview [Date] c_date_of_interview 
[standard AHRI date variable; range 
2017/11/01-2019/12/31] 
Assessment of Capacity to Consent 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  
Section taken from PIP 
Eligibility Checklist 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
 Eligibility Checklist (Previous/current TB treatment) 
Before giving detailed information about the study, perform the following eligibility checklist for the study participant 
 
 1.1  
Interview 
Have you ever received treatment for TB disease? 
 
NB: Participant may confuse IPT from TB treatment. 
Make sure this is clear. 
(If needed, explain that treatment for TB disease will 
have been with at least four drugs [though it may 
have been in one tablet, e.g., Rifafour] every day for 
two months, and then two drugs [again, may have 
been in one tablet, e.g., Rifinah] every day for a 
further four months [i.e., a total of at least 6 months].   
 
This is different from isoniazid preventive therapy 
[IPT], which is used to treat TB infection, and will have 




9 Don’t know 
 
c_tbtx_ever 
[integer; 1 digit; range 0–1, 9] 
 if No or Don’t Know, Pop Up Message: 
 
178 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
Please provide detailed information about the study to the participant and obtain informed consent 
  1.1.1 
Interview 
If yes, when did you start TB treatment? 
(If more than once, get details for the most recent 
episode) 
[Dropdown] 
99 = Don’t know 
c_tbtx_dstartm 
[integer; 2 digits; range 1–12, 99] 
[Dropdown] c_tbtx_dstarty 
[integer; 4 digits; range 1998–2017] 
  1.1.2 
Interview 
Where (at which health facility) did you start TB 
treatment? 
[Dropdown] [List of hospitals and clinics in PIP] 
96 = Other (specify) 
99 = Don’t know 
c_tbtx_clin 
[integer; 2 digits; range 01–XX, 96, 99] 
   1.1.2.1  
Interview 
Other, specify 
[only appear if 96] 
[Text] c_tbtx_clin_o 
[string, 30 characters] 
If Q1.1 is Yes, Pop Up Message: 
Participant is not eligible please go to the End of Survey Instrument and terminate the interview 
Informed Consent Form 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  Informed consent – Memory aid 
* Check if participant can read and write and can read information sheet on their own. 
* If the participant is not able to read or write, ask for a witness within the homestead to witness the process of giving information and obtaining 
consent. 
 *Informed Consent Information sheet* 
 1.1 
Interview 
Name of interviewer Text p_staff_name 
[Text; 50 Characters] 
 1.2 
Interview 




Date Date and time p_staff_date 











[integer; 1 digit; range 0–1] 
  If No, Pop Up Message 
Parent/guardian refused participation, please go to the End of Survey Instrument and conclude the interview. 
 1.5 
Interview 
Name of respondent Text p_pg_name 
[Text; 50 Characters] 
 
179 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
 1.6 
Interview 




Date Date and time p_pg_date 




Is the participant able to sign? [Radio]  
0 No 
1 Yes 
(If Yes, skip to section 6) 
p_sign 
[integer; 1 digit; range 0–1] 
  1.8.1 
Interview 
Name of witness Text p_witness_name 
[Text; 50 Characters] 
  1.8.2 
Interview 
Signature Picture p_witness_signature 
[format: .png] 
  1.8.3 
Interview 
Date Date and time p_witness_date 
[standard AHRI date variable; range 
2017/11/01-2019/12/31, 00.00-23.59] 
 
Adolescent TB Study (Study specific questions) 








Have you ever been to school? [Dropdown] 
0 No, never been to school 
1 Yes, previously 
2 Yes, currently 
(If No, skip to Q7) 
c_edu  
[integer; 1 digit; range 0–2] 
  6.1.1 
Interview  
What is the highest grade of school that you have 
reached? 
[Number] 
96 = Other, specify 
c_edu_grade  
[integer; 2 digits; range 01–12, 96] 
   6.1.1.1 
Interview 
Other grade if not on the list 
[only appear if 96] 
[Text] c_edu_grade_o 
[Text, 30 characters] 
  6.1.2 
Interview 
Which school do you currently go to? 
(Most recent school if not going to school now) 





[integer; 2 digits; range 01–XX, 96] 
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96 Other, specify 
 
   6.1.2.1 Other, specify 
[only appear if 96] 
[Text] c_edu_school_o 
[string, 30 characters] 
 




Have you ever been vaccinated against TB? 
(If the participant is unsure, explain that this would 
have been an injection in one of the arms (upper side) 
at birth [before the mother was discharged from 
hospital] or within the first year of life. The site of the 
injection may have become very inflamed (a swollen 
and painful blister), and may have developed into an 
opening in the skin with pus.  This will then have left a 




9 Don’t know 
 
c_bcg_vac 
[integer; 1 digit; range 0–1, 9] 
 7.2  
Interview/ 
[Parent CRF] 
Is your road to health card available? 
(Ask participant if RTHC card is available and if you 





(if No, skip to Q7.3) 
c_rthc 
[integer; 1 digit; range 0–1] 
  7.2.1 
Interview/ 
[Parent CRF] 





[integer; 1 digit; range 0–1] 
 
Ask participant if they have a visible scar on the right or left upper arm, obtain permission to examine the scar: 
 7.3 
Interview 
May I examine your arm for a TB vaccination scar? [Radio] 
0 No 
1 Yes 
(If No, skip to Q8) 
c_bcg_check 
[integer; 1 digit; range 0–1] 
  7.3.1 
Interview 






[integer; 1 digit; range 0–2] 
 
Question 8 TB Symptoms 
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Tell participant: I will now ask some questions about symptoms of TB. If I think it might be needed, I might ask you to give me sputum samples, at the 
end of the interview, which will then be tested for TB at the clinic.  
 8.1 
Interview 
Do you currently have a cough? [Radio] 
0 No 
1 Yes 
(If No, skip to Q8.2) 
c_cough 
[integer; 1 digit; range 0–1] 
  8.1.1 Interview If yes, how long have had the cough? [Number] (weeks) 
Enter 1 if less than one week 
99 = Don’t know 
c_cough_dur 
[integer; 2 digits; range 1–52, 99] 
 8.2  
Interview 
Do you have fever? [Radio] 
0 No 
1 Yes 
(If No, skip to Q8.3) 
c_fever 
[integer; 1 digit; range 0–1] 
  8.2.1  
Interview 
If yes, how long have you had fever? [Number] (weeks) 
Enter 1 if less than one week 
99 = Don’t know 
c_fever_dur 
[integer; 2 digits; range 01–52, 99] 
 8.3  
Interview 
Do you have drenching night sweats? 





(If No, skip to Q8.4) 
c_nsweat 
[integer; 1 digit; range 0–1] 
  8.3.1  
Interview 
If yes, how long have you had drenching night sweats? [Number] (weeks) 
Enter 1 if less than one week 
99 = Don’t know 
c_nsweat_dur 
[integer; 2 digits; range 01–52, 99] 
 8.4 
Interview 
How much do you weigh? [Number] (kilograms) 
999 = Don’t know 
c_wt 
[integer; 3 digits; range 015–120, 999] 
 8.5  
Interview 
Have you lost weight in the last 6 months? 
(Explain to the participant that this is unexplained or 




9 Don’t know 
(If No or Don’t know, skip to Q8.6) 
c_wtloss_6m 
[integer; 1 digit; range 0–1, 9] 
  8.5.1  
Interview 
If yes, how much weight have you lost in the last 6 
months? 
[Number] (kilograms) 
99 = Don’t know 
c_wtloss_kg 
[integer; 2 digits; range 01–52, 99] 
 8.6 
Interview 






[integer; 1 digit; range 0–1] 
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(Prompt for TB specific symptoms [fatigue, 
haemoptysis, chest pain, and lymphadenitis]) 
(If No, skip to Q9) 
 [Add sub-form for each symptom for questions 8.6.1 to 8.6.1.2] 









3 Chest pain 
4 Lymphadenitis 
6 Other, specify 
 
c_tbsx_oth1 
[integer; 1 digit; range 1–4, 6] 
   8.6.1.1 
Interview 
Other, specify 
[only appear if 6] 
[Text] c_tbsx_oth1_o 
[string, 30 characters] 
    8.6.1.1.1 
Interview 
Duration of symptom [Number] (weeks) 
Enter 1 if less than one week 
99 = Don’t know 
c_tbsx_oth1_dur 
[integer; 2 digits; range 01–52, 99] 
    8.6.1.2 
interview 
Do you have another symptom? [Radio] 
0 No 
1 Yes 
[If Yes, add sub-form for another symptom (Qs 
8.6.1–8.6.1.2)] 
c_tbsx_oth1 
[integer; 1 digit; range 0–1] 
Question 9 TB contacts: Household 
 9.1  
Interview 
Has anyone in your homestead (or residential plot), 
during your lifetime, ever had TB disease?  
(Including those who might not have started TB 





9 Don’t know 
(If No, or Don’t know skip to Q9.2) 
c_hh_tbever 
[integer; 1 digit; range 0–1, 9] 
 9.1.2  
Interview 
Is anybody in your homestead (or residential plot) 




9 Don’t know 
 
c_hh_tbcur  
[integer; 1 digit; range 0–1, 9] 
 TB contacts memory aid 
Please tell the participant that you would like to ask them a few questions about the people in their homestead who have ever had TB in their 
lifetime.  Tell them that you will ask about each person separately and encourage them to think back and remember how many individuals in their 
homestead have ever had TB 
   Details of person(s)  
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 9.1.3.1  
Interview 
What was the age of this person at the time you lived 
in the same homestead (or residential plot)? 
[Number] (years) 
999 = Don’t know 
c_curhh_tbcontact1age 
[integer; 3 digits; range 001–099, 999] 
 9.1.3.2  
Interview 





[integer; 1 digit; range 1–2] 
 9.1.3.3  
Interview 
In which isigodi did you live with this person? [Dropdown] [List of isigodis] 
96 = Other, specify 
99 = Don’t know 
c_curhh_tbcontact1isi 




[only appear if 96] 
[Text] c_curhh_tbcontact1isi_o 
[string, 30 characters] 
 9.1.3.4  
Interview 
In which year did you live with this person? [Dropdown] 
9999= don’t know 
c_curhh_tbcontact1yr 
[standard AHRI year variable; range 1998–
2017] 
 9.1.3.5  
Interview 
For how long did you live in the same homestead (or 
residential plot) with this person when they had TB? 
[Number] (Months) 
(enter 01 if less than one month)  
99 = Don’t know 
c_curhh_tbcontact1dur 
[integer; 2 digits; range 01–24, 99] 
 9.1.3.6  
Interview 
Did you live in the same house as this person when 




(If No, skip to 9.1.3.7) 
c_curhh_tbcontact1house 
[integer; 1 digit; range 0–1] 
 9.1.3.6.1 
Interview 





[integer; 1 digit; range 0–1] 
 9.1.3.7  
Interview 
Were you involved in the care of this person when 
they were ill? 
(i.e., you came into close contact with this person 






[integer; 1 digit; range 0–1] 
 9.1.3.8 
Interview 
Apart from the person(s) described above, has anyone 
else in your homestead ever had TB disease during 
your lifetime? 
 
Encourage the participant to think back about 




If yes, add sub-form (Qs 9.1.3.1 to 9.1.3.8) 
c_curhh_tbcontact_o1 
[integer; 1 digit; range 0-1] 
  TB Contacts in other households   
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 9.2 
Interview 
Apart from your homestead, have you ever lived 
(slept overnight) in the same homestead (or 
residential plot) as someone with TB for a total of 2 or 
more weeks?  
(Including those who might not have started TB 





9 Don’t know 
(If No, skip to Q9.4) 
c_hh_tbcontact 
[integer; 1 digit; range 0–1, 9] 
   Details of person(s)  
   9.2.1.1  
Interview 
What was the age of this person at the time you lived 
in the same homestead (or residential plot)? 
[Number] (years) 
999 = Don’t know 
c_hh_tbcontact1age 
[integer; 3 digits; range 001–099, 999] 
   9.2.1.2  
Interview 





[integer; 1 digit; range 1–2] 
   9.2.1.3  
Interview 
In which isigodi did this person live? [Dropdown] [List of isigodis] 
96 = Other, specify 
99 = Don’t know 
c_hh_tbcontact1isi 
[integer; 2 digits; range 01–XX, 96, 99] 
    9.2.1.3.1  
Interview 
Other, specify 
[only appear if 96] 
[Text] c_hh_tbcontact1isi_o 
[string, 30 characters] 
   9.2.1.4  
Interview 
In which year did you live with this person? [Dropdown] 
9999= don’t know 
c_hh_tbcontact1yr 
[standard AHRI year variable; range 1998–
2017] 
   9.2.1.5  
Interview 
For how long did you live in the same homestead (or 
residential plot) with this person when they had TB? 
[Number] (Months) 
(enter 01 if less than one month)  
99 = Don’t know 
c_hh_tbcontact1dur 
[integer; 2 digits; range 01–24, 99] 
   9.2.1.6  
Interview 
Did you live in the same house as this person when 




(If No, skip to 9.2.1.7) 
c_hh_tbcontact1house 
[integer; 1 digit; range 0–1] 
    9.2.1.6.1 
Interview 





[integer; 1 digit; range 0–1] 
   9.2.1.7  
Interview 
Were you involved in the care of this person when 
they were ill? 
(i.e., you came into close contact with this person 






[integer; 1 digit; range 0–1] 
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   9.2.1.8 Apart from the person(s) described above, have you 
ever lived (slept overnight) in the same homestead 
with anyone else with TB? 
 
Encourage the participant to think back about 








TB Contacts: Care of TB Patients 
 9.3 
Interview 
Apart from people with TB who you lived with in the 
same homestead (the ones described above), have 
you ever been involved in the care of another 
person(s) with TB disease? 
(i.e., you came into contact with this person whilst 




(if No, skip to Q10) 
c_tb_care 
[integer; 1 digit; range 0–1] 
   Details of person(s)  
   9.3.1.1  
Interview 
What was the age of this person at the time you were 
involved in their care? 
[Number] 
999 = Don’t know 
c_tb_care1age 
[integer; 3 digits; range 001–099, 999] 
   9.3.1.2  
Interview 





[integer; 1 digit; range 1,2] 
   9.3.1.3  
Interview 
In which isigodi did this person live at the time you 
were involved in their care? 
[Dropdown] [List of isigodis] 
96 = Other, specify 
99 = Don’t know 
c_tb_care1isi 
[integer; 2 digits; range 01–XX, 96, 99] 
    9.3.1.3.1  
Interview 
Other, specify 
[only appear if 96] 
[Text] c_tb_care1isi_o 
[string, 30 characters] 
   9.3.1.4  
Interview 





[standard AHRI year variable; range 1998–
2017] 
   9.3.1.5 Is there another person with TB who did NOT live in 
the same homestead, but in whose care you was 
involved when this person was ill? 
 
Encourage the participant to think back about 




[If Yes, add sub-form (Qs 9.3.1.1–9.3.1.5)] 
 
Question 10 Health care utilisation  
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 10.1  
Interview 
Have you ever been admitted to a hospital? 
(Explain, that ‘admitted’ means sleeping for at least 




9 Don’t know 
(If No, or don’t know skip to Q10.2) 
c_adm_ever 
[integer; 1 digit; range 0–1, 9] 
  10.1.1  
Interview 
If yes, how many times have you ever been admitted 
(slept overnight) to hospital? 
 [Number] 
99 - don’t know 
c_adm_n 
[integer; 1 digit; range 1–9] 
  10.1.2  
Interview 
When were you most recently admitted to hospital? [Dropdown] 
99 = Don’t know 
c_adm_dadmm 





[standard AHRI year variable; range 1998–
2017] 
  10.1.3  
Interview 
Which hospital were you most recently admitted to?  [Dropdown] [List of hospitals] 
34 = Private GP 
96 = Other, specify 
99 = Don’t know 
c_adm_hosp 
[integer; 2 digits; range 1–XX, 96, 99] 
   10.1.3.1 
Interview 
Other, specify 
[only appear if 96] 
[Text] c_adm_hosp_o 
[string, 30 characters] 
  10.1.4  
Interview 
What was the reason for your most recent admission? [Dropdown] 
01 Respiratory tract infection 
02 Diarrhoea 
03 Injury 
04 Convulsions (fits) 
05 Other infection 
06 Surgery 
96 Other, specify 
99 Don’t know 
(If 96 go to 10.1.4.1, otherwise skip to Q10.2) 
c_adm_reas 
[integer; 1 digit; range 1–4, 6, 9] 
   10.1.4.1 
Interview 
Other, specify 
[only appear if 6] 
[Text] c_adm_reas_o 
[string, 50 characters] 
  Visits to Hospitals   
 10.2  
Interview 
Excluding overnight admission, did you visit any 
hospital in the last 12 months for any reason 





[integer; 1 digit; range 0–1] 
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(Clarify hospital, as participant may confuse with 
other health facilities) 
(If No, skip to Q10.3) 
  10.2.1  
Interview 
If yes, how many times did you visit any hospital in the 
last 12 months?  
[Number] 
99 = Don’t know 
c_hospvis_12m_n 
[integer; 2 digits; range 01–20, 99] 
  10.2.2  
Interview 
When was your most recent visit to any hospital? [Dropdown] 
99 = Don’t know 
c_hospvis_dvism 





[standard AHRI year variable; range 1998–
2017] 
  10.2.3  
Interview 
Which hospital did you visit most recently? [Dropdown][List of hospitals] 
34 = Private GP 
96 = Other, specify 
c_hospvis_hosp 
[integer; 2 digits; range 01–XX, 96] 
   Other hospital if not on the list 
[only appear if 96] 
[Text] c_hospvis_hosp_o 
[text, 30 characters] 
   10.2.4.1 
Interview 
Other, specify 
[only appear if 96] 
[Text] c_hospvis_reas_o 
[string; 50 characters] 
  10.2.5  
Interview 
What was the duration of your most recent visit to 
hospital? 
[Number] (hours) 
Enter 1 if less than one hour. 
99 = Don’t know 
c_hospvis_dur 
[integer; 2 digits; range 1–23, 99] 
  Visits to PHC Facilities   
 10.3  
Interview 
In the last 12 months, did you visit any primary health 
care (PHC) facility or clinic for any reason (including 




(If No, skip to Q11) 
c_phcvis_12m 
[integer; 1 digit; range 0–1] 
  10.3.1  
Interview 
If yes, how many times did you visit any primary 
health care facility (PHC) in the last 12 months?  
[Number] 
99 = Don’t know 
c_phcvis_12m_n 
[integer; 2 digits; range 01–20, 99] 
  10.3.2  
Interview 
When was your most recent visit to a PHC facility? [Dropdown] 
99 = Don’t know 
c_phcvis_dvism 





[standard AHRI year variable; range 1998–
2017] 
  10.3.3  Which PHC facility did you visit most recently? [Dropdown] [List of PHC facilities] c_phcvis_clin 
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Interview 96 = Other, specify 
99 = Don’t’ know 
[integer; 2 digits; range 01–XX, 96, 99] 
   10.3.3.1 
Interview 
Other facility if not on the list 
[only appear if 96] 
[Text] c_phcvis_clin_o 
[text, 30 characters] 
  10.3.5  
Interview 
What was the duration of your most recent visit to a 
PHC facility (in hours)? 
[Number] 
Enter 1 if less than one hour. 
99 = Don’t know 
c_phcvis_dur 
[integer; 2 digits; range 01–23, 99] 
  10.3.6 At your most recent visit to a PHC facility, how many 
people were present at the clinic? 
[Number] 
999= Don’t know 
C_phcvis_natt 
[integer; 3 digits; range 01–200, 999] 
 
Question 11 Chronic illnesses  
(ARV uptake can be captured and noted at this point) 
Tell participant: “I will now ask you questions about any chronic/long-term illnesses that you might have and whether you are taking regular medication for that illness” 
 11.1 
Interview 
Do you have asthma? [Radio] 
0 No 
1 Yes 
(if No, skip to Q11.2) 
c_asthma 
[integer; 1 digit; range 0–1] 
  11.1.1. 
Interview 
If Yes, are you taking regular medication for asthma? [Radio] 
0 No 
1 Yes 
(if No, skip to Q11.2) 
c_asthmamed 
[integer; 1 digit; range 0–1] 
   11.1.1.1 
Interview 
If Yes, what medication are you taking (tick all that 
apply)? 
[Tick box] 
01 Short-acting beta-agonist inhaler  
(e.g., Albuterol, Asthavent, Fenoterol, 
Salbutamol, Terbutaline, Ventolin, 
Volmax) 
02 Long-acting beta-agonist inhaler  
(e.g., Formoterol, Foradil, Foratec, 
Foxair, Oxis, Salmeterol, Serevent)  
03 Steroid inhaler  
(e.g., Aerobec, Beclomethasone, 
Beclate, Becotide, Beloforte, Budeflam, 
Budesonide, Ciclesonide, Clenil, 
Flixotide, Flomist, Fluticasone, 
Inflammide, Rhinocort, Viarox) 
c_asthmamed 
[integer; 2 digits; range 01-06,96,99] 
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04 Combination inhaler 
(e.g., Budesonide-Formoterol, Seretide, 
Symbicort 
05 Oral steroid  
(e.g., Prednisone, prednisolone, 
methylprednisone, 
methylprednisolone) 
06 Oral leukotriene receptor antagonists  
(e.g., Accolate, Montelukast, Singulair, 
Zafirlukast) 
96 Other, specify 
99 Don’t know 
(if No, skip to Q9.2) 
    11.1.1.1.1 
Interview 
Other, Specify   
   11.1.1.2 
Interview 
When did you start taking regular medication for 
asthma? 
[Dropdown] 
99 = Don’t know 
c_asthmamed_dstartm 









Do you have diabetes? [Radio] 
0 No 
1 Yes 
(if No, skip to Q11.3) 
c_diab 
[integer; 1 digit; range 0–1] 
  11.2.1 
Interview 
If Yes, are you taking regular medication for diabetes? [Radio] 
0 No 
1 Yes 
(if No, skip to Q11.3) 
c_diabmed 
[integer; 1 digit; range 0–1] 
   11.2.1.1 
Interview 
If Yes, what medication are you taking for diabetes? 
(Select all that apply) 
[Tick box] 
01 Biguanide 
(e.g., Metformin [Bigsens, Diabetmin, 
Diaformin, Diamin, Diaphage, Forminal, 
Glucophage, Mengen, Metcheck, 
Metforal, Metored, Romidab])  
02 Sulphonylurea 
c_diabmed_det 
[integer; 2 digits; range 01–09, 96, 99] 
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(e.g., Glibenclamide [Daonil, Glycomin]; 
Gliclazide [Adco-Glucomed, Diaglucide, 
Diaglumed, Diamicron, Gycron, 
Glygard]; Glimepiride [Amaryl, Diaglim, 
Euglim, Glamaryl, Sulphonur]; Glipizide) 
03 PPAR agonist 
(e.g., Pioglitazone [Actos]) 
04 SGLT2-inhibitor 
(e.g., Canagliflozin, Dapagliflozin, 
Empagliflozin) 
05 DPP-4 inhibitor 
(e.g., Saxagliptin [Onglyza, Kombiglyze], 
Sitagliptin [Januvia, Janumet, Juvisync], 
Vildagliptin) 
06 GLP-1 agonist 
(e.g., Exenatide [Byetta, Bydureon], 
Liraglutide [Victoza], Lixisenatide, 
Semaglutide) 
07 Alpha-glucosidase inhibitor 
(e.g., Acarbose) 
08 Short-acting insulin  
(e.g., Isophane insulin [Humulin, 
Insulin-HMGE-Protaphane], Insulin 
Lispro [Humalog]) 
09 Long-acting insulin 
(e.g., Glargine [Basaglar, Lantus, 
Optisulin]) 
96 Other, specify 
99 Don’t know 
 
    11.2.1.1.1 
Interview 
Other, Specify   
   11.2.1.2 
Interview 
When did you start taking regular medication for 
diabetes? 
[Dropdown] 
99 = Don’t know 
c_diabmed_dstartm 
[standard AHRI month variable; range 1–
12, 99] 
[Dropdown] c_diabmed_dstarty 
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 11.3 Do you have any other chronic or long-term illness? [Radio] 
0 No 
1 Yes 
(if No, skip to Q12) 
c_cillness 
[integer; 1 digit; range 0–1] 





If yes, what illnesses? [Dropdown]  
1 HIV/AIDS 
2 Epilepsy 
6 Other (Specify) 
9 Don’t know 
(If  HIV/AIDS, skip to Q11.3.4 inform the 
participant that you will ask the details of ARV 
uptake later] 
c_cillness_det 
[integer; 1 digit; range 1–3, 6, 9] 
   11.3.1.1 
Interview 
Other, specify 
[only appear if 6] 
[Text] c_cillness_det_o 
[string, 30 characters] 
  11.3.2 
Interview 








9 Don’t know 
(If No, Skip to 11.3.4) 
If yes, and illness=epilepsy – go to 11.3.2.1 
If yes, and illness = other – go to 11.3.2.1.1 
c_regmed 
[integer; 1 digit; range 0–1, 9] 
   11.3.2.1 
Interview 
If Yes, what medication? [Dropdown] [List of medications] 
1 Sodium valproate 
(e.g., Epilim, Epilizine, Epiproate, 
Eprolep, Navalpro, Valeptic) 
2 Phenytoin sodium 
(e.g., Epanutin, Phlexy) 
3 Carbamazepine 
(e.g., Degranol, Tegretol) 
4 Lamotrigine 
(e.g., Epitec, Girotec, Lamictin, 
Lamidus, Lamitor) 
5 Levetiracetam 
(e.g., Epikepp, Keppra, Redilev, 
Torcetam) 
c_regmed_det 
[integer; 1 digit; range 1–6,9] 
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6 Other, specify 
9 Don’t know 
 
    11.3.2.1.1 
Interview 
Specify medication 
[only appear if 6, or if Q11.3.1=6 (other illness) and 
Q11.3.2=yes] 
[Text] c_regmed_det_o 
[string; 50 characters] 
  11.3.3 
Interview 
When did you start taking regular medication for this 
condition? 
[Dropdown] 
99 = Don’t know 
c_regmed_dstartm 
[standard AHRI month variable; range 1–
12, 99] 
[Dropdown] c_regmed_dstarty 
[standard AHRI year variable; range 1998–
2017] 
  11.3.4 
Interview 
Do you have any other chronic illness that you take 




[if Yes, add sub-form for questions 11.3.1–
11.3.4] 
c_cillness_o 
[integer; 1 digit; range 0–1] 
Question 12 Smoking 
 12.1 
Interview 
Have you ever smoked tobacco before?  




(If No, skip to Q13) 
c_smoke_ever 
[integer; 1 digit; range 0–1] 
  12.1.1 
Interview 
If yes, when did you start smoking regularly? [Dropdown] 
99 = Don’t know 
c_smoke_dstartm 





[standard AHRI year variable; range 1998–
2017] 
  12.1.2  
Interview 
Do you still smoke? [Radio] 
0 No 
1 Yes 
(If Yes, skip to Q12.2) 
c_smoke_still 
[integer; 1 digit; range 0–1] 
   12.1.2.1 
Interview 
If No, when did you stop smoking? [Dropdown] 
99 = Don’t know 
c_smoke_dstopm 
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9 Don’t know 
(If No, Skip to Q13) 
c_smoke_hh 











[integer; 1 digit; range 0–1, 9] 
 
Question 13 Alcohol consumption 
 13.1  
Interview 
Have you ever taken alcohol? [Radio] 
0 No 
1 Yes 
(If No, skip to Q14) 
c_etoh_ever 
[integer; 1 digit; range 0–1] 
  13.1.1 
Interview 





[integer; 1 digit; range 0–1] 
  13.1.2 
Interview 
When was the last time you took alcohol? [Dropdown] 
99 = Don’t know 
c_etoh_dlastm 





[standard AHRI year variable; range 1998–
2017] 
 
Question 14 HIV & ARVs 
 
REDCap Memory support - HIV Section 
* Take a moment for rapport 
* Begin the HIV section with a general discussion.  
* Initial evaluation of mental state 
* Assess knowledge of HIV / sex / sexual transmission 
* Benefits of treatment / routes of transmission 
* Remind participant that if they already know their status, importance of telling us for appropriate clinical management of the IGRA results  
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 14.3 
[Piped variable from Q11.3.1] 
What chronic illnesses did the participant mention in 
section 11? 
((This question displays the chronic illnesses that the 
participant mentioned in Q11. This helps you how to 
proceed if the participant had already told you that 





 [integer, 1 digit, range 1-3] 
 14.1 
Interview 
Have your ever tested for HIV before? 
 
If the participant said they are HIV positive: 
You mentioned that you are HIV positive; I assume 




2 Prefer not to say 
9 Don’t know 
(If Yes, go to 14.1.1 otherwise skip to Q14.2) 
c_hivtest_ever 
[integer; 1 digit; range 0–2, 9] 
  14.1.1  
Interview 
If yes, what was the result? 
 
If the participant already said they are HIV positive, 




2 Prefer not to say 
9 Don’t know 
(if 0, 2 or 9, skip to Q14.1.1.2) 
c_hivres 
[integer; 1 digit; range 0–1, 9] 
   14.1.1.1  
Interview 
If Positive, when did you first test HIV positive? [Dropdown] 
99 = Don’t know 
c_hivres_pos_dtestm  





[standard AHRI year variable, range 1998-
2017] 
    14.1.1.1.1 
Interview 
Where did you first test HIV positive? [Dropdown]  
1 DOH Hospital 
2 DOH clinic 
3 AHRI Home 
4 AHRI Mobile Clinic 
6 Other, specify 
9 Don’t know 
 
c_hivptest_loc 
[integer; 1 digit; range 1–4, 6,9] 
    14.1.1.1.1.1 
Interview 
Other, specify 
[only appear if Q14.1.1.1.1 = 6] 
[Text] c_hivtest_loc_o 
[integer; 1 digit; range 0–1] 
   14.1.1.2 [Dropdown] c_hivres_pos_dtestm 
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Interview If negative, prefer not to say, or don’t know, when 
was your most recent HIV test? 





[integer; 4 digits; range 1998–2017] 
    14.1.1.2.1 
Interview 
Where did you test most recently test for HIV? [Dropdown]  
1 DOH Hospital 
2 DOH clinic 
3 AHRI Home 
4 AHRI Mobile Clinic 
6 Other, specify 
9 Don’t know 
 
c_hivptest_loc 
[integer; 1 digit; range 1–4, 6,9] 
     14.1.1.2.1.1 
Interview 
Other, specify 
[only appear if Q14.1.1.2.1 = 6] 
[Text] c_hivtest_loc_o 
[integer; 1 digit; range 0–1] 
 14.2 
Interview 





9 Don’t know 
(If No or Don’t know, skip to Q14.3) 
c_ipt_ever 
[integer; 1 digit; range 0–2, 9] 
 Isoniazid Preventive Therapy :Memory AId 
Explain to the respondent that this is treatment given to prevent development of TB disease unlike TB treatment which is given to treat TB disease. 
 
 [If needed, explain that treatment for TB disease will have been with at least four drugs [though it may have been in one tablet, e.g., Rifafour] every day for two months, and then two 
drugs [again, may have been in one tablet, e.g., Rifinah] every day for a further four months [i.e., a total of at least 6 months].   
 
This is different from isoniazid preventive therapy [IPT], which is given to prevent development of TB disease, and will have involved taking one drug every day for six months.] 
  14.2.1 
Interview 
If Yes, when did you stop taking IPT? [Dropdown] 
97 = Currently on IPT 
99 = Don’t know 
c_ipt_dstopm 
[standard AHRI month variable; range 1–
12, 97, 99] 
[Dropdown] 
9997 = Currently on IPT 
9999=don’t know 
c_ipt_dstopy 
[standard AHRI year variable; range 1998–
2017, 9997] 
 14.3 
[Piped variable from Q11.3.1] 
What chronic illnesses did the participant mention in 
section 11? 
(This question displays the chronic illnesses that the 





 [integer, 1 digit, range 1-3] 
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the participant already told you that they are HIV 
positive) 
 14.4 (piped from Q14.1.1) Reported HIV status of the participant   
  ARV Question Memory Aid 
* Think back about what the participant said regarding their HIV status. Use this information to guide you 




Have you ever taken ARVs (Including PEP or PrEP)? 
 
If the participant is HIV negative (or has never tested 
for HIV), explain that PrEP (Pre-Exposure Prophylaxis) 
may be given to people who are at high-risk, to reduce 
their risk of acquiring HIV and  
PEP (Post Exposure Prophylaxis) is given after 
someone may have been exposed to HIV (e.g., through 






2 Prefer not to say 
9 Don’t know 




[integer; 1 digit; range 0–2, 9] 
  14.5.1 
Interview 
If Yes, why did you take ARVs? 
 
(if the participant had already mentioned that they 
are HIV positive and taking ARVs, select 1 for this 
question and proceed with follow-up questions) 
 
[Radio] 
1 For routine HIV care 
2 As post-exposure prophylaxis (PEP) 
3 As pre-exposure prophylaxis (PrEP) 
6 Other, specify 
9 Don’t know 
(if 6 go to 14.5.1.1 otherwise skip to 14.5.3) 
c_arv_reas 
[integer; 1 digit; range 0–3, 6, 9] 
   14.5.1.1 
Interview 
Other, specify text c_arv_o 
[text; 30 characters] 
  14.5.3  
Interview 
When did you first start taking ARVs? [Dropdown] 
99 = Don’t know 
c_arv_dstartm 





[standard AHRI year variable; range 1998–
2017] 
  14.5.4  
Interview 
Do you still take ARVs? [Radio] 
0 No 
1 Yes 
(If No, skip to Part II) 
c_arv_still 
[integer; 1 digit; range 0–1] 
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   14.5.4.1 
Interview 
If No, when did you stop? [Dropdown] 
99 = Don’t know 
c_arv_dstopm 
[standard AHRI month variable; range 1–





[standard AHRI year variable; range 1998–
2017, 9997] 
  14.5.5 
Interview 
Which regimen are you taking, or did you take before 
stopping? 
[Dropdown] [List of ARV regimens] 
01 ABC + 3TC + LPV/r 
(e.g., ABC/3TC fixed-dose [ Dumiva, 
Heteruam, Kivexa] + LPV/r [Norvir, 
Rinavo]) 
02 ABC + 3TC + EFV 
(e.g., ABC/3TC fixed-dose [ Dumiva, 
Heteruam, Kivexa] + EFV [Efamat, 
Efrin, Erige, Hevaz, Stocrin, Viref]) 
03 TDF + FTC + EFV 
(e.g., Fixed-dose combination [Atenef, 
Atreslawin, Atripla, Atroiza, Citenvir, 
Eftenem, Heftenam, Odimune, Rizene, 
Trenvir, Tribuss, Triolar]) 
04 TDF + 3TC + EFV 
(e.g., Fixed-dose combination [Arion, 
eflaten, Elteno, Tenarenz, Virlaten]) 
05 AZT + 3TC + LPV/r 
06 AZT + ABC + LPV/r 
96 Other, specify 
99 Don’t know 
 
c_arv_still_det 
[integer; 2 digits; range 01–06, 96, 99] 
   14.5.5.1 
Interview 
Other, specify 
[only appear if 96] 
[Text] c_arv_still_det_o 
[string; 30 characters] 
  14.5.6 
Interview 
Which clinic (or facility) are you currently taking ARVs 
from?  Or, if no longer taking ARVs, clinic were you 
using before stopping? 
[Dropdown] [List of PIP clinics] 
96 = Other (Specify) 
99 = Don’t know 
c_arv_curclin 
[integer; 2 digits; range 01–XX, 96, 99] 
   14.5.6.1 
Interview 
Other, specify 
[only appear if 96] 
[Text] c_arv_curclin_o 
[string, 30 characters] 
 HIV DECISION RULES 
Do NOT attempt to gain consent for HIV testing if any of the following apply:  
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1. The parent/guardian reported that the participant is HIV-positive AND taking ARVs. 
2. The parent/guardian did not give consent for the child to be tested for HIV. 
3. The participant is aged 10-11 years, and parent/guardian did not consent to be present during the test 
4. The participant reported themselves as HIV-positive AND taking ARVs. 
5. The date of the last HIV test in PIP was within 3 months.  
 HIV Testing Memory Aid 
* Participants reporting themselves to be HIV positive but not on ARVs should be offered a rapid test and referred to care. 
 
 Memory Aid - Date for last HIV Test in PIP 
* The question below gives date for the participant’s last test in PIP. Use the date in deciding whether to offer a rapid HIV test. 
* If the date is not available, this means that the participant has never been tested by AHRI. 
* If the date is within 3 months, do not offer a rapid test 
* If the date is more than 3 months and the participant is not taking ARVs, offer rapid HIV test. 
 15.1 
Preloaded 
Date of last HIV test in PIP: date c_piplhivdate 
[Standard Date Variable] 
 Question 15.2 
Interview 
Basing on the HIV Decision rules above, should the 




(If No, skip to 16.1.3) 
c_hiv_dec 




Consent for rapid HIV testing (if participant should be offered an HIV test) 
 REDCap Memory support - Offering rapid HIV testing 
* Initial evaluation of mental state 
* Confirm: has child capacity to assent? 
* Duty of confidentiality/with limits 
* Right to withhold assent 
* If age 15+, explain that test result can remain confidential, explore who to tell  
* If aged 12-14 years, explain that they must have their own phone so that you will be able to check on them if needed, or they must be willing to 
share the results with their parent  
* If age 12-14 years with own phone, encourage to share with parent/explore who to tell 
* Deeper assessment of reaction to positive 
* Consider referral to clinic for testing 
* Reaffirm assent of child, then conduct test. 
* Confirm: proceed with test?  
* Choices re presence of parent 
* Would you like your (parent) present now? 
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* If age 12+, explain that it is their choice whether parent is present (if aged 10-11 years, must be tested with parent present) 
* Ask: have they wondered if they could have HIV? 
* Ask if they have fear of a key adult 
* Check age of partner (if appropriate) 
 16.1 
Interview 
Would you like to have an HIV test today? 
 
If participant is not willing to have a rapid test, and the 
parent gave permission for HIV testing of venous blood, 
obtain permission to test HIV using the venous blood 




(If Yes, and aged <15, go to 16.1.1) 
(If Yes, and aged 15+, go to 16.1.4 then skip to 
next instrument [Social contacts]) 
(If No, go to 16.1.3]) 
(If No and HIV positive not on ART, go to 
Q16.1.3 then Q16.2) 
c_hiv_rapidconsent 
[integer; 1 digit; range 0–1] 
 16.1.1 
Interview 
If age <15 years:  Would you prefer to have your 
parent/guardian present during the process of HIV 
testing?  
 
If aged 12-14 years, explain that this is their preference. 
If aged 10-11 years, both parent/guardian and 
participant must agree for parent/guardian to be 




(If yes, and age 10-11, skip to 16.1.4, then go 
to next instrument [Social contacts]) 
(If no, and age 10-11, show pop-up message, 
skip to 16.1.3, then go to next instrument 
[Social contacts]) 
(If age 12-14, go to 16.1.2) 
 
c_parpresent 
[integer; 1 digit; range 0–1] 
   If age 10-11 and NO, Pop up Message: 
Please explain to the participant that you cannot offer them an HIV test without parent present 
 
     
 16.1.2 
Interview 






(If No, go to 16.1.2.2) 
(If Yes, go to 16.1.4 then skip to next 
instrument [Social contacts]) 
c_ownphone 
[integer; 1 digit; range 0–1] 







[integer; 1 digit; range 0–1] 
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Explain that you may need to use their parent’s phone 
number if you need to contact them  
 
If not willing to share the result with parent, explain that 
you will not be able to offer them an HIV test 
 
(If No, show pop up message, go to 16.1.3 then 
skip to next instrument [Social contacts]) 
(If Yes, go to 16.1.4 then skip to next 
instrument) 
   Pop up Message: 
Please explain to the participant that you cannot offer them an HIV test 
 
     
  16.1.3 
Interview 
If participant does not want an HIV test, or cannot be 
offered a test based on the decision rules:  can we test 
HIV using the venous blood that we have collected for 
research purposes?  
 
Explain to the participant that the HIV test will be for 
research purposes only and that the result will not be 
available. This is to help us understand better the link 
between HIV and TB. Should they want to know their 
status at a later stage, advise them that they should go to 
nearest clinic to be tested. 
 
If the participant has reported that they are HIV positive 








[integer; 1 digit; range 0–1] 
   If YES, Pop up Message: 
Please make sure HIV ELISA is ticked on the Lab Requisition Form 
 
  16.1.4 
Interview 
(If Yes, ask participant to sign consent for HIV testing) 
I agree that my blood can be tested for HIV as part of this 
study 
Signature c_hivcons_sign 
  16.1.5 
Interview 
If HIV test was not offered or refused, please comment Text c_hiv_noconsent 





REFERRAL TO CARE FOR HIV CARE (PREVIOUS HIV+ NOT LINKED TO CARE) 
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Referral To care Memory Aid: 
* If the participant self-reports that they are HIV positive and not on ART, they should be referred to 
clinic in this section. 
* Inform the participant that you need to refer them to clinic in PIP where there is an AHRI nurse. 
* Ask the participant to choose a clinic within PIP. 
 
* If age <15, tell the participant that an AHRI paediatric HIV nurse the AHRI paediatric HIV nurse can see 
them at the one of following clinics in PIP:  KwaMsane (Mondays); Mtubatuba (Tuesdays); Somkhele 
(Thursdays).  If the participant is not able to attend one of those clinics, ask them to choose another 
clinic in PIP. 
  16.2.1 
Interview 
Which clinic would you like to be referred to? 
 
The AHRI Paediatric nurse can see participants in the 
following clinics: KwaMsane (Mondays); Mtubatuba 
(Tuesdays); Somkhele (Thursdays) 
 





If 99, skip to 16.2.1.2 
c_prevhiv_prefclin 
[integer; 2 digits; range 0–99] 
  16.2.1.2 Specify other clinic   
  16.2.2 
Interview 
What is the agreed target date for attending clinic? 
 
Agree with the participant a target date to attend clinic 
(this should be within 2 weeks). 
 
[date] c_prevhiv_tdat 
[standard AHRI date variable, range: 
today () + 14] 
  16.2.3 
Interview 
What is your primary contact number? 
 
Explain that you need the phone number to be able to 






  16.2.4 
Interview 
Do you share this phone with other people? [Radio]  
0 No 
1 Yes 
If aged <15, skip to 16.2.6 
If aged 15+, go to 16.2.5 
c_prevhiv_contnum_share 
[integer; 1 digit; range 0–1] 
  16.2.5 
Interview 
If aged 15+:  




[integer; 1 digit; range 0–1] 
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1 Yes 
(if No, Skip to Q16.2.6) 
   16.2.5.1 
Interview 
If Yes, what SMS reminder wording did the participant 
choose? 
Please choose from standard SMS reminders or use own 
words. 
[Radio]  
1 Please don't forget your appointment 
2 We hope you will visit us soon 
3 Don't forget to get that present 
6 Choose your own words 
(If 1-3, Skip to Q16.2.6) 
c_prevhiv_sms_opt 
[integer; 1 digit; range 1-3, 6] 
    16.2.5.1.1 
Interview 
Provide your own words for SMS reminder message [Text] c_prevhiv_sms_opt_o 
[Text,50 characters] 
  16.2.6 
Interview 





[integer; 1 digit; range 0–1] 
  If No, Pop Up Message 
Please verify the number to check if it is working 
 
Blood Sample Collection 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
 Memory Aid – Scanning Sample Barcode 
* Before scanning the barcode for each sample, make sure the sample has been obtained first. 
Question 1 Venepuncture: EDTA 
 1.0 
Interview 













[integer; 1 digit; range 0–1] 
  1.2.1 
Interview 
If no, please give a reason [Text] 
(Skip to Q2) 
c_edta_noreas 
[string; 50 characters] 
  1.2.2 
Interview 
If yes, time of collection [Number] c_edta_tcollhh 
[integer; 2 digits; range 00–23] 
[Number] c_edta_tcollmm 
[integer; 2 digits; range 00–59] 
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 1.2 
Interview 
Has the specimen been successfully QC-ed and can it be 























[integer; 1 digit; range 0–1] 
  2.2.1 
Interview 
If no, please give a reason [Text] 
(Skip to Q2) 
c_lihep_noreas 
[string; 50 characters] 
  2.2.2 
Interview 
If yes, time of collection [Number] c_lihep_tcollhh 
[integer; 2 digits; range 00–23] 
[Number] c_lihep_tcollmm 
[integer; 2 digits; range 00–59] 
 2.2 
Interview 
Has the specimen been successfully QC-ed and can it be 






[integer; 1 digit; range 0–1] 
 
Rapid HIV Testing 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  REDCap Memory support - Pre-rapid HIV test 
* Younger child (age 10-11 years): parent present now? 
 
    
  REDCap Memory support - Pre-test information: 
* Importance of knowing status (whether positive or negative) 
* Explain confidentiality/shared confidentiality; how it will be maintained. 
 
o Give the participant information with regards HIV  
 
* Check that the participant has understood the following items: 
o The benefits of knowing status (whether positive or negative) 
+ Lifesaving benefits of treatment that is available immediately  
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+ Window period. 
+ Add the following information: 
- The meaning of HIV and AIDS 
- Transmission of HIV 
 
* It is helpful if you tell me if you are taking ARVs already 
* If you are already on ARVs, the test may react as negative, even though you have HIV.  
* Meaning of both positive and negative results and other results 
* Prevention of HIV infection  
* Right to refuse to test 
* If the participant is not ready DO NOT TEST but emphasize the importance of testing in and knowing their status. 
    
  REDCap Memory support - Test Procedure: Items to prepare 
[Review which samples are to be collected for this participant] 
* Bar code stickers/pen etc. 
*  Linen saver 
* 2x cotton wool balls 
* Lancet 
* Alcohol swabs 
* One Step HIV testing Kit: Cassette, buffer/diluent and pipette 
* Biotracer HIV testing Kit: Cassette, buffer/diluent and pipette 
* Gloves 
* Sharps container 
* Red bag for non-sharp waste 
* Timer 
 
    
  REDCap Memory support - Test Procedure: Collecting samples 
* Put gloves on 
* Finger chosen (middle and ring finger) in less dominant hand 
* Milk the chosen finger properly to get enough blood  
* Clean finger with swab 
* Prick lateral aspect of finger with lancet 
* Review if a fresh sample needed / avoid excess squeezing 
* Using Pipette from One Step kit draw up one drop of blood  
* Using Pipette from Biotracer kit draw up blood until the second line on the pipette 
 
    
 
205 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  REDCap Memory support - Test Procedure: Rapid testing kits 
* Squeeze 1 drop blood into S- well of One Step cassette  
* Squeeze 1 entire drop of blood (drawn up to 2nd line on pipette) into S-sample well of Biotracer 
cassette  
* Put 1drops of One Step buffer into the (S)- well of One Step cassette 
* Put 3 drops of Biotracer buffer into (S) well of Biotracer cassette 
* Set timer and wait for tests to process for full 20 minutes. 
* Move the cassette away from participants eyes. 
* Whilst waiting for the results, check if the client still remembers how to read the results and * 
Labelling 
 
    
  REDCap Memory support - Test Procedure: Results 
* Clearly evaluates if One Step test is valid, and gives correct interpretation 
* Clearly evaluates if Biotracer test is valid, and gives correct interpretation 









What was the LOT number for the test kit? [Text] c_advancekit_lotnum 
[Text; 20 digits] 
 1.2. 
Interview 
What is the Rapid HIV test result? [Radio] 
0 Valid Negative 




[integer; 1 digit; range 0–2] 
  Invalid results  
  REDCap Memory support - Post-test information giving  
  *Check if the client would like to consent for another rapid test 
*Explain the possibility of a second prick. 
*Repeat the test with same kit (Kit 1) 
 
    
Test Kit 1: Attempt 2 
 
  1.2.1. 
Interview 
What was the LOT number for the test kit? Number c_advancekit_lotnum_2 
[Text; 20 digits] 
  1.2.2. 
Interview 
What is the Rapid HIV test result? [Radio] 
0 Valid Negative 
1 Valid Positive 
c_advance_rapid_2 
[integer; 1 digit; range 0–2] 
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2 Invalid 
 
Question 2 Kit 2: Attempt 1  
 2.1 
Interview 
What was the LOT number for the test kit? Number c_abonkit_lotnum 
[Text; 20 digits] 
 2.2 
Interview 
What is the Rapid HIV test result? [Radio] 
0 Valid Negative 
1 Valid Positive 
2 Invalid 
(If invalid, second attempt) 
c_abon_rapid 
[integer; 1 digit; range 0–2] 
  Invalid results  
  REDCap Memory support - Post-test information giving  
  *Check if the client would like to consent for another rapid test 
*Explain the possibility of a second prick. 
*Repeat the test with same kit (Kit 2)  
 
    
Kit 2: Attempt 2 
 
  2.2.1 
Interview 
What was the LOT number for the test kit? Number c_abonkit_lotnum_2 
[Text; 20 digits] 
  2.2.2 
Interview 
What is the Rapid HIV test result? [Radio] 
0 Valid Negative 




[integer; 1 digit; range 0–2] 
    









Confirm the Summary HIV test result? [Radio] 
0 HIV Negative 
1 HIV Positive 
2 Discordant 
3 Invalid 
(If 0, skip to the next instrument) 
(If 1, Skip to Q4.1) 
(If 2-3, go to Q3.2) 
c_hivrapid_result 
[integer; 1 digit; range 0–2] 
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Please ensure that you have entered the kit results correctly 
 
     
  HIV Positive results 
  REDCap Memory support - Post-test information giving 
  * Show the participant both cassettes and let the participant read the results. 
* Agree on the positive results. 
* Allow time for the client to absorb the results. 
* Assess if participant understands meaning of results 
* Use open ended questions to ensure that the participant believes the result. 
* Deal with the immediate emotions reactions.  
* Help participant identify the main concerns at this stage.  
 
* Remind about lifesaving benefits of treatment. 
* Give information of how to access ARV and linkage to care (participant to visit clinic within 10 days). 
* If aged <15 years, AHRI paediatric HIV nurse will help them, and will meet them at their first appointment 
* Encourage disclosure, especially to parent/guardian if aged <15 years. 
* Assess / caution re inappropriate disclosure. 
* If alone: assess when parent to be brought in, & what to say. 
* Discuss the risk of STIs and opportunistic infections l  
* Check availability of immediate support at home. 
* Discuss positive healthy living with HIV. 
* Including prevention of transmission  
* Discuss the implications of not taking ARV. 
* Ask if there are questions, listen to participant's concerns. 
* Complete the referral letter and refer participant to the fixed clinic. 
* If aged 15+, add referral target date and inform re SMS reminder by using REDCap. 
 
    
  Negative Results 
  REDCap Memory support - Post-test information giving 
  * Show the participant both cassettes and let the participant read the results 
* Agree on the negative results 
* Allow time for the participant to absorb the results 
* Discuss window period and future re-testing 
* Check that the participant understands that someone on long term ARV may test negative while being infected. 
* Encourage healthy lifestyle i.e. stay negative, circumcision for males 
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* Encourage participant to know partner's status (if age-appropriate) 
* Ask if there are questions, listen to participant's concerns  
   
  Discordant/Invalid results 
  REDCap Memory support - Post-test information giving 
  * Ensure that the participant understands the discordant results. 
* Explain that the result can be confirmed in the lab using the venous blood that has already been collected. 
* Request HIV ELISA on LRF. 
* Explain that you will feedback this result in person. 
   
 3.2 
Interview 
If final rapid HIV test result is invalid or discordant, was 










REFERRAL TO CARE FOR HIV CARE (NEW HIV DIAGNOSIS) 
 
    
Referral To care Memory Aid: 
* Inform the participant that you need to refer them to clinic in PIP where there is an AHRI nurse. 
* Ask the participant to choose a clinic within PIP. 
 
* If age <15, tell the participant that an AHRI paediatric HIV nurse the AHRI paediatric HIV nurse can see 
them at the one of following clinics in PIP:  KwaMsane (Mondays); Mtubatuba (Tuesdays); Somkhele 






Which clinic would you like to be referred to? 
 
The AHRI Paediatric nurse can see parents in the 
following clinics: KwaMsane (Mondays); Mtubatuba 
(Tuesdays); Somkhele (Thursdays) 
 






[integer; 2 digits; range 0–99] 
 4.1.2 
Interview 
What is the agreed target date for attending clinic? 
 
Agree with the participant/parent a target date to 
attend clinic (this should be within 2 weeks). 
[date] c_rapidhiv_tdat 
[standard AHRI date variable, range: 
today () + 14] 
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What is your primary contact number? 
 
Explain that you need the phone number to be able to 
















If aged <15, skip to 4.1.6 
If aged 15+, go to 4.1.5 
c_rapidhiv_contnum_share 
[integer; 1 digit; range 0–1] 
 4.1.5 
Interview 
If aged 15+:  





(if No, Skip to Q4.1.6) 
c_rapidhiv_sms_cons 
[integer; 1 digit; range 0–1] 
 4.1.5.1 
Interview 
If Yes, what SMS reminder wording did the participant 
choose? 
Please choose from standard SMS reminders or use own 
words. 
[Radio]  
1 Please don't forget your appointment 
2 We hope you will visit us soon 
3 Don't forget to get that present 
6 Choose your own words 
(If 1-3, Skip to Q4.1.6) 
c_rapidhiv_sms_opt 
[integer; 1 digit; range 1-3, 6] 
 4.1.5.1.1 
Interview 









[integer; 1 digit; range 0–1] 
  If No, Pop Up Message 






Sputum Sample Collection 








Should sputum be collected from this participant? [Dropdown] 
1 Yes 
2 No, not required 
(If No skip to next section-end of survey) 
c_sputum 
[integer; 1 digit; range 1-4] 
  1.1.1 
Interview 
Sputum sample 1 barcode 
Use DOH sputum specimen container and barcode 
Barcode c_sput_specno1 
[Barcode] 
   1.1.1.1 
Interview 
Time of collection [Number] c_sput1_tcollhh 
[integer; 2 digits; range 00–23] 
   [Number] c_sput1_tcollmm 
[integer; 2 digits; range 00–59] 
  1.1.2 
Interview 
Sputum sample 2 specimen number 
Use AHRI sputum specimen container and barcode 
Barcode c_sput_specno2 
[Barcode] 
   1.1.2.1 
Interview 
Time of collection [Number] c_sput2_tcollhh 
[integer; 2 digits; range 00–23] 
   [Number] c_sput2_tcollmm 
[integer; 2 digits; range 00–59] 
   1.1.2.1.1 Total number of sputum samples collected [Number] Integer; 1 digit, range 0-2] 
 1.2 
Interview 
If sputum should be collected, but fewer than 2 
samples are collected, please comment 
[Text] c_sput_n1reas 
[string; 200 characters] 
   
If participant is not able to produce sputum, initiate referral to clinic 
 
 1.2.1 Does the participant need to be referred? [Radio]  
0 No 
1 Yes 




REFERRAL TO CARE (TB SYMPTOMS, UNABLE TO PRODUCE SPUTUM)  
   
Referral To care Memory Aid: 
* Explain to the participant that because they have symptoms suggestive of TB, they need to be 




Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
* Provide reassurance and reiterate that they are free to contact you whenever necessary 
 * Tell the participant that you need to refer them to clinic in PIP where there is an AHRI nurse. 
* Ask the participant to choose a clinic within PIP. 
* If you have already referred the participant during the visit for another reason, ask if can be contacted 
on the same number for this referral. 
  1.3.1 
Interview 






[integer; 2 digits; range 0–99] 
  1.3.2 
Interview 
What is the agreed target date for attending clinic? 
 
Agree with the participant on a target date to attend 
clinic (this should be within 2 weeks). 
[date] c_nsput_tdat 
[standard AHRI date variable, range: today 
() + 14] 
  1.3.3 
Interview 
What is your primary contact number? 
Explain that you need the phone number to be able to 






  1.3.4 
Interview 





[integer; 1 digit; range 0–1] 
  1.3.6 
Interview 





[integer; 1 digit; range 0–1] 
     If No, Pop Up Message 






End of Survey Instrument 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
 1.1 
Interview 
Summary of results to feedback: 
 
* Inform the participant and/or the parent/guardian that you may feedback the following results: 
* Give estimated timelines for feeding back the result. 
c_res_feedback 
[lebel] 
  1.1.1 
Calculated 
HIV ELISA. if rapid HIV test is discrepant or invalid c_hivelisa_fdback 
 
  1.1.2 
Calculated 
GeneXpert (Sputum) if sputum1 was collected c_xpert_fdback 
 
  1.1.3 
Calculated 
Culture (Sputum) If Sputum2 is collected.  Results only fed back if 
Sputum 2 is positive and Sputum 1 is negative 
c_sptcult_fdback 
 
  1.1.4 
Calculated 
IGRA result  
Tell the participant you will feed back if IGRA is positive 
if the participant also knows their HIV positive 
status, and the IGRA result is positive 
c_igra_fdback 
 




Contact Details for Feeding Back Result 
 
   Memory Aid – Feeding Back Results 
* Tell Participant: Results will fed back in person (except geneXpert negative), but you will call first to arrange 
and appointment 
 
   1.2.1 
Interview 
Which number can I contact you on to feedback laboratory 
results? 
[Text] c_res_cntnum 
[text; 10 characters] 
   1.2.2 
Interview 





[integer; 1 digit; range 0–1] 
   1.2.3 
Interview 







[integer; 1 digit; range 0–1] 
   1.2.4 
Interview 





[integer; 1 digit; range 0–1] 
     If No, Pop Up Message 
Please verify the number to check if it is working 
 
       
 2.1 Reimbursement  
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Interview 
  2.1.1 
Interview 
How would you like to be reimbursed? [Radio]  
1 Airtime 
2 Food Refreshment 
 
c_reimburse_opt 
[integer; 1 digit; range 1-2] 
   If airtime, please confirm number to be reimbursed on   
  2.1.1.1 
Preloaded/Interview 
Please provide your primary contact number (mobile) Number c_prim_cntnum 
[text; 10 characters] 
  2.1.1.2 
Preloaded/Interview 








[integer; 1 digit; range 0–4,6] 
  2.1.1.2.1 
Interview 
Specify network Text c_prim_cntnum_network_o 
[text; 50 characters] 
  2.1.2.1 
Preloaded/Interview 
Alternative contact number (mobile) Number c_alt_prim_cntnum 
[text; 10 characters] 
  2.1.2.2 
Preloaded/Interview 
 








[integer; 1 digit; range 0–4,6] 
  2.1.2.2.1 
Interview 
Specify network Text c_alt_prim_cntnum_network_o 









Has the participant answered all the questions? [Radio]  
0 No 
1 Yes 
(if Yes, Skip to Q15.2) 
c_surv_comp 
[integer; 1 digit; range; 0-1] 
  3.1.1.1 
Interview 
If No, why were some questions not answered? 
(give comments why some questions were not completed) 
[Text] c_nocomp_reas 
[Text, 200 characters] 
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  3.1.2 Please add any other comments or notes that you feel are 
needed 
[text] c_survey_comments 
[Text, 300 characters] 
 3.1.3 
Interview 
Interviewer Code Dropdown 
1 Staffcode 1 
2 Staffcode 2 
3 Staffcode 3 
4 Staffcode 4 
 
c_intid 
[integer; 1 digit; range; 1-4] 
 3.1.4 
Interview 
Time interview completed [Number] c_tintstophh 
[integer; 2 digits; range 00–23] 
[Number] c_tintstopmm 






Appendix 10: Social Contacts questionnaire for participants (10-19 years) 
HAYA TB Study – Social Contacts Case Report Form 
Tell the participant: 
Tuberculosis is an air borne infection. This means that it is transmitted by inhaling TB bugs that have been released into the air by people with disease through: coughing, sneezing, 
singing, or speaking. In this part of the interview I will ask you about the places that you visit, the numbers of people that were present the last time you were at these places, and the 
numbers of people that you had contact with. This information will help us understand how people mix in their households and in the community. It will also help us understand the 
link between different social mixing patterns and TB infection. 
 
Describe the following definition of a social contact to the participant and proceed with the interview 
 
Definition of a social contact: 
Explain to the participant that for the purposes of this study a social contact is defined as a person with whom the study participant either: 
1) Had a conversation in the physical presence of the other person, within arm’s reach; OR  
2) Physical skin to skin contact, like a handshake, hug, or kiss; OR  
3) Had sat next to each other in an enclosed environment, like a classroom, church, hospital or public transport. 
 
Non-physical contacts made by phone call, WhatsApp, Facebook or other social media do not qualify as social contacts for the purposes of this study. 
 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
 
Question 1: Visit to other households 
 1.1 
Interview 
Do you sleep in the same room as another person? [Radio] 
0 No 
1 Yes 
(If No, skip to Q1.3) 
c_hh_roomshare 
[integer; 1 digit; range 0–1] 
  1.2. 
Interview 





[integer; 2 digits; range 01–19] 




Can you provide me details of each person that you 
sleep in the same room with? 
[Enter sub-form for each person] c_hh_roomshare_det 
    1.2.1.1 
Interview 
Age of person [Number] (years) 
999 = Don’t know 
c_hh_roomshareage 
[integer; 3 digits; range 001–099, 999] 
    1.2.1.2 
Interview 
Sex of person [Radio] 
1 Male 
c_hh_roomsharesex 
[integer; 1 digit; range 1–2] 
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In the last 12 months, did you spend nights in 
homesteads other than your own for a total of 2 weeks 
or more? 





(If No, skip to Q1.4) 
c_hh_vis12m  
[integer; 1 digit; range 0–1] 
  1.3.1 
Interview 
If Yes, how many homesteads? [Number] 
99 = Don’t know 
c_hh_vis12m_n  
[integer; 2 digits; range 01–10, 99] 
 1.4 
Interview 
In the last four weeks, did you visit homesteads other 
than your own for 30 minutes or longer (where you did 




(If No, skip to Q2) 
c_hh_vis1m  
[integer; 1 digit; range 0–1] 
  1.4.1 
Interview 
If Yes, how many homesteads? [Number] 
99 = Don’t know 
c_hh_vis1m_n  
[integer; 2 digits; range 01–10, 99] 
 
Question 2: Attendance to church or prayer meetings 
 2.1 
Interview 
In the last 12 months, did you attend church or any 




(If No, skip to Q3) 
c_church_att12m 
[integer; 1 digit; range 0–1) 
  2.1 
Interview 
If Yes, how many times did you attend church in the 
last 4 weeks? 
[Number] 
99 = Don’ know 
c_church_natt12m 
[integer; 2 digits; range 01–31] 
 2.2 
Interview 
Which church/religion do you belong to? Dropdown [List of religions] 
1 African Evangelical Church 
2 Anglican (Church of South Africa) 
3 Assemblies of God 
4 Baptists 
 …. 
96 Other, specify 
97 None 
98 Prefer not to say 
(If None or Prefer not to say, skip to Q2.3) 
c_church  
[integer; 2 digits, range 01–XX, 96–98] 
  2.2.1 
Interview 
Other religion if not on the list: [Text] c_church_o 
[string; 30 characters] 
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  2.2.2 
Interview 
Which branch (location of place of worship) of your 
church or place of worship do you go to? 
[Text] c_church_loc 
[string; 30 characters] 
 2.3 
Interview 
When was the last time that you attended church or 
any prayer meeting? 
[Number] (day) 
99 = Don’t know 
c_churchvis_dvisd 
[standard AHRI day variable; range 01–31, 
99] 
[Number] (month) 
99 = Don’t know 
c_churchvis_dvism 
[standard AHRI month variable; range 01–
12, 99] 
[Number] (year) c_churchvis_dvisy 
[standard AHRI year variable; range 1998–
2017] 
  2.3.1 
Interview 
Was church service or prayer meeting conducted 
indoors or outdoors? 
Drop down 
1 Entirely indoors 
2 Mostly indoors 
3 Mostly outdoors 
4 Entirely outdoors 
 
c_church_indoor 
[integer; 1 digit; range 1–4] 
   Memory Aid – Contacts at last day of attending school 
* Questions 2.3.2 to 2.3.2 ask about the time spent in a classroom and the number of students present. 
* If the participant is not able to recall the time spent in a classroom or the number of students present, 
assist them to come up with a realistic estimate as much as possible. 
* if you have assisted the participant to come up with this number indicate this by ticking on the tick box 
next to the question. 
 
  2.3.2 
Interview 
How much time did you spend the last time you 
attended church or player meeting? 
[Number] (hours) 
99 = Don’t know 
c_church_dur 
[integer; 2 digits; range 01–15, 99] 
    Tick box c_church_dur_est 
[integer; 1 digit; range 1] 
  2.3.3 
Interview 
How many people were present the last time you 
attended church or player meeting? 
[Number] 
999 = Don’t know 
c_church_natt 
[integer; 3 digits; range 001–500, 999] 
    Tick box c_church_natt_est 
[integer; 1 digit; range 1] 
   2.3.3.1 
Interview 
How many of these people were aged 11 years or 
below? 
[Number] 
999 = Don’t know 
c_church_nchild 
[integer; 3 digits; range 001–500, 999] 
     Tick box c_church_nchild_est 
[integer; 1 digit; range 1] 
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   2.3.3.2 
Interview 
How many of these people were males aged 12 years 
and above? 
[Number] 
999 = Don’t know 
c_church_nadultm 
[integer; 3 digits; range 001–500, 999] 
     Tick box c_church_nadult_est 
[integer; 1 digit; range 1] 
 




Piped from participant 
CRF 
Do you currently go to school? 
(This question shows what the participant said on 
whether they attend school, it guides you how to 
proceed with Q3.2) 
[Ribbon] 
1 No, never been to school 
1 Yes, previously 
1 Yes, currently 
 
c_school 
[integer; 1 digit; range 1] 
 3.2. 
Interview 
In the last 12 months, did you attend school? 
(if participant mentioned that they are currently 
attending school, you do not need to ask this question 





(If No, skip to Q3.3) 
c_school12m 
[integer; 1 digit; range 0–1] 
  3.2.1 
Interview 
If you are not going to school, why? Dropdown 
1 Illness 
2 Finished Matric 
3 Taking care of relative 
6 Other specify 
(Skip to Q4) 
c_school12m_no_reas 
[integer; 1 digit; range 0–X, 6] 
  3.2.1.1 
Interview 
Other reason if not on the list [Text] c_school12m_no_reas_o 
[text, 30 characters] 
 3.3. 
Interview 
In the last week, how many days did you go to school? 
(if on holiday, ask in the last week attended school) 
[Number] c_school_nvis1wk 
[integer; 1 digit; range 1–7] 
 3.4. 
Interview 
When was the last time you attended school? [Number] (day) 
99 = Don’t know 
c_school_dattd 
[standard AHRI month variable; range 01–
31, 99] 
[Number] (month) 
99 = Don’t know 
c_school_dattm 
[standard AHRI month variable; range 01–
12, 99] 
[Number] (year) c_school_datty 
[standard AHRI year variable; range 1998–
2018] 
  Memory Aid – Attendance to church or Prayer meetings:  
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* Questions 3.4.1 to 3.4.3 ask about the duration of prayer meetings and the number of people present. 
* If the participant is not able to recall the duration of the prayer meeting or the number of people present, 
assist them to come up with a realistic estimate as much as possible. 
* if you have assisted the participant to come up with this number indicate this by ticking on the tick box 
next to the question. 
  3.4.1 
Interview 
How much time in total did you spend in a classroom 
the last day that you attended school? 
[Number] (hours) 
99 = Don’t know 
c_school_class_dur 
[integer; 2 digits; range 01–12, 99] 
    Tick box c_school_classdur_est 
[integer; 1 digit; range 1] 
  3.4.2 
Interview 
What was the highest number of students in your 
classroom among the classes that you attended? 
[Number] 
999 = Don’t know 
c_school_class_nstud 
[integer; 2 digits; range 01–70, 999] 
    Tick box c_school_classdnstud_est 
[integer; 1 digit; range 1] 
   3.4.2.1 
Interview 
How many of these students were aged 11 years or 
below? 
[Number] 
999 = Don’t know 
c_school_class_nchild 
[integer; 2 digits; range 01–70, 999] 
     Tick box c_school_classdnchild_est 
[integer; 1 digit; range 1] 
   3.4.2.2 
Interview 
How many of these students were males aged 12 years 
and above? 
[Number] 
999 = Don’t know 
c_school_class_nadultm 
[integer; 2 digits; range 01–70, 999] 
     Tick box c_school_classd_nadultm_est 
[integer; 1 digit; range 1] 
  3.4.3 
Interview 
On the last day that you attended school, how many 
people did you contact at school, including your 
teachers and other students not in your class? 
 
(repeat the above definition of a contact to the 
participant) 
[Number] 
999 = Don’t know 
c_school_ncontact 
[integer; 2 digits; range 01–70, 999] 
    Tick box c_school_ncontact_est 
[integer; 1 digit; range 1] 
 
Question 4 Travel on Public Transport 
 4.1 
Piped from participant 
CRF 
Do you currently go to school? [List] 
1 No, never been to school 
1 Yes, previously 
c_school_2 
[integer; 1 digit; range 1] 
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(This question shows what the participant said on 
whether they attend school, it guides you how to 
proceed with Q4.2) 




If currently in school or not been in school in the last 12 
months: 
In the last 7 days, did you make road trips in a closed 
vehicle like a minibus, taxi, bakkie/pickup, or private 
car? 
If currently in school but on holiday; ask in the last week 




(If No, skip to Q4.2) 
c_rdtrip 
[integer; 1 digit; range 0–1] 
  4.2.1 
Interview 
If yes, how many road trips in a vehicle did you make in 
the last 7 days? 
If on holiday, ask in the last week you attended school. 
[Number] 
99 = Don’t know 
c_rdtrip_n1wk 
[integer; 2 digits; range 01–20, 99] 
 4.3 
Interview 
When was the last time you made a road trip in a 
vehicle? 
[Number] (day) 
99 = Don’t know 
c_rdtrip_dlastd 
[standard AHRI month variable; range 01–
31, 97, 99] 
[Number] (month) 
99 = Don’t know 
c_rdtrip_dlastm 
[standard AHRI month variable; range 01–




[standard AHRI year variable; range 1998–
2017] 
  Memory Aid – Travel on public transport: 
* Questions 4.3.1 to 4.3.2.2 ask about the duration of road trips and the number of other passenger. 
* If the participant is not able to recall the duration of the road trip or the number of passengers assist them 
to come up with a realistic estimate as much as possible. 
* if you have assisted the participant to come up with this number indicate this by ticking on the tick box 
next to the question. 
 
  4.3.1 
Interview 
On the last day that you travelled, how much time 
were you in a vehicle in total? 
[Number] (hours) 
99 = Don’t know 
c_rdtrip_dur 
[integer; 2 digits; range 01–20, 99] 
    Tick box c_rdtripdur_est 
[integer; 1 digits; range: 1] 
  4.3.2 
Interview 
On the last day that you travelled, how many people 
were in the vehicle with you? 
[Number] 
99 = Don’t know 
c_rdtrip_npasseng 
[integer; 2 digits; range 01–70, 99] 
    Tick box c_rdtrip_npasseng_est 
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[integer; 1 digits; range: 1] 
   4.3.2.1 
Interview 
How many of these people were aged 11 years or 
below? 
[Number] 
99 = Don’t know 
c_rdtrip_nchild 
[integer; 2 digits; range 01–70, 99] 
     Tick box c_rdtrip_nchild_est 
[integer; 1 digits; range: 1] 
   4.3.2.2 
Interview 
How many of these people were males aged 12 years 
and above? 
[Number] 
99 = Don’t know 
c_rdtrip_nadultm 
[integer; 2 digits; range 01–70, 99] 
     Tick box c_rdtrip_nadultm_est 
[integer; 1 digits; range: 1] 
 
Question 5: Visit to bars, nightclubs, or shebeens 
 5.1 
Interview 





(If No, skip to 6) 
c_barvis 
[integer; 1 digits; range 0–1] 
  5.1.1 
Interview 
In the last four weeks, how many times did you go to 
bars, nightclubs, or shebeens? 
[Number] 
99 = Don’t know 
c_barvis_n1m 
[integer; 2 digits; range 01–20, 99] 
 5.2 
Interview 
When was the last time that you went to a bar, 
nightclub, or shebeen? 
[Number] (month) 
97 = Never 
99 = Don’t know 
c_barvis_dvism 
[standard AHRI month variable; range 01–
12, 97, 99] 
[Number] (year) 
9997 = Never 
c_barvis_dvisy 
[standard AHRI year variable; range 1998–
2017, 9997] 
  Memory Aid – Visits to bars and night clubs: 
* Questions 5.2.1 to 5.3.2.1 ask about the duration of visits to night clubs and the number of people present 
during the visit. 
* If the participant is not able to recall the duration of the visit or the number of people present, assist them 
to come up with a realistic estimate as much as possible. 
* if you have assisted the participant to come up with this number indicate this by ticking on the tick box 
next to the question. 
 
  5.2.1 
Interview 
How much time did spend at the bar, nightclub, or 
shebeen at your last visit? 
[Number] (hours) 
99 = Don’t know 
c_barvis_dur 
[integer; 2 digits; range 01–20, 99] 
    Tick box c_barvis_dur_est 
[integer; 1 digits; range1] 
 
222 
Q number; source Question Var type; dropdown options; skip logic Var name; field type; size; limits 
  5.2.2 
Interview 
The last time you were at bar was it indoors or 
outdoors? 
Drop down 
1 Entirely indoors 
2 Mostly indoors 
3 Mostly outdoors 
4 Entirely outdoors 
 
c_barvis_indoor 
[integer; 1 digit; range 1–4] 
  5.3.2 
Interview 
How many people were present at your last visit to a 
bar, nightclub, or shebeen? 
[Number] 
999 = Don’t know 
c_barvis_natt 
[integer; 3 digits; range 001–200, 999] 
    Tick box c_barvis_natt_est 
[integer; 1 digits; range1] 
   5.3.2.1 
Interview 
How many of these people were males aged 12 years 
and above? 
[Number] 
999 = Don’t know 
c_barvis_nadultm 
[integer; 3 digits; range 001–200, 999] 
     Tick box c_barvis_nadultm_est 
[integer; 1 digits; range1] 
 
Question 6: Visits to other places 
 6.1 
Interview 
In the last 3 months, did you visit any other gathering 
places apart from school, church, hospital, clinic, bar 




(If No, skip to the next instrument) 
c_othvis 
[integer; 1 digit; range 0–1] 
  6.1.1 
Interview 
If yes, can you tell me more about the gathering places 
that you visited in the last 3 months? 
 c_othvis_det 
   6.1.1.1 
Interview 
If yes, what is the name of this this gathering place? [Text] c_othvis1_loc 
[string; 30 characters] 
  6.1.1.2 
Interview 
When was the last time that you went to this place? [Number] (day) 
99 = Don’t know 
c_othvis1_dvisd 
[standard AHRI month variable; range 01–
31, 99] 
[Number] (month) 
99 = Don’t know 
c_othvis1_dvism 
[standard AHRI month variable; range 01–
12, 99] 
[Number] (year) c_othvis1_dvisy 
[standard AHRI year variable; range 1998–
2017] 
   Memory Aid – Visits [*Other Places*]:  
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* Questions 6.1.1.3 to 6.1.1.5.2 ask about the duration of visits to [other places] and the number of people 
present during the visit. 
* If the participant is not able to recall the duration of the visit or the number of people present, assist 
them to come up with a realistic estimate as much as possible. 
* if you have assisted the participant to come up with this number indicate this by ticking on the tick box 
next to the question. 
   6.1.1.3 
Interview 
The last time you went to this place, how much time 
did you spend? 
[Number] (hours) c_othvis1_dur 
[integer; 2 digits; range 01–20] 
     Tick box c_othvis1_dur_est 
[integer; 1 digits; range 1] 
   6.1.1.4 
Interview 
Was this gathering place indoors or outdoors? Drop down 
1 Entirely indoors 
2 Mostly indoors 
3 Mostly outdoors 
4 Entirely outdoors 
 
c_othvis1_indoor 
[integer; 1 digit; range 1–4] 
   6.1.1.5 
Interview 
How many people were present at your last visit? [Number] 
999 = Don’t know 
c_othvis1_natt 
[integer; 3 digits; range 001–500, 999] 
     Tick box c_othvis1_natt_est 
[integer; 1 digits; range 1] 
    6.1.1.5.1 
Interview 
How many of the people present were aged 11 years or 
below? 
[Number] 
999 = Don’t know 
c_othvis1_nchild 
[integer; 3 digits; range 001–500, 999] 
      Tick box c_othvis1_nchild_est 
[integer; 1 digits; range 1] 
    6.1.1.5.2 
Interview 
How many of the people present were males aged 12 
years and above? 
[Number] 
999 = Don’t know 
c_othvis1_nadultm 
[integer; 3 digits; range 001–500, 999] 
      Tick box c_othvis1_nadultm_est 
[integer; 1 digits; range 1] 
   6.1.1.6 
Interview 
Is there another gathering place that you visited in the 




(If No, continue to Q7; 
If Yes, add sub-form [Q6.1.1–6.1.7]) 
c_othvis1_another 
[integer; 1 digit; range 0–1) 
        Sub-form variables: second visit 








Appendix 11: Study questionnaire for parent/guardian 
Contact Attempts 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
 Memory Aid 
* Introduce AHRI 
* I am a nurse (AHRI uniform and badges) 
* Structure and time outline 
* Find private space to speak with parent 
 Section taken from PIP 
[Up to 6 attempts will be made. At 4th attempt, provide information to study coordinator to evaluate whether further attempts are necessary.] 
Personal Information 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
 1 
Pre-loaded 
Participant’s (child’s) name: [Text] p_parti_name 
[Text, 50 characters] 
 2 
Interview 
Is the participant’s (child’s) pre-loaded name correct? Ribbon 
0 No 
1 Yes 
If Yes, Skip to Q3 
p_partnam_corr 
[integer; 1 digit; range 0–1] 
  2.1 
Interview 









[Text, 50 characters] 
 3 
Pre-loaded 









Participant's (child’s) date of birth [Date] p_dobd 




Age Number p_age 
[integer; 2 digits; range 10-19] 
 6 
Interview 
Is the participant’s (child’s) pre-printed date of birth correct? Ribbon 
0 No 
p_d_prep_dob 
[integer; 1 digit; range 0–1] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
1 Yes 
If Yes, Skip to Q7 
  6.1 
Interview 
If not correct, please provide the correct date of birth 
 
If exact date of birth is not known, please request to see a 
ID or birth certificate and check the date of birth from this 
document.  
 
If document is not available and only the year of birth is 




[integer; 2 digits; range 01-31] 
   Age Eligibility Memory Aid 
* Participants are eligible if date of birth is after 1 May 1999 
and before 30 April 2008 
  
  6.2 
Interview 





If Yes, Go to Q7 
p_age_eligible 
[integer; 1 digit; range 0–1] 
  6.2.1 
calculated 
Participant’s correct age Number p_age_correct 
If No, Pop Up Message: 
Participant if not eligible, please terminate the interview 
 7 
Pre-loaded 
BSID Number p_resp_bsid 




BS Owner Text p_bs_owner 
[text; 50 characters] 
 9 
Pre-loaded 
Location/Isigodi Text p_location_isigodi 
[text; 50 characters] 
 10 
Pre-loaded 
Household Head Text p_hh_head 
[text; 50 characters] 
 11 
Interview 




[integer; 1 digit; range 0–1] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
If Yes, Skip to Q12 
  11.1 
Interview 
Respondent's first name Text p_resp_fname 
[text; 50 characters] 
  11.2 
Interview 
Respondent's last name Text p_resp_lname 
[text; 50 characters] 
  11.3 
Interview 





[integer; 1 digit; range 1,2] 
  11.4 
Interview 
Respondent's date of birth [Date] p_resp_dob 
[standard AHRI date variable; range 
1900/01/01-2009/12/31] 
  11.5 
Interview 
Respondents relationship to participant: Drop down 
1 Biological Parent (Father/Mother) 
2 Legal guardian 
3 Foster parent caregiver 
4 Nominated trusted adult 
(If 3 or 4 go to Q11.5.1) 
p_resp_rel 
[integer; 2 digit; range 1-6, 96] 
  11.5.1 
Interview 
Specify relationship Text p_resp_rel_o 
[Text, 50 characters] 
 12 
Interview 







[integer; 1 digit; range 1,2] 
 13 
Interview 
Start time of interview [Time] p_resp_dob 




Date of Interview [Date] p_date_of_interview 
[standard AHRI date variable; range 
2017/11/01-2019/12/31] 
 
Assessment of Capacity to Consent 
 
228 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
  Section taken from PIP   
 
Eligibility Checklist 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
 Eligibility Checklist (Previous/current TB treatment) 
Before giving detailed information about the study, perform the following eligibility checklist for the study participant 
 1.1  
Interview 
Has your child ever received treatment for TB disease? 
 
(If needed, explain that treatment for TB disease will have 
been with at least four drugs [though it may have been in one 
tablet, e.g., Rifafour] every day for two months, and then two 
drugs [again, may have been in one tablet, e.g., Rifinah] every 
day for a further four months [i.e., a total of at least 6 
months].   
 
This is different from isoniazid preventive therapy [IPT], 
which is used to treat TB infection, and will have involved 




9 Don’t know 
 
p_tbtx_ever 
[integer; 1 digit; range 0–1, 9] 
  if No or Don’t Know, Pop Up Message: 
Please provide detailed information about the study to the parent/guardian and obtain informed consent 
  1.1.1 
Interview 
If yes, when did your child start TB treatment? 
(If more than once, get details for the most recent episode) 
[Dropdown] 
99 = Don’t know 
p_tbtx_dstartm 





[standard AHRI year variable; range 
1998–2017] 
  1.1.2  
Interview 
Where (which facility) did your child start TB treatment? [Dropdown] [List of clinics in PIP] 
96 = Other (specify) 
99 = Don’t know 
p_tbtx_clin 
[integer; 2 digits; range 1–XX, 96, 99] 
   1.1.2.1  
Interview 
Other, specify [Text] p_tbtx_clin_o 
[string; 30 characters] 
 If Q1.1 is Yes, Pop Up Message 
Participant is not eligible please go to the End of Survey Instrument and conclude the interview 
 
229 
Informed Consent Form 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
  
Informed consent – Memory aid 
* If the parent is not able to read or write, ask for a witness within the home to witness the process of giving information and obtaining consent 
 *Insert Informed Consent Information sheet* 
 1.1 
Interview 
Name of interviewer Text p_staff_name 
[Text; 50 Characters] 
 1.2 
Interview 




Date Date and time p_staff_date 




Did parent/guardian consent to participation in the study? [Radio]  
0 No 
1 Yes 
(If No, Show IC1) 
p_consent 
[integer; 1 digit; range 0–1] 
  If No, Pop Up Message 
Parent/guardian refused participation, please go to the End of Survey Instrument and conclude the interview. 
 1.5 
Interview 
Name of respondent Text p_pg_name 
[Text; 50 Characters] 
 1.6 
Interview 




Date Date and time p_pg_date 




Is the parent/guardian able to sign [Radio]  
0 No 
1 Yes 
(If Yes, No go to Q1.8.1) 
p_sign 
[integer; 1 digit; range 0–1] 
  1.8.1 
Interview 
Name of witness Text p_witness_name 
[Text; 50 Characters] 
  1.8.2 
Interview 




Q number; source Question Field type; dropdown options Variable name, type, size, limits 
  1.8.3 
Interview 
Date Date and time p_witness_date 




Adolescent TB Study (Study specific questions) 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Question 5 BCG Vaccination 
 5.1  
Interview 
Has your child been vaccinated against TB? 
(If the parent is unsure, explain that this would have been 
an injection in one of the child’s arms at birth [before the 
mother was discharged from hospital] or within the first 
year of the child’s life. The site of the injection may have 
become very inflamed (a swollen and painful blister), and 
may have developed into an opening in the skin with pus.  




9 Don’t know 
 
p_bcg 
[integer; 1 digit; range 0–1, 9] 
 5.2  
Interview 
Is your child’s road to health card available? 
(Ask parent/guardian if RTH card is available and if you 




(If No, skip to Q6) 
p_rthc 
[integer; 1 digit; range: 0–1] 
  5.2.1  
Interview 











Health care utilisation 
 6.1  
Interview 
Has your child ever been admitted to hospital? 
(Explain, if needed, that ‘admitted’ means sleeping for at 




9 Don’t know 
(if No, skip to Q7) 
p_adm_ever 
[integer; 1 digit; range 0–1, 9] 
 
  6.1.1  
Interview 
If yes, how many times has your child ever been 
admitted to hospital? 
[Number] 
99 = Don’t know 
p_adm_num 
[integer; 2 digits; range 01–20, 99] 
  6.1.2  
Interview 
When was your child most recently admitted to hospital? [Dropdown] 




Q number; source Question Field type; dropdown options Variable name, type, size, limits 





[standard AHRI year variable; range 1998–
2017] 
  6.1.3  
Interview 
Where (to which hospital) was your child most recently 
admitted? 
[Dropdown] [List of facilities in PIP] 
96 = Other (specify) 
99 = Don’t know 
p_adm_hosp 
[integer; 2 digits; range 01–XX, 96] 
   6.1.3.1 
Interview 
Other, specify [Text] p_adm_hosp_o 
[string; 50 characters] 
  6.1.4  
Interview 
What was the reason for your child’s most recent 
admission to hospital? 
[Dropdown] 
01 Respiratory tract infection 
02 Diarrhoea 
03 Injury 
04 Convulsions (fits) 
05 Other infection 
06 Surgery 
96 Other, specify 
99 Don’t know 
(If 1, 2, 3, 4, 5, or 9, skip to Q7) 
p_adm_reas 
[integer; 1 digit; range 01–06,96,99] 
 
   6.1.4.1  
Interview 
Other, specify [Text] p_adm_reas_o 




TB contacts: Household 
 7.1  
Interview 
Has anyone in your homestead (or residential plot) ever 
had TB disease during your child’s lifetime?  
 
(Including those who might not have started TB 





9 Don’t know 
(if No or don’t know, skip to Q7.2) 
p_hh_tbever 
[integer; 1 digit; range 0–1, 9] 
 7.1.1 
Interview 
Is anybody in your household currently on TB treatment? [Dropdown] 
0 No 
1 Yes 
9 Don’t know 
 
p_hh_tbcur 
[integer; 1 digit; range 0–1, 9] 
 TB contacts memory aid 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Please tell the parent that you would like to  ask them a few questions about these people.  Tell them that you will ask about each person separately 
and encourage them to think back and remember how many individuals in their homestead had TB in their child’s lifetime 
   Details of person(s)  
  7.1.2 
Interview 
What was the age of this person at the time they lived in 
the same homestead as your child? 
[Number] 
999 = Don’t know 
p_curhh_tbcontact 
[integer; 3 digits; range 001–099, 999] 
  7.1.3 
Interview 





[integer; 1 digit; range: 1–2] 
  7.1.4 
Interview 
In which year did your child live in the same homestead 
as this person? 
[Dropdown] 
9999 = Don’t know 
p_curhh_tbcontactyr  
[Integer; 4 digits; range 1998–2018, 9999] 
  7.1.5 
Interview 
In which isigodi was the person staying at the time? [Dropdown] [List of isigodis] 
96 = Other, specify 
99 = Don’t know 
 
If 96 go to 7.1.4.1, otherwise skip to 7.1.5 
p_curhh_tbcontactisi 
[integer; 2 digits; range 01–XX, 96, 99] 
  7.1.5.1 
Interview 
Other, specify [Text] p_curhh_tbcontactisi_o 
[string; 30 characters] 
  7.1.6 
Interview 
Did your child sleep in the same house as this person 




9 Don’t know 
(if No or Don’t know, skip to Q7.1.6) 
p_curhh_contacthouse 
[integer; 1 digit; range 0–1, 9] 
  7.1.6.1 
Interview 
Did your child sleep in the same room as this person 




9 Don’t know 
 
p_curhh_tbcontactshare 
[integer; 1 digit; range 0–1, 9] 
  7.1.7 
Interview 
Was your child involved in the care of this person when 
the person was ill? 
(i.e., your child came into close contact with this person 




9 Don’t know 
 
p_curhh_tbcontactcare 
[integer; 1 digit; range 0–1, 9] 
  7.1.8 
Interview 
Apart from the person(s) described above, has anyone 






[If Yes, add new sub-form (Qs 7.1.1–7.1.7)] 
p_curhh_tbcontactotherp  
[integer; 1 digit; range 0–1] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Encourage the parent to think back about whether there 
have been any others  
      
    




Apart from your homestead (or residential plot), has 
your child ever lived (slept overnight) in the same 
homestead (or residential plot) as someone with TB for a 
total of 2 weeks or more? 
(Including those who might not have started TB 





9 Don’t know 
(If No or Don’t know, skip to Q8) 
p_hh_tbcontact 
[integer; 1 digits; range 0–1,9] 
   Details of person(s)  
   7.2.1.1 
Interview 
What was the age of this person at the time they lived in 
the same homestead as your child? 
[Number] 
999 = Don’t know 
p_hh_tbcontact 
[integer; 3 digits; range 001–099, 999] 
   7.2.1.2 
Interview 





[integer; 1 digit; range: 1–2] 
   7.2.1.3 
Interview 
In which year did your child live in the same homestead 
as this person? 
[Dropdown] 
9999 = Don’t know 
p_hh_tbcontactyr  
[Integer; 4 digits; range 1998–2018, 9999] 
   7.2.1.4 
Interview 
In which isigodi was the person staying at the time? [Dropdown] [List of isigodis] 
96 = Other, specify 
99 = Don’t know 
p_hh_tbcontactisi 
[integer; 2 digits; range 01–XX, 96, 99] 
    7.2.1.4.1 
Interview 
Other, specify [Text] p_hh_tbcontactisi_o 
[string; 30 characters] 
   7.2.1.5 
Interview 
Did your child sleep in the same house as this person 




9 Don’t know 
(if No or Don’t know, skip to 7.2.1.7) 
p_hh_contacthouse 
[integer; 1 digit; range 0–1, 9] 
    7.2.1.6 
Interview 
Did your child sleep in the same room as this person 




9 Don’t know 
 
p_hh_tbcontactshare 
[integer; 1 digit; range 0–1, 9] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
   7.2.1.7 
Interview 
Was your child involved in the care of this person when 
the person was ill? 
(i.e., your child came into close contact with this person 




9 Don’t know 
 
p_hh_tbcontactcare 
[integer; 1 digit; range 0–1, 9] 
   7.2.1.8 
Interview 
Apart from the person(s) described above, has your child 
ever lived (slept overnight) in the same homestead as 
another person with TB? 
 
Encourage the parent to think back about whether there 




[If Yes, add sub-form (Qs 7.2.1.1–7.2.1.8)] 
p_hh_tbcontactotherp  




TB contacts: Carer 
 8.1 
Interview 
Apart from people with TB who lived in the same 
homestead as your child (the ones mentioned in the 
sections above), has your child ever been involved in the 




9 Don’t know 
(If No or Don’t know, skip to Q9) 
p_tb_care 
[integer; 1 digit; range 0–1, 9] 
 Details of person(s)  
  8.1.1  
Interview 
What was the age of this person at the time your child 
was involved in their care? 
[Number] 
999 = Don’t know 
p_tb_careage  
[integer; 3 digits; range 001–099, 999] 
  8.1.2  
Interview 





[integer; 1 digit; range 1–2] 
  8.1.3  
Interview 
In which isigodi was this person staying at the time? [Dropdown] [List of isigodis] 
96 = Other, specify 
99 = Don’t know 
p_tb_careisi 
[integer; 2 digits; range 01–XX, 96, 99] 
   8.1.3.1  
Interview 
Other, specify [Text] p_tb_careisi_o 
[string; 30 characters] 
  8.1.4  
Interview 
In which year did your child care for this person? [Dropdown] 
9999 = Don’t know 
p_tb_careyr  
[integer; 4 digits; range 1998–2018, 9999] 
  8.1.5 
Interview 
Is there another person with TB who did NOT live in the 
same house as your child, but in whose care your child 





[If Yes, add sub-form (Qs 8.1.1–8.1.5)] 
p_tb_careotherp  
[integer; 1 digit; range 0–1] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Encourage the parent to think back about whether there 




Chronic conditions  
(ARV uptake can be captured and noted at this point. If the parent indicates that the child is taking ARVs, record details later, in the HIV section) 
 9.1 
Interview 
Does your child have asthma? [Radio] 
0 No 
1 Yes 
(if No, skip to Q9.2) 
p_asthma 
[integer; 1 digit; range 0–1] 
  9.1.1. 
Interview 





(if No, skip to Q9.2) 
p_asthmamed_take 
[integer; 1 digit; range 0–1] 
   9.1.1.1 
Interview 
If Yes, what medication? (Select all that apply) [Radio] 
01 Short-acting beta-agonist inhaler  
(e.g., Albuterol, Asthavent, Fenoterol, 
Salbutamol, Terbutaline, Ventolin, 
Volmax) 
02 Long-acting beta-agonist inhaler  
(e.g., Formoterol, Foradil, Foratec, 
Foxair, Oxis, Salmeterol, Serevent)  
03 Steroid inhaler  
(e.g., Aerobec, Beclomethasone, 
Beclate, Becotide, Beloforte, Budeflam, 
Budesonide, Ciclesonide, Clenil, 
Flixotide, Flomist, Fluticasone, 
Inflammide, Rhinocort, Viarox) 
04 Combination inhaler 
(e.g., Budesonide-Formoterol, 
Seretide, Symbicort 
05 Oral steroid  
(e.g., Prednisone, prednisolone, 
methylprednisone, 
methylprednisolone) 
06 Oral leukotriene receptor antagonists  
p_asthmamed 
[integer; 2 digits; range 01-06,96,99] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
(e.g., Accolate, Montelukast, Singulair, 
Zafirlukast) 
96 Other, specify 
99 Don’t know 
(if No, skip to Q9.2) 
    9.1.1.1.1 
Interview 
Other, specify [Text] p_asthmamed_o 
[text; 30 characters] 
   9.1.1.2 
Interview 
When did your child start taking regular medication for 
asthma? 
[Dropdown] 
99 = Don’t know 
p_asthmamed_dstartm 









Is your child diabetic (or has diabetes)? [Radio] 
0 No 
1 Yes 
(if No, skip to Q9.3) 
p_diab 
[integer; 1 digit; range 0–1] 
  9.2.1 
Interview 





(if No, skip to Q9.3) 
p_diabmed 
[integer; 1 digit; range 0–1] 
   9.2.1.1 
Interview 




(e.g., Metformin [Bigsens, Diabetmin, 
Diaformin, Diamin, Diaphage, Forminal, 
Glucophage, Mengen, Metcheck, 
Metforal, Metored, Romidab])  
02 Sulphonylurea 
(e.g., Glibenclamide [Daonil, 
Glycomin]; Gliclazide [Adco-Glucomed, 
Diaglucide, Diaglumed, Diamicron, 
Gycron, Glygard]; Glimepiride [Amaryl, 
Diaglim, Euglim, Glamaryl, Sulphonur]; 
Glipizide) 
03 PPAR agonist 
(e.g., Pioglitazone [Actos]) 
p_diabmed_o 
[integer; 1 digit; range 0–1] 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
04 SGLT2-inhibitor 
(e.g., Canagliflozin, Dapagliflozin, 
Empagliflozin) 
05 DPP-4 inhibitor 
(e.g., Saxagliptin [Onglyza, 
Kombiglyze], Sitagliptin [Januvia, 
Janumet, Juvisync], Vildagliptin) 
06 GLP-1 agonist 
(e.g., Exenatide [Byetta, Bydureon], 
Liraglutide [Victoza], Lixisenatide, 
Semaglutide) 
07 Alpha-glucosidase inhibitor 
(e.g., Acarbose) 
08 Short-acting insulin  
(e.g., Isophane insulin [Humulin, 
Insulin-HMGE-Protaphane], Insulin 
Lispro [Humalog]) 
09 Long-acting insulin 
(e.g., Glargine [Basaglar, Lantus, 
Optisulin]) 
96 Other, specify 
99 Don’t know 
 
    9.2.1.1.1 
Interview 
Other, Specify  p_diabmed_o 
[integer; 1 digit; range 0–1] 
   9.2.1.2 
Interview 
When did your child start taking regular medication for 
diabetes? 
[Dropdown] 
99 = Don’t know 
p_regmed_dstartm 














(if No, skip to Q10) 
p_cillness 
[integer; 1 digit; range 0–1] 
 [add sub-form for each illness]  
  9.3.1.1 If yes, what illnesses? [Dropdown]  p_cillness_det 
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Interview 1 HIV/AIDS 
2 Epilepsy 
6 Other (Specify) 
9 Don’t know 
(If [1] HIV/AIDS, skip to Q9.3.1.3, inform the 
parent that you will ask them for more details  
later] 
[integer; 1 digit; range 1–2, 6, 9] 
   9.3.1.1.1 
Interview 
Other, specify 
[only appear if 6] 
[Text] p_cillness_det_o 
[string, 30 characters] 
  9.3.1.2. 
Interview 
Does your child take regular medication for this illness? [Dropdown] 
0 No 
1 Yes 
9 Don’t know 
(If No, Skip to 9.3.1.3) 
(If yes, and illness=epilepsy – go to 9.3.1.2.1 
If yes, and illness = other – go to 9.3.1.2.1.1 
p_regmed 
[integer; 1 digit; range 0–1, 9] 
   9.3.1.2.1 
Interview 
If Yes, what medication? [Dropdown] [List of medications] 
1 Sodium valproate 
(e.g., Epilim, Epilizine, Epiproate, 
Eprolep, Navalpro, Valeptic) 
2 Phenytoin sodium 
(e.g., Epanutin, Phlexy) 
3 Carbamazepine 
(e.g., Degranol, Tegretol) 
4 Lamotrigine 
(e.g., Epitec, Girotec, Lamictin, 
Lamidus, Lamitor) 
5 Levetiracetam 
(e.g., Epikepp, Keppra, Redilev, 
Torcetam) 
6 Other, specify 
9 Don’t know 
 
p_regmed_det 
[integer; 2 digits; range 01–XX, 96, 99] 
    9.3.1.2.1.1 
Interview 
Specify medication 
[only appear if 6 – or if 9.3.1.1 = other illness & 
9.3.1.2=yes] 
[Text] p_regmed_det_o 
[string; 50 characters] 
   9.3.1.2.2 [Dropdown] p_regmed_dstartm 
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Interview When did your child start taking regular medication for 
this condition? 





[standard AHRI year variable; range 1998–
2017] 
  9.3.1.3 
Interview 
Does your child have any other chronic illness? [Radio] 
0 No 
1 Yes 
[if Yes, add sub-form for questions 9.3.1-9.3.3] 
p_cillness_o 
[integer; 1 digit; range 0–1] 
Question 10 HIV Section 
 
HIV Section Memory Aid 
* Assess parental knowledge of HIV 
* Give general HIV information 
* Benefits of treatment / routes of transmission 
* Need to know re ARVs due to impact on test 
 
 10.1 
Piped from Q9.3.1.1 
 
What chronic illnesses did the parent mention in Q 9 
(This question displays the chronic illnesses that the 
parent/guardian mentioned in Q9. This helps you how to 
proceed if the parent had already told you that the child 






[integer, 1 digit, range 1] 
 10.2 
Interview 
Has your child ever tested for HIV before? 
 
If the parent said the child is HIV positive: 
You mentioned that your child is HIV positive; I assume 




2 Prefer not to say 
9 Don’t know 
 (If Yes, go to 10.2.1;  
If 0,2 or 9, skip to Q11) 
p_hivtest_ever 
[integer; 1 digit; range 0–2, 9] 
  10.2.1 
Interview 
If yes, what was the result? 
if parent said child is HIV positive in section 9; 




9 Don’t know 
(if Negative or Don’t know, skip to Q10.2.1.2) 
p_hivres 
[integer; 1 digit; range 0–1, 9] 
   10.2.1.1 If positive, when did your child first test positive? [Dropdown] p_hivres_pos_dtestm  
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Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Interview  
 





[standard AHRI year variable, range 1998-
2017] 
    10.2.1.1.1 
Interview 
Where did your child first test positive? [Dropdown]  
1 DOH Hospital 
2 DOH clinic 
3 AHRI Home 
4 AHRI Mobile Clinic 
6 Other, specify 
9 Don’t know 
 
p_hivptest_loc 
[integer; 1 digit; range 1–4, 6, 9] 
     10.2.1.1.1.1 
Interview 
Other, specify [Text] p_hivptest_loc_o 
[string; 30 characters] 
   10.2.1.2 
Interview 
If Negative, when was your child’s most recent test? [Dropdown] 
99 = Don’t know 
p_hivtest_neg_drecm 
[standard AHRI month variable; range 01–
12, 99] 
   [Dropdown] 
9999=don’t know 
p_hivtest_neg_drecy 
[standard AHRI year variable; range 1998–
2017] 
    10.2.1.2.1 
Interview 
Where did your child most recently test for HIV [Dropdown]  
1 DOH Hospital 
2 DOH clinic 
3 AHRI Home 
4 AHRI Mobile Clinic 
6 Other, specify 
9 Don’t know 
 
p_hivntest_loc 
[integer; 1 digit; range 1–4, 6, 9] 
     10.2.1.2.1.1 
Interview 
Other, specify [Text] p_hivntest_loc_o 




IPT and ART 
 11.1 
Interview 






9 Don’t know 
p_ipt_ever 
[integer; 1 digit; range 0–1, 9] 
 
241 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
(explain to the respondent that this is treatment given to 
prevent development of TB disease unlike TB treatment 
which is given to treat TB disease) 
 
Pop-up information: 
[If needed, explain that treatment for TB disease will 
have been with at least four drugs [though it may have 
been in one tablet, e.g., Rifafour] every day for two 
months, and then two drugs [again, may have been in 
one tablet, e.g., Rifinah] every day for a further four 
months [i.e., a total of at least 6 months].   
 
This is different from isoniazid preventive therapy [IPT], 
which is given to prevent development of TB disease, and 
will have involved taking one drug every day for six 
months.] 
(If No or Don’t know skip to Q11.3) 
  11.1.1 
Interview 
If Yes, when did your child stop taking IPT? [Dropdown] 
97 = Currently on IPT 
99 = Don’t know 
p_ipt_dstopm 
[standard AHRI month variable; range 01–
12, 97, 99] 
   [Dropdown] 
9997 = Currently on IPT 
9999=don’t know 
p_ipt_dstopy 
[standard AHRI year variable, range 1998–
2017, 9997] 
 11.2 
Piped variable from Q9.3 
What chronic illnesses did the parent mention in section 
9 
(This question displays the chronic illnesses that the 
parent/guardian mentioned in Q9. This helps you know if 







[integer, 1 digit, range 1-3] 
  Memory aid – HIV Status 
* Think back about what the parent/guardian said regarding the participant’s HIV status.  They may have 
already told you that the child is on ART. Use the information to guide you how to ask the next set of 









2 Prefer not to say 
p_arv_ever 
[integer; 1 digit; range 0–2, 9] 
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(if the parent had already mentioned that the child is HIV 
positive and taking ARVs, select YES for this question and 
proceed with follow-up questions) 
 
If needed, explain to the parent/guardian that ARVs may 
be given to HIV negative individuals in the form of PrEP or 
PEP. 
 
* PrEP (Pre-Exposure Prophylaxis) is given to people who 
are at high-risk, to reduce their risk of acquiring HIV and 
  
* PEP (Post Exposure Prophylaxis) is given after someone 
may have been exposed to HIV (e.g., through a 
needlestick injury) to prevent them from becoming 
infected. 
 
9 Don’t know 
(if No, Prefer not to say, or Don’t know AND the 
child was reported HIV-positive and less than 
15 years, skip to Q11.4) 
 
(if No, Prefer not to say, or Don’t know AND the 
child was reported HIV-positive, skip to Q12) 
 
(If No, Prefer not to say, or Don’t know AND the 
child was reported HIV-negative or with 
unknown HIV status, skip to Q13) 
  11.3.1 
Interview 
If Yes, why did your child take ARVs/PEP/PrEP? 
 
(if the parent had already mentioned that the child is HIV 
positive and taking ARVs select “For Routine care” for this 
question and proceed with follow-up questions 
[Radio] 
1 For routine HIV care 
2 As post-exposure prophylaxis (PEP) 
3 As pre-exposure prophylaxis (PrEP) 
6 Other, specify 
9 Don’t know 
(if 6 go to 11.3.1.1 otherwise skip to 11. 3.2) 
(if 1, and parent has not mentioned child is HIV 
positive, please show pop up message) 
p_arv_reas 
[integer; 1 digit; range 0–3, 6, 9] 
    Pop Up Message 
Parent has not previously mentioned that child is HIV positive, please check  
 
 
      
   11.3.1.1 
Interview 
Other reason if not on list 
 
[Text] p_arv_reas_o 








If Yes, when did your child first start taking 
ARVs/PrEP/PEP? 
[Dropdown] 
99 = Don’t know 
p_arv_dstartm 









Q number; source Question Field type; dropdown options Variable name, type, size, limits 
  11.3.3 
Interview 





9 Don’t know 
(If Yes, skip to 11.3.3.2) 
p_arv_still 
[integer; 1 digit; range 0–1, 9] 
   11.3.3.1 
Interview 
If No, when did your child stop taking ARVs (for routine 
care, as PEP, or as PrEP]? 
[Dropdown] 
99 = Don’t know 
p_arv_dstopm 





[standard AHRI year variable, range 1998–
2017] 
   11.3.3.2 
Interview 
Which regimen is your child taking, or took before 
stopping? 
[Dropdown] [List of ARV regimens] 
01 ABC + 3TC + LPV/r 
(e.g., ABC/3TC fixed-dose [ Dumiva, 
Heteruam, Kivexa] + LPV/r [Norvir, 
Rinavo]) 
02 ABC + 3TC + EFV 
(e.g., ABC/3TC fixed-dose [ Dumiva, 
Heteruam, Kivexa] + EFV [Efamat, 
Efrin, Erige, Hevaz, Stocrin, Viref]) 
03 TDF + FTC + EFV 
(e.g., Fixed-dose combination [Atenef, 
Atreslawin, Atripla, Atroiza, Citenvir, 
Eftenem, Heftenam, Odimune, Rizene, 
Trenvir, Tribuss, Triolar]) 
04 TDF + 3TC + EFV 
(e.g., Fixed-dose combination [Arion, 
eflaten, Elteno, Tenarenz, Virlaten]) 
05 AZT + 3TC + LPV/r 
06 AZT + ABC + LPV/r 
96 Other, specify 
99 Don’t know 
 
p_arv_regimen 
[integer; 2 digits; range 01–XX, 96, 99] 
   11.3.3.3 
Interview 
At which clinic is your child taking ARVs now? 
(or last clinic attended if not taking ARVs now) 
[Dropdown]  
96 = Other, specify 
99 = Don’t know 
p_arvclin 
[integer; 2 digits; range 01–XX, 96, 99]  
    11.3.3.3.1 Other, specify  [Text] p_arvclin_o 
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Child HIV status Disclosure and linkage to care 
 This question should ONLY be asked if the parent/guardian reports that the child is HIV-positive or is taking ARVs.   
If the child’s reported HIV status is negative or unknown, skip to Q13. 
 12.1 
Interview 
Does your child know his/her HIV status? [Radio]  
0 No 
1 Yes 
9 Don’t know 
(If Yes and on ARVs, Skip to Q14) 
(If Yes but not on ARVs, skip to Q13) 
p_hivknown 
[integer; 1 digit; range 0–1, 9] 
  12.1.1 
Interview 
If No or Don’t know, would you like assistance in 
disclosing the HIV status to your child? 
 
(If the parent/guardian needs help in disclosing HIV 






(If No and on ARVs, Skip to Q14) 
(If No but not on ARVs, skip to Q13) 
p_hivdisclos 
[integer; 1 digit; range 0–1] 
   
12.2 
 
REFERRAL TO CARE FOR CHILD HIV DISCLOSURE 
 
   Referral To care Memory Aid: 
*Explain that the AHRI paediatric HIV nurse can help them with disclosure 
 
*Check if the participant (child) is currently attending a clinic for ARVs. Explain that ideally disclosure 
should take place at this clinic.       
 
* If the child is not on ARVs, inform the parent that the AHRI paediatric HIV nurse can see them at the one 
of following clinics in PIP:  KwaMsane (Mondays); Mtubatuba (Tuesdays); Somkhele (Thursdays)  
 
If the parent is not able to attend one of those clinics, ask them to choose another clinic in PIP, where an 








[integer; 1 digit; range 0–1,7] 
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Piped from Q11.3.3,  
Q11.3.3.3 and 
Q11.3.3.3.1 
  12.2.2 
Interview 
Which clinic would you like to be referred to?  
 
The AHRI Paediatric nurse can see parents in the 
following clinics: KwaMsane (Mondays); Mtubatuba 
(Tuesdays); Somkhele (Thursdays) 
[Dropdown] [List of PIP clinics) 
96 = Other, specify 
 
p_prefclin 
[integer; 2 digits; range 0–99] 
  12.2.3 
Interview 
Other, specify  
 
[Text] p_prefclin_0 
[Text, 50 characters] 
  12.2.4 What is the agreed target date for attending the clinic [Date] p_hivdis_tdate 
[standard AHRI date variable] 
  12.2.5 
Interview 
What is your primary contact number? 
 
[number] p_hivdis_contnum 
[Number, 10 digits] 
   12.2.5.1 
Interview 





[integer; 1 digit; range 0–1] 
   12.2.5.2 
Interview 





[integer; 1 digit; range 0–1] 
    If No, Pop Up Message 
Please verify the number to check if it is working 
 
 
Q number; source Question Field type; dropdown options Variable name, type, size, limits 
Question 13 Consent for Rapid HIV test 
 Rapid HIV Test Memory Aid 
Rapid HIV test should not be offered if: 
* Date of last HIV test in PIP was within 3 months (check date below) 
* Participant is HIV+ and taking ARVs 
 Rapid HIV Testing: Parent Consent Memory Aid 
 * Confirm: has the parent capacity to consent? 
* Parental preference re child seen alone  
* Explain right of child to be tested alone (if aged 12+) 
* Explain that if child is aged 10-11 years, he/she can only be tested with parent present 
* Consider referral to clinic for testing  
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* Confirm: proceed with HIV testing?  
* Reaffirm parental consent 
* Duty of confidentiality to parent (and child) 
 
  Date for last HIV Test in PIP 
* The question below gives date for the participant’s last test in PIP. Use the date in deciding whether to 
offer a rapid HIV test. 
* If the date is not available, this means that the participant has never been tested by AHRI. 
* If the date is within 3 months, do not offer a rapid test 





Date of last HIV test in PIP: [date] p_lhivdate 
[standard AHRI date] 
 13.2 
Interview 
Basing on the HIV decision rules, should consent for rapid 




If No, skip to Q13.4 
If No and HIV+ not taking ARVs skip to Q13.5 
If No and HIV+ taking ARVs skip to Q14 
p_hivrdec 
[integer; 1 digit; range 0–1] 
 13.3 
Interview 






If Yes, skip to Q13.4.1 
 
p_hivrap_cons 
[integer; 1 digit; range 0–1] 
 13.4 
Interview 
If No, or if your child does not want a rapid test, can we 
offer to test your child for HIV using venous blood for 
research purposes?  
 
(If needed, explain to the parent/guardian that with their 
permission we can test for HIV in the lab using the venous 
blood collected for IGRA testing only for research purposes.  
Make it clear that this result will remain anonymous – 
neither you (the researcher) or the parent or child will be 




7 Not Applicable 
(If No, Skip to Q13.5) 
 
p_hivven_cons 
[integer; 1 digit; range 0–1] 
  13.4.1 
Interview 
If Yes, ask parent to sign consent for HIV testing [Signature] p_hivcons_sign 
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  13.4.2 
Interview 
Would you prefer to be present for the process of HIV 
testing?  
 
Explain that this is only a preference and depends also on 
the wishes of the child (if the child is aged 12 years or 
above).  If the child is aged 10-11 years, the parent must 
agree to be present.  ‘Process’ in this case refers to 





If No, go to Q13.5 
If Yes, skip to Q14 
p_hivrap_pres 
[integer; 1 digit; range 0–1] 
    
Parent has refused being present during the test. Do not offer HIV Testing to participant 
 
  13.5 
Interview 
If HIV rapid test is not offered or refused, please 
comment. 
Text c_hiv_noconsent 
[text 200 characters] 
 
Question 14 Adolescent consent 
 14.1 
Interview 
Do you wish to be present when we obtain assent from 
your child for their participation in the study? 
(Explain that this is only the process of obtaining assent 
with the child. The interview with the child should take 




(If no, proceed to obtain consent/assent 
WITHOUT the parent/guardian.) 
(If yes, proceed to obtain consent assent WITH 
the parent/guardian.) 
p_childcons_pres 
[integer; 1 digit; range 0–1] 
End of Survey Instrument 






  Memory Aid: Contact Details for Feeding Back Results 
* Inform the parent/guardian that you may need to feed back some of the participant’s lab test results 
to them and that you will need their contact details to be able to do this. 
 
  1.1.1 
Interview 
Which number should we use to contact you? [Text] p_res_contnum 
[text, 10 characters] 
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  1.1.2 
Interview 





[integer; 1 digit; range 0–1] 
  1.1.4 
Interview 





[integer; 1 digit; range 0–1] 
     If No, Pop Up Message 
Please verify the number to check if it is working 
 
    1.2 
Interview 
Details of interview   
  1.2.1 
Interview 
Has the parent/guardian answered all the questions? [Radio]  
0 No 
1 Yes 
(if Yes, Skip to Q15.2) 
p_surv_comp 
[integer; 1 digit; range; 0-1] 
   1.2.1.1 
Interview 
If No, why were some questions not answered? [Text] p_nocomp_reas 
[Text, 200 characters] 
   1.2.1.2 
Interview 
Please add any other comments or notes that you feel are 
needed 
[text] p_gencomment 
[text, 300 characters] 
  1.2.2 
Interview 
Interviewer Name [Text] p_intid 
[Text, 50 characters] 
  1.2.3 
Interview 
Time interview ended [Number] p_tintstophh 
[integer; 2 digits; range 00–23] 
  [Number] p_tintstopmm 






Appendix 12: Risk factors for M. tuberculosis infection 
Appendix Table 1: Risk factors for Mycobacterium tuberculosis infection showing odds ratios obtained from the crude, partial and fully adjusted 
models at each level of hierarchical approach (not taking account for clustering within households). 




p-value  Adjusted OR1 
(95% CI) 




Community Level factors 
 
       
Community HIV prevalence (%)        
<25% 12/85 (14.1) 1 0.05     
25-34.9% 133/618 (21.5) 1.67 (0.88 -3.16)      
35-44.9% 61/261 (23.4) 1.86 (0.95 -3.64)      
≥45% 26/82 (31.7) 2.82 (1.31 -6.08)      
Location        
Rural 156/715 (21.8) 1 0.31 1a 0.81   
Urban 93/379 (24.5) 1.17 (0.87-1.56)  0.95 (0.63-1.43)    
 
Household Level factors 
 
       
Distance to nearest clinic (km) 
(quartiles) 
       
 <1.85 84/301 (27.9) 1 0.08 1a 0.15 1b 0.24 
1.85-3.41 80/403 (19.9) 0.64 (0.45-0.91)  0.67 (0.46-0.97)  0.73 (0.50-1.06)  
3.42-5.36 55/259 (21.2) 0.70 (0.47-1.03)  0.77 (0.50 -1.20)  0.82 (0.52-1.29)  
 >5.36 30/131 (22.9) 0.77 (0.48-1.24)  0.96 (0.58 -1.60)  1.10 (0.65-1.85)  
Household social economic index score 
(tertiles) 
       
Low 74/305 (24.3) 1 0.62 1a 0.71 1b 0.72 
Middle 79/350 (22.6) 0.91 (0.63 -1.31)  0.87 (0.59 -1.26)  0.87 (0.59-1.26)  
High 83/393 (21.1) 0.84 (0.59 -1.19)  0.88 (0.61 -1.27)  0.89 (0.61-1.28)  
Number of residents        
<6 87/333 (26.1) 1 0.20 1a 0.30 1b 0.38 
6-7 58/252 (23.0) 0.85 (0.58-1.24)  0.85 (0.57 -1.26)  0.90 (0.60-1.36)  
8-10 50/248 (20.2) 0.71 (0.48-1.06)  0.72 (0.48 -1.08)  0.73 (0.48-1.12)  
>10 46/237 (19.4) 0.68 (0.45-1.02)  0.71 (0.47 -1.08)  0.74 (0.48-1.13)  
Reported smoker in household        
No 197/880 (22.4) 1 0.92 1a 0.66 1b 0.62 
Yes 47/207 (22.7) 1.02 (0.71 -1.46)  0.92 (0.63 -1.34)  0.91 (0.62-1.33)  
 
Individual Level factors 
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p-value  Adjusted OR1 
(95% CI) 




Sex        
Female 123/548 (22.4) 1 0.80 1c 0.98 1d 0.81 
Male 126/546 (23.1) 1.04  (0.78 -1.38)  1.00 (0.74 -1.35)  0.96 (0.70-1.32)  
Age (years)        
10-11 49/237 (20.7) 1 <0.01 1c <0.01 1d <0.01 
12-14 62/349 (17.8) 0.83  (0.55 -1.26)  0.86 (0.56 -1.35)  0.92 (0.58-1.44)  
15-17 71/297 (23.9) 1.21  (0.80 -1.82)  1.13 (0.72 -1.77)  1.22 (0.77-1.92)  
≥18 67/211 (31.8) 1.79  (1.16 -2.74)  1.83 (1.16 -2.89)  1.96 (1.23-3.15)  
Lifetime household TB contact        
   No  168/823 (20.4) 1 <0.01 1c 0.01 1d <0.01 
   Yes 78/266 (29.3) 1.62  (1.18 -2.21)  1.57 (1.12 -2.20)  1.73 (1.22-2.45)  
HIV Status        
Negative 193/855 (22.6) 1 0.88 1c 0.34 1d 0.33 
Positive 9/43 (20.9) 0.91  (0.43 -1.93)  0.72 (0.31 -1.68)  0.72 (0.31-1.71)  
Unknown 47/196 (24.0) 1.08  (0.75 -1.56)  1.27 (0.85 -1.91)  1.30 (0.86-1.97)  
BCG Vaccination        
Vaccinated  216/984 (22.0) 1 0.20 1c 0.94 1d 0.67 
Not vaccinated 28/101 (27.7) 1.36 (0.86 -2.16)  1.02 (0.60 -1.72)  1.13 (0.66 -1.92)  
Smoking        
No 240/1070 (22.4) 1 0.29 1c 0.86 1d 0.61 
Yes 6/18 (33.3) 1.73 (0.64 -4.66)  0.90 (0.31 -2.70)  0.74 (0.24-2.26)  
Alcohol intake        
No 226/1021 (22.1) 1 0.21 1c 0.68 1d 0.65 
Yes 16/54 (29.6) 1.48 (0.81 -2.71)  1.15 (0.60 -2.21)  1.16 (0.59-2.28))  
Education level        
Primary 130/631 (20.6) 1 0.05 1c 0.21 1d 0.33 
Secondary or above 118/459 (25.7) 1.33 (1.00 -1.77)  0.72 (0.42-1.21)  0.77 (0.4 -1.33)  
Admission to hospital        
No 221/967 (22.9) 1 0.58 1c 0.28 1d 0.18 
Yes 25/121 (20.7) 0.88 (0.55 -1.40)  0.76 (0.47-1.25)  0.70 (0.4 -1.18)  
 
Social contact factors 
 
       
Contact hours with adult men        
<100 63/274 (23.0) 1 0.97 1c 0.72 1d 0.63 
100-1047 63/275 (22.9) 1.00 (0.67 -1.48)  1.22 (0.80-1.88)  1.34 (0.85-2.10)  
1048-2400 59/272 (21.7) 0.93 (0.62 -1.39)  1.01 (0.65-1.57)  1.14 (0.72-1.81)  
>2400 64/273 (23.4) 1.03 (0.69 -1.53)  1.17 (0.76-1.80)  1.17 (0.75-1.82)  
Contact hour with adult females        
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p-value  Adjusted OR1 
(95% CI) 
p-value Adjusted OR2 
(95% CI) 
p-value 
<160 68/277 (24.5) 1 0.42 1c 0.82 1d 0.85 
160-1216 53/274 (19.3) 0.74 (0.49 -1.11)  0.84 (0.54-1.29)  0.92 (0.59-1.44)  
1216-2880 66/270 (24.4) 0.99 (0.67 -1.47)  1.01 (0.66-1.54)  1.11 (0.71-1.72)  
>2880 62/273 (22.7) 0.90 (0.61 -1.34)  0.99 (0.64-1.51)  1.07 (0.69-1.66)  
Church attendance in previous month        
None 165/664 (24.8) 1 0.06 1c 0.11 1d 0.03 
1-2 times 37/176 (21.0) 0.81 (0.54 -1.20)  0.77 (0.50-1.18)  0.70 (0.45-1.08)  
≥3 times 41/233 (17.6) 0.65 (0.44 -0.94)  0.68 (0.46-1.01)  0.60 (0.40-0.90)  
Health facility attendance (12 months)        
No 142/667 (21.3) 1 0.20 1c 0.70 1d 0.65 
Yes 104/422 (24.6) 1.21 (0.91 -1.61)  1.06 (0.78 -1.45)  1.08 (0.78-1.49)  
Visiting other houses during the day        
None 169/720 (23.5) 1 <0.01 1c 0.01 1d 0.01 
1-2 houses 59/227 (26.0) 1.15 (0.81 -1.61)  1.12 (0.78 -1.61)  1.03 (0.71-1.49)  
≥3 houses 17/136 (12.5) 0.47 (0.27 -0.80)  0.42 (0.24 -0.75)  0.39 (0.22 -0.70)  
Sharing sleeping room with other people        
None 84/363 (23.1) 1 0.84 1c 0.55 1d 0.44 
1 person 78/336 (23.2) 1.00 (0.71 -1.43)  1.23 (0.84-1.80)  1.29 (0.87-1.90)  
≥2 persons 84/389 (21.6) 0.91 (0.65 -1.29)  1.06 (0.73-1.55)  1.09 (0.74-1.62)  
BCG: Bacillus Calmette-Guérin; CI: confidence interval; HIV: Human immunodeficiency virus; OR: odds ratios; QFT: QuantiFERON TB-Gold plus; TB: tuberculosis 
1 Partially adjusted by a priori confounders and variables remaining significant (p<0.2) at higher levels in the hierarchy 
2 Fully adjusted by a priori confounders, variables remaining significant (p<0.2) at higher levels in the hierarchy and variables remaining significant (p<0.2) that levels 
in the hierarchy. 
a Adjusted by community HIV prevalence 
b Adjusted by community HIV prevalence, distance to clinic and socioeconomic status (a priori confounder) 
c Adjusted by community HIV prevalence, socioeconomic status and age (a priori confounder) 
d Adjusted by community HIV prevalence, socioeconomic status, age, lifetime household TB contact, attendance to church and visiting other houses during the day 
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